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ABSTRACT 
 
 
Using a ligand-based approach, we designed and synthesised novel non-steroidal 17β-
HSD2 inhibitors from two scaffolds described in literature as potential drugs for the treatment 
of osteoporosis. These compounds bear a hydrophobic core and two polar moieties, distant 
from each other circa 11Å, mimicking the two hydroxy group at the C3 and C17 position of 
the steroid E2. The best OH-OH substitution pattern was first elucidated in an optimisation 
process. Addition of further substituents to the best scaffold was investigated to enhance its 
activity and selectivity. Most of the synthesised compounds are potent 17β-HSD2 inhibitors 
with IC50 values in the low nanomolar range. Besides an outstanding selectivity towards 17β-
HSD1 and a negligible affinity to the ERα and ERβ, the most promising compound of this 
thesis (II.19) displays high selectivity towards 17β-HSD4 and 17β-HSD5. It exhibits also 
good cell permeability in MDA-MB-231 cells, expressing naturally 17β-HSD2 and an 
excellent activity in rat, mouse and monkey enzymes. 
To conclude, the present work presents a broad SAR study of two classes of compounds 
regarding 17β-HSD2 inhibition and all of these results helped to generate a good homology 
model of the protein with the goal to better understand how potential drug binds in the 
enzymatic pocket. 
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ZUSAMMENFASSUNG 
 
 
Aus zwei in der Literatur beschriebenen Grundgerüsten und mit Hilfe eines Ligand-
basierten Ansatzes, wurden neue nicht-steroidale 17β-HSD2 Hemmstoffe designet und 
synthetisiert, als potentielle Therapeutika für die Behandlung von Osteoporose. Diese 
Verbindungen besitzen ein hydrophobes Grundgerüst und zwei polare Reste in einem Abstand 
von 11Å, die die Positionen C3 und C17 von Estradiol nachahmen. Im ersten 
Optimierungsprozess wurde das optimale Substitutionsmuster für die zwei OH-Funktionen 
ermittelt. Zusätzlich wurde die Einführung von weiteren Substituenten in die beste 
Leitstruktur untersucht, um Aktivität und Selektivität zu erhöhen. Die meisten synthetisierten 
Verbindungen sind hochpotente 17β-HSD2 Inhibitoren mit IC50-Werten im nanomolaren 
Bereich. Die beste Verbindung in dieser Doktorarbeit (II.19) besitzt eine sehr gute 
Selektivität gegenüber 17β -HSD1 sowie ein sehr geringe Affinität zum ERα und ERβ, und 
zeigt eine hohe Selektivität gegen 17β -HSD4 und 17β-HSD5. II.19 weist auch gute 
Zellgängigkeit in MDA-MB-231 Zellen auf und eine exzellente Aktivität am Ratten-, Mäuse- 
und Affen-Enzym.  
Die vorliegende Arbeit liefert einen breiten Einblick in die Struktur-Wirkungbeziehungen 
zweier neuer Klassen von 17β-HSD2-Hemmstoffen. Diese Ergebnisse haben dazu 
beigetragen, ein gutes Homologiemodell des Proteins zu entwickeln. Mit ihnen war es ferner 
möglich die Bindungstelle von potentiellen Therapeutika in der enzymatischen Bindetasche 
zu charakterisieren. 
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1. INTRODUCTION 
 
1.1. Sex steroid hormones 
 
1.1.1. Androgens and estrogens 
 
Sex steroid hormones are lipophilic compounds derived from cholesterol. Two main 
classes of sex steroid have been identified: androgens and estrogens. Androstenedione (A-
dione), testosterone (T) and dihydrotestosterone (DHT) constitute the main androgens over 
the body and belong to the C19-steroids. After aromatisation of the A-ring of A-dione or T, 
estrone (E1) and estradiol (E2), characterised as C18-steroids are obtained as the principal 
estrogens.  
Androgens and estrogens are both essential for sexual differentiation and reproduction in 
men and women, respectively, but are not considered just as male and female hormones. 
Indeed, estrogens are also important to the development and maintenance of the functional 
integrity of the brain, as they modulate functions like memory, behaviour and neuronal 
protection1. Estrogens are crucial for maintening the equilibrium between bone formation and 
bone resorption2. Thus, after menopause, estrogen deficiency is responsible for the imbalance 
observed between bone resorption mediated by osteoclasts (OCs) and bone formation directed 
by osteoblasts (OBs). Furthermore, studies proved that estrogen deficiency may increase the 
risk of cardiovascular disease3. Regarding androgens, they increase mineralisation of the bone 
matrix 4  and are responsible for the muscle protein synthesis. Studies proved that 
supplementation of T in elderly men is beneficial for the muscle protein synthesis 5
 
 and 
decrease the risk of muscle wasting. 
1.1.2. Biosynthesis of androgens and estrogens  
 
The gonads are the main source of biologically active androgens and estrogens in men 
and premenopausal women (endocrine mechanism, Figure 1A). Bioactive hormones are 
therefore transported through the blood into their target tissue, where they act. But other 
tissues including bone, brain, prostate and breast are also able to synthesise bioactive 
hormones over the body using inactive adrenal precursors (Figure 1B). Estrogens and 
androgens are therefore biologically activated from their inactive precursor directly in the 
local tissue, where the synthesis takes place, without being released in the blood. An 
intracrine mechanism (Figure 1B) is therefore refered to this concept. The concentrations in 
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sex steroids in the target tissues are adjusted by their local requirements. In addition to 
prostate and breast cancers, in which efficient blockade of sex steroids synthesis in peripheral 
tissues have proved their benefits6,7, the intracrine approach in non-malignant diseases has 
been developed, as in the skin8
 
, for example.  
Figure 1: Representation of endocrine (A) and intracrine (B) concept (taken from Suzuki T. 
et al. 9) 
 
       B 
  
 inactive hormone; bioactive hormone;  receptor;  promoter region of the target gene 
 
1.2. 17β-HSDs 
 
1.2.1. Generality 
 
Most 17β-hydroxysteroid dehydrogenases (17β-HSD)10
 
 are essential enzymes involved in 
the last step of steroid hormone formation and degradation. They catalyse oxidation and 
reduction reactions at position C17 (Figure 2), using NAD(P)H or NAD(P)+ as cofactor. 
Figure 2: General pathway of reactions catalysed by 17β-HSDs 
OH O
+ NAD(P)+ + NAD(P)H17 17 + H+
   active
sex steroid
   inactive
sex steroid  
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Until now, fourteen 17β-HSDs have been identified, but only twelve have been 
characterised in human (17β-HSD6 and 17β-HSD9 only in rodents). The numbering follows 
the chronological order of the first description of the enzyme designated. Most 17β-HSDs 
belong to short chain dehydrogenase/reductase (SDR) protein family, except 17β-HSD5, 
which is an aldo/ketoreductase (AKR) family member. 17β-HSDs from the SDR family share 
low sequence identity (25% - 30%) but they conserved all characteristics of the SDR family, 
i.e. the Rossmann fold implicated in cofactor binding.  
 
1.2.2. Cofactor preference 
 
While 17β-HSDs are able to convert both oxidation and reduction reactions in cells, they 
only catalyse preferentially one type of reaction depending on two factors: the concentration 
of the cofactor present in cells and the preference of the cofactor for each 17β-HSD. Thus, in 
cells, NADPH, being the main source of electron for reduction (concentration of NADPH is 
500 times higher than the one of the corresponding state NADP+), is responsible for the 
reductive process, while NAD+, being the principal electron acceptor (concentration of NAD+ 
is 700 times higher than the one of the corresponding state NADH), assures the oxidative 
reactions11,12
 
. To maintain equilibrium, NADPH and NAD+ are constantly regenerated from 
their respective state NADP+ and NADH (Figure 3). 
Figure 3: Interplay between metabolism and 17β-HSD reactions 
 
INTRODUCTION   
 - 4 - 
 Apart from the difference between the concentrations of the cofactors in cells, kinetic 
studies showed that a large difference is observed between the Km values of NADP(H) and 
NAD(H) for each 17β-HSD subtype. For example, in case of 17β-HSD1, a preference appears 
for NADPH (Km = 0.07 μM) compared to NADH (Km = 0.42 μM)13. That means that in 
cofactor binding site of each 17β-HSD subtype, amino acid residues are present which are 
able to differentiate the phosphorylated cofactor from the non phosphorylated one. Analysis 
of X-ray structure of 17β-HSD1 proves the presence of an arginine residue in the N-terminal 
part of the Rossmann fold, which can form a salt-bridge with the 2´-phosphate moiety of 
NADPH and increase the affinity of the substrat with the phosphorylated cofactor14,15. On the 
contrary, “oxidative” 17β-HSDs, as 17β-HSD2 prefer the non-phosphorylated cofactor 
because of a negatively charged amino acid presents in place of the arginine in 17β-HSD1. 
Repulsion is then observed between the 2´-phosphate moiety of NADPH and the negatively 
charged amino acid. Attraction will be observed by hydrogen bond formation between the 2´-
OH group of NAD+ and the negative amino acid, thus favorising the presence of the non-
phosphorylated cofactor in the reactions implicating “oxidative” 17β-HSDs16,17
 
 (Figure 4). 
 Figure 4: Cofactor preference for reductive (NADPH) and oxidative (NAD+) 17β-HSDs 
 
 
  1.2.3. Characteristics of the 17β-HSDs 
 
 17β-HSDs catalysing the last step of the sex steroid biosynthesis play an important role in 
the formation of active androgens and estrogens or in the inactivation of potent sex steroids. 
17β-HSDs do not only differ in their cofactor preference and the direction of the reaction, but 
also in their localisation in body and their preference for a specific substrate. In the following 
17β-HSDs are distinguished according to their reductive or oxidative functions in human.  
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1.2.3.1. Reductive forms 
 
 “Reductive” 17β-HSDs catalyse the reduction of inactive sex steroids into their active 
forms. Table 1 sums up the features of the “reductive” 17β-HSDs. Briefly, 17β-HSD1, 7 and 
12 are the main enzymes responsible for E2 production. But 17β-HSD7 and 12 are also 
implicated in cholesterol and fatty acid (FA) synthesis, respectively. 17β-HSD3 and 5 catalyse 
principally the conversion of A-dione into T. As 17β-HSD1, 3, 5 and 7 are overexpressed in 
breast or prostate cancer tissues, inhibition of these enzymes could be an interesting approach 
for the treatment of these diseases. Until now, the implication of 17β-HSD12 in a disease has 
not been elucidated. 
 
Table 1: Features of the “reductive” 17β-HSDs 
Name Localisation Substrat Function Disease implication 
17β-HSD1 
Breast, ovary, 
endometrium, 
placenta 
Estrogens, 
androgens 
E2 
production 
Breast and prostate 
cancer, endometriosis 
17β-HSD3 Testis Androgens 
T 
production 
Pseudohermaphroditism 
17β-HSD5 Prostate, liver Androgens 
T 
production 
Breast and prostate 
cancer 
17β-HSD7 
Liver, lung, 
thymus 
Estrogens, 
zymosterone 
E2 
production 
and 
cholesterol 
synthesis 
Breast cancer 
17β-HSD12 
Breast, liver, 
placenta, kidney 
Estrogens, long 
chain FA 
E2 
production, 
FA 
synthesis 
- 
17β-HSD13 Liver Androgens 
T 
production 
Prostate cancer 
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   1.2.3.2. Oxidative forms 
 
Table 2 gives a summary of the principal features of the “oxidative” 17β-HSDs. While 
17β-HSD2, 4, 8 and 10 catalyse the inactivation of active sex steroids E2 and/or T, 17β-HSD2 
is the main enzyme responsible for the deactivation of E2 and T. Furthermore, 17β-HSD10 
could be an interesting target for Alzheimer´s disease18, as it is able to bind to amyloid 
plaques and is overexpressed in patients suffering from this pathology19
 
. The real role of 17β-
HSD11 has not been elucidated until now. 
Table 2: Characteristics of the “oxidative” 17β-HSDs 
Name Localisation Substrat Function Disease implication 
17β-HSD2 
Liver, breast, 
endometrium, 
placenta, prostate, 
bones 
Estrogens, 
androgens, 
progestins 
E2 and T 
inactivation 
Breast and prostate 
cancer 
17β-HSD4 
Liver, prostate, 
lung, placenta 
Estrogens, 
androgens 
E2 and T 
inactivation 
Prostate cancer 
17β-HSD8 
Liver, placenta, 
kidney 
Estrogens, 
androgens 
E2 and T 
inactivation, 
FA 
metabolism 
Kidney disease20 
17β-HSD10 
Central nervous 
system, brain 
Estrogens, cholic 
acid 
FA 
metabolism, 
sex steroids 
inactivation 
Neuronal disease21 
17β-HSD11 
Liver, kidney, 
lung, placenta 
Androgens, 
retinoid 
 - 
17β-HSD14 
Liver, placenta, 
brain 
Estrogens, 
androgens 
E2 and T 
inactivation 
Breast cancer22 
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1.3. 17β-HSD2 
 
1.3.1. Generality 
 
17β-HSD2 (EC = 1.1.1.62) was first isolated by Wu et al.25 in 1993. Human 17β-
HSD2 is composed of 387 amino acids and possesses a molecular weight of 42.8 kDa. It is 
expressed in a wide variety of tissues like placenta, kidney, uterus, prostate, liver, breast23 and 
bones24
17β-HSD2 is able to convert both C18- and C19-steroids and catalyses therefore the 
conversion from highly active E2 and T to their corresponding less active forms, E1 and A-
dione
. It is a membrane bound protein and is localised in microsomal fraction. No X-ray 
structure of the protein is still available.  
25, respectively in the presence of NAD+26 as cofactor. In a minor extent, it is also able 
to convert 20α-dihydroprogesterone (20α-DHP) into progesterone (P). The Km values of 17β-
HSD2 for E2, T and 20α-DHP are 0.21 μM, 0.39 μM and 0.71 μM27
As a member of th e SDR family, 1 7 β-HSD2 conserves amino acid motifs as for 
example NAG motif (position 167-169) essential for stabilisation of the structure and YxxxK 
motif (position 232-236) , which represents the catalytic triad in the active site. 
, respectively. 
 
1.3.2. State of knowledge: inhibition of 17 β-HSD2 
 
Until now, only few inhibitors of 17β-HSD2 have been described in the 
literature 28 , 29 , 30 , 31 . The first one, identified by Poirier et al. 32 , 33
Among the non-steroidal compounds, a novel highly potent derivative (compound C) 
was discovered by Wood et al.
 beared a steroidal core 
(compound A, Table 3) and exhibited an IC50 value of 6 nM. Compound A is selective toward 
17β-HSD1, 3 and 7 but is a highly potent inhibitor of 17β-HSD5 (IC50 (17β-HSD5) = 10 nM). 
It is therefore no longer investigated as a potential 17β-HSD2 inhibitor. A series of 
fluorinated estradiene derivatives was published as unselective and moderate inhibitors of 
17β-HSD2. The most potent one of this series, compound B, showed 95% inhibition at 2μM.  
34 , 35 , 36  as the most active 17β-HSD2 inhibitor described 
hitherto in the literature. The stereochemistry of C is very important, the C4 and C5 must be 
in the cis configuration. C shows an IC50 value of 50 nM, and was evaluated in a monkey 
osteoporosis model 37  to establish a proof of concept. Administration of compound C in 
monkey led to a slight decrease in bone resorption and increase in bone formation leading to 
maintenance of bone balance. However, a strong variability is observed, certainly due to non 
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appropriate pharmacokinetic properties. Compounds D and E, derivatives of isoxazole and 
oxazole, respectively, were identified in the frame of our 17β-HSD1 project. They show 
moderate inhibitory activity of 17β-HSD2 with IC50 values of 249 nM and 270 nM, 
respectively.  
 
Table 3: Selection of the most active 17β-HSD2 inhibitors 
Compound Structure IC50 (17β-HSD2) 
A 
O
OH
O
 
6 nM 
B 
OH
F
F
 
95%* 
C 
NO
OH
S N
 
50 nM 
D 
OH
ON
OH
 
249 nM 
E 
OH
N
O
OH
 
270 nM 
*: percentage inhibition at 2μM 
 
1.4. Disorders of bone remodeling and osteoporosis 
 
1.4.1. Bone remodeling 
 
Bone remodelling is a process, where old bone material is removed from the skeleton and 
new bone is formed. It requires the actions of four main cells: bone lining cells, osteocytes, 
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osteoclasts (OCs) and osteoblasts (OBs) (Figure 5). In a passive state, the bone surface is 
covered by bone lining cells. Osteocytes play the principal role in the initiation and activation 
of bone remodeling. When osteocytes detect bone damage, a signal is sent to the OC 
precursors, which are afterwards differentiated in OCs (osteoclastogenesis) by attaching to the 
bone matrix. Thus bone resorption processes and continues for a period of 2-4 weeks. The OC 
differentiation is regulated by macrophage colony-stimulating factor (M-CSF) and receptor 
activator of nuclear factor κβ ligand (RANKL)38
 
. After the osteoclastic resorption eroded a 
lacuna, the process is directly followed by bone formation over a period of 4-6 months. OB 
precursors and OBs direct the phase of bone formation. OB formation and function continue 
after cessation of bone resorption to have equilibrium between bone resorption and bone 
formation. The mineralisation step finishes the bone remodeling cycle. 
Figure 5: Bone remodeling sequence (taken from Riggs B. L. et al.39) 
 
 
1.4.2. Role of sex steroids in adult skeleton  
 
The reproductive system plays an important role in the bone remodeling system during 
adult life. Androgens and estrogens are not considered as just male and female hormones. 
Androgens can be converted into estrogens within the gonads and peripheral tissues (Figure 6) 
and both are present in men and women, but in different concentrations. 50% of total 
androgens in men, 75% of estrogens in premenopausal women and almost all of the estrogens 
in postmenopausal women are generated from extragonadal synthesis40
E2 plays the major role in regulating bone metabolism not only in women but also in 
men
 . 
41. T has some effect on bone resorption and clearly helps to maintain bone formation in 
Osteocyte 
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men, but T mainly provides the necessary substrate for aromatisation to E2 in the testis and in 
peripheral tissues, including bones42
 
.  
Figure 6: Extragonadal pathways of androgens (boxes) and estrogens (circles). Asteriks 
indicate the enzymes that are present in osteoblasts 
 
 
The mechanism by which estrogens act in bones is not yet clear, and still needs to be 
elucidated. But it has been proven that high doses of estrogen exert anabolic skeletal effects in 
postmenopausal women and elderly men and therefore conserve bone mass at the organ 
level43. The most postulated mechanism points out the importance of RANKL, crucial for 
bone formation and its two receptors: RANK (functional receptor) and osteoprotegerin 
(OPG). OPG inhibits osteoclastogenesis by binding to RANKL, preventing also interaction 
with its functional receptor RANK. This mechanism is validated by OPG and RANKL 
knockout (KO) mice 44 , 45 , 46 , which develop severe osteoporosis and osteopetrosis, 
respectively, stressing the importance of OPG and RANKL for bone remodeling. 
Additionnally, an estrogen antagonist (ICI 182,780) is able to abrogate the expression of 
OPG, RANKL and ER in OBs, suggesting that estrogens stimulate the expression of ER and 
OPG and that the mechanism is ER mediated47
 
. 
1.4.3. Osteoporosis 
 
Osteoporosis48,49 is a silent and systemic skeletal disease, characterised by a low bone 
mineral density (BMD) and deterioration of bone tissue (Figure 7), with a consequent increase 
in bone fragility and risks of fracture. As the effect of osteoporosis is systemic, all types of 
fractures in patients with low BMD is considered as osteoporotic fractures. But the typical 
ones are at hip, wrist and spine. Hip fractures are the most devastating in elderly people and 
provoke serious handicaps to walk and increase mortality. 
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Figure 7: 3D reconstruction of a lumbar spine sample from a young adult woman (left) and 
from a woman with postmenopausal osteoporosis (right) (taken from Riggs B. L. et al.50) 
 
 
Bone loss takes place as a result of estrogen defiency in postmenopausal women and 
elderly men. An imbalance between the activity of OCs and the one of OBs is observed at the 
cellular level, which leads to an excess of bone resorption over bone formation.  
Osteoporosis is divided in two types: postmenopausal (type I) and aged-related (type II) 
osteoporosis. Aged-related osteoporosis, which is characterised by a slow phase of continuous 
bone loss, affects both women and men, while postmenopausal osteoporosis (type I), defined 
as an early rapid bone loss due to the brutal decrease of sex steroid secretion after menopause, 
is only observed in women (Figure 8). The type II osteoporosis is principally associated with 
a continuous elevation of parathyroid hormone (PTH) level leading to an increased bone 
resorption. Principal reasons of the hyperparathyroidism are a vitamin D deficiency and 
consequences of estrogen deficiency. As mentioned above, estrogens play the major role in 
regulating bone resorption in men, whereas both estrogens and testosterone are important for 
maintaining bone formation51
 
, explaining the late slow bone loss in elderly men. Men are 
therefore more protected against osteoporosis. 
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Figure 8: Differences in bone gain and bone loss in men and women (taken from 
Pietschmann P. et al.52) 
 
Because the elderly people represent the fastest growing age-group worldwide, 
osteoporosis is an important public disease, which needs to have efficient treatments. 
 
1.4.4. Approach to the treatment of osteoporosis 
 
Several drugs are already available to treat osteoporosis53. They are classified depending 
on their action on bone resorption (antiresorptive agents) or on bone formation (anabolic 
agents 54
 
). Antiresorptive drugs include calcium, vitamin D, hormone therapy, 
bisphosphonates, selective estrogen-receptor modulators (SERM) and calcitonin, while 
anabolic treatment cover only parathyroid hormone (PTH). As summarised in table 4, various 
drugs are efficient for the treatment of osteoporosis, but their efficacy depends on the age, the 
presence or absence of prevalent fractures and the BMD. In the following part, the most often 
used drugs to treat osteoporosis will be described in more detail.  
Table 4: Antifracture efficacy of the most frequently used treatments of osteoporosis 
Drug Vertebral fractures Non-vertebral fractures  
Parathyroid hormone (PTH) +++ ++ 
Alendronate (bisphosphonate) +++ ++ 
Risedronate (bisphosphonate) +++ ++ 
Raloxifene (SERM) +++ 0 
Hormone replacement therapy + 0 
Calcitonin + 0 
Denosumab (RANKL inhibitor) +++ ++ 
+++: strong evidence; ++: good evidence; +: some evidence; 0: no effects. 
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1.4.4.1. Parathyroid hormone (PTH) 
 
Human recombinant PTH peptide 1-34 (teriparatide) 55, which is able to rebuild bone, is 
the treatment of choice for elderly patients, who already suffer from advanced bone loss. It 
improves bone density and reduces vertebral and non-vertebral fracture risks of about 50%. 
The main risk of teriparatide is a probable increase of osteosarcoma, seen in rat studies56
 
. 
Because of this risk and a restrictive daily subcutaneous injection, it is used as second line 
therapy and no more than two years. 
1.4.4.2. Bisphosphonates 
 
Bisphosphonates57
 
, analogues of pyrophosphate characterised by a P-C-P bond, are potent 
inhibitors of bone resorption and effective therapies for the treatment of osteoporosis. Several 
bisphosphonates have been synthesised and their activity depend on the side chain directly 
bond to the carbon. Bisphosphonates reduce the activity of OC and increase their apoptosis. 
They have only low oral bioavailability (between 1% and 3% of the taken dose) and the half 
time of these drugs in bone is several years. Four main bisphosphonates are used nowadays 
for the treatment of osteoporosis: ibandronate, alendronate, risedronate and zoledronate 
(Figure 9).  
Figure 9: Structures of some bisphosphonates used to treat osteoporosis 
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All biphosphonates clearly prevent postmenopausal bone loss. Zoledronate seems to be 
the most efficacious bisphosphonates for reducing vertebral fractures by 79%, and with 
alendronate also for reducing hip fractures, 47% and 37% respectively, while risedronate 
showed the greatest non vertebral-non hip fracture reductions (87%). Various adverse 
effects 58 , 59
 
 are attributed to bisphosphonates, as e.g. gastrointestinal problems or 
hyperparathyroidism and musculoskeletal pain. 
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1.4.4.3. Selective estrogen receptor modulators (SERMs) 
 
SERMs are a class of chemically diverse molecules, which possess a tertiary structure 
able to bind to ERα and/or ERβ. They act as estrogen agonists or antagonists, dependent on 
the target tissue. Therefore they offer the opportunity to dissociate favourable estrogenic 
effects on the bone (agonist) from unfavourable effects on the breast and endometrium 
(antagonist). Raloxifene60,61, the first SERM synthesised, reduces risk of vertebral fractures  
by about 30-50% but was not active towards non-vertebral fractures. It also decreases the risk 
of developing breast cancer. However, it can increase the risk of venous thromboembolic 
disease and hot flushes. The potential of raloxifene to reduce fracture and breast cancer risks 
led to further development of new SERMs62. Tamoxifene, initially used to treat breast cancer, 
has a positive effect on bone but increases risk of endometrial cancer. It was eliminated as a 
possible therapy for osteoporosis. A new generation of SERMs is now under investigation, 
like lasofoxifene63
 
, which reduces risks of vertebral and non-vertebral fractures, breast cancer, 
coronary heart disease and stroke but is associated with an increased risk of venous 
thromboembolism and hot flushes. The research is going on for new SERMs that have 
beneficial effect on bones and reduced breast cancer risks. 
1.4.4.4. RANKL inhibitor 
 
As the interaction of RANKL with its functional receptor RANK is the final step of the 
regulation of bone resorption, inhibition of RANKL64 is a new concept to treat osteoporosis. 
Thus, binding to its receptor, RANK is able to control the differentiation and the survival of 
OCs. Inhibition of RANKL could therefore reduce and regulate the activity of the OCs. 
Denosumab65, which was recently admitted to the market by the European and American 
Commissions (May and June 2010, respectively), is the only RANKL inhibitor known until 
today. It is a fully human immunoglobin G2 monoclonal antibody. It binds to RANKL, 
blocking interaction with its receptor on the surface of OCs, permitting a decrease of bone 
resorption and an enhancement of bone mass. Denosumab is as effiective as the 
bisphosphonate risendronate and it has to be given subcutaneously every six months, but it 
has been proved its efficacy only in post-menopausal women with a high risk of fractures66
 
. 
Further studies will be extended to other group of patients with normal risks of fractures. 
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1.5. Is 17β-HSD2 a good target for the treatment of osteoporosis? 
 
As described in chapter 1.4.2., estradiol plays a crucial role in the development of 
osteoporosis because the hormone deficiency in elderly people has a direct effect on the 
cellular level of the skeleton and thus it enhances bone resorption. As 17β-HSD2 is present in 
osteoblastic cells, inhibition of this enzyme could increase the E2-level in this tissue, thus 
allowing for a novel approach for the treatment of osteoporosis. 
Recently, the in vivo efficacy of the pyrrolidinone C (Table 3, 17β-HSD2 inhibitor) has 
been evaluated in an osteoporosis monkey model. The study proved that inhibition of 17β-
HSD2 leads to high local E2 and T levels and maintains a balance between bone formation 
and bone resorption. But when compound C is orally administrated, a strong variability is 
observed, certainly due to non appropriate pharmacokinetic properties of C. Thus, according 
to this study, inhibition of 17β-HSD2 could be a novel approach for the treatment of 
osteoporosis. To be sure this needs to be demonstrated again in an animal disease model with 
potent 17β-HSD2 inhibitors, provided they have good pharmacokinetic properties. 
In conclusion, new potent and selective 17β-HSD2 inhibitors with appropriate 
pharmacokinetic properties should be identified for further in vivo experiments, to prove the 
concept that inhibition of 17β-HSD2 is able to inhibit osteoclastogenesis and induce bone 
formation. 
 
AIM   
 - 16 - 
2. AIM OF THE PRESENT STUDY 
 
2.1. Scientific goal 
 
Osteoporosis is a skeletal disease characterised by an accelerated bone loss after 
menopause and in elderly men due to the rapid decrease of E2 and T levels in blood. E2 is 
therefore essential for the health of bones. 17β-HSD2 is responsible for the conversion of the 
highly active E2 into the less active E1. 17β-HSD2 is expressed in bone tissue. Thus, the 
development of drug-like selective 17β-HSD2 inhibitors could be a new promising approach 
for the treatment of osteoporosis. The efficacy of the proposed new treatment has yet to be 
proven. Only few inhibitors of 17β-HSD2 have been described in the literature. The effect of 
one of them, the pyrrolidinone C, has been evaluated in a monkey osteoporosis model. High 
local estrogen and testosterone levels have been observed, leading to a desirable bone balance 
between bone formation and bone resorption. Strong variablity has also been reported when 
orally administrated, certainly due to non appropriate pharmacokinetic properties. 
Therefore, the goal of this thesis was to develop new non-steroidal drug-like 17β-HSD2 
inhibitors, with IC50 values in the low nanomolar range, selective towards 17β-HSD1, 
catalysing the reverse reaction and towards ERα and ERβ as it is expected that the effects are 
ER-mediated. In a first step, compounds exhibiting activity in cell-free as well as in intact 
cells (MDA-MB-231) have to be found. After having identified potent human enzyme 
inhibitors, their activity will be determined in other species (rat, mouse and monkey) in order 
to have potential candidates for validation in animals to obtain the proof of concept that 17β-
HSD2 inhibitors can act as inductor of bone formation. 
The present work is focused on the design, synthesis and evaluation of the structure 
activity relationships (SAR) of potential 17β-HSD2 inhibitors. The work starts from 
derivatives obtained as part of the in-house 17β-HSD1 project.  
 
2.2. Working strategy 
 
As no X-ray structures and no homology model were available, in this thesis a ligand 
based approach was pursued. The compounds should have a non-steroidal structure, however, 
they should bind in the substrate binding site of 17β-HSD2 mimicking E2. For this they 
should have two polar moities distant from each other circa 11Å, mimicking position C3 and 
C17 of the steroid and possess a hydrophobic central core as E2 (Figure 10). 
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Figure 10: Simple pharmacophore model 
HO
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A preliminary study of Frotscher M. et al.67
 
 aiming at the design of non-steroidal 17β-
HSD1 inhibitors, resulted in a promising starting point for the development of 17β-HSD2 
inhibitors. The scaffold, composed from a naphthalene moiety substituted in position 6 by a 
phenyl ring mimicks the central hydrophobic core of E2. The positions of both hydroxy 
groups (distant from each other circa 11 Å) have been investigated in the first chapter of this 
thesis, as well as the influence of substituents replacing the OH group on the phenyl moiety. 
Additionally, structural optimisation of the naphthalene moiety has been explored (Figure 11). 
The results of this study are presented in chapter 3.I. 
According to the results of the first project (Chapter 3.I), and after synthesis of fourty 
four derivatives, a clear SAR has been depicted: a H-bond donor is highly necessary in meta 
or para position of the phenyl and some space is available around the phenyl moiety. The 
investigation of the size and the nature of additional substituents was the subject of the second 
part of this work. (Figure 11, Project II, chapter 3.II).  
 
In order to have access to a broad structural diversity of potential drug candidates, the 
decision was taken to also investigate other compound classes. In the frame of the in-house on 
going 17β-HSD1 project, Oster A. et al.68
 
 identified compound F (Figure 12) as a moderate 
17β-HSD2 inhibitor. Compound F has been taken as starting point for an additional 
compound class as it satisfies the two conditions mentioned above (Figure 11, Paper III, 
chapter 3.III). Structural optimisation of the thiophene derivative (replacement of the methyl 
group, introduction of substituents on the benzoyl part of the molecule) has been studied to 
increase activity of F and to reverse the selectivity in favour of 17β-HSD2. Results of this 
work are presented in chapter 3.III (Figure 11, Paper III). 
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Figure 11: Structure overview of the molecules reported in this thesis 
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Figure 12: Starting point of a new class of 17β-HSD2 inhibitor (Chapter 3.III) 
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3. RESULTS 
 
3.1. 17β-HSD2 inhibitors for the treatment of 
osteoporosis: identification of a promising scaffold 
 
Marie Wetzel
 
, Sandrine Marchais-Oberwinkler and Rolf W. Hartmann  
This manuscript has been published as an article in the journal  
Bioorganic and Medicinal Chemistry, 2011, 19, 807-815 
 
Paper I 
Abstract 
 
17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyses the conversion of active 
17β-hydroxysteroids into the less active 17-ketosteroids thereby controlling the availability of 
biologically active estrogens (E2) and androgens (T) in the tissues. The skeletal disease 
osteoporosis occurs mainly in post-menopausal women and in elderly men when the levels of 
estrogens and androgens, respectively, decrease. Since 17β-HSD2 is present in osteoblasts, 
inhibition of this enzyme may provide a new and promising approach to prevent the onset of 
osteoporosis, keeping a certain level in estrogens and androgens in bone cells of ageing 
people. Hydroxynaphthyl, hydroxyphenyl and hydroxymethylphenyl-substituted moieties 
were synthesised as mimetics of the steroidal substrate. Compound 8 has been identified as 
promising scaffold for 17β-HSD2 inhibitors displaying high activity and good selectivity 
toward 17β-HSD1, ERα and ERβ. 
 
Introduction 
 
Osteoblasts (OB) and osteoclasts (OC), two bone cells, are responsible for bone formation and 
bone resorption, respectively. In bone physiology of healthy individuals, bone mass is 
maintained by a well regulated balance between the activity of OBs and OCs. 
Osteoporosis1 is a skeletal disease, characterised by a reduced bone mineral density (BMD), 
increased bone fragility and predisposition to fractures. The most common osteoporotic 
fractures occur at the hip, spine and wrist, leading to pain and amplifying mortality. In post-
menopausal women and elderly men, there is an acceleration of bone loss, because of higher 
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activity of the OCs compared to the one of OBs. As androgens and estrogens appear to be the 
most important sex steroids2 involved in osteoclastic resorption and osteoblastic formation, a 
decrease in estrogens in post-menopausal women and in both androgens and estrogens in 
elderly men results in a disproportion between bone loss and bone formation and often leads 
to osteoporosis. 
Antiresorptive agents, including bisphosphonates and selective estrogen receptor modulators 
(SERM) are often used to treat osteoporosis. Bisphosphonates (like alendronate)3 are 
currently the most potent agents for the treatment of osteoporosis. However they lead to 
reduction of only 50% of fracture risks in post-menopausal women3, 4 and elderly men.5 The 
SERM raloxifene,6 is also efficient to treat osteoporosis but is associated with an increased 
risk of venous thromboembolism.7 
As all therapies used nowadays for the treatment of osteoporosis have limitations and none of 
them offers a complete cure, there is a need to develop other efficient drugs for this disease. 
There is evidence that androgens and estrogens play a crucial role in the development of 
osteoporosis.8 Although they belong to the antiresorptive agents, estrogens act on the OBs, 
regulating the ability of the OC precursors to differentiate to OCs (osteoclastogenesis). 
Estrogens can also enhance OB proliferation9 as well as osteoprotegerin (OPG) gene 
expression10 and alkaline phosphatase (ALP) activity10. While OB proliferation and ALP 
increase11 are beneficial for bone formation, OPG via osteoclastogenesis inhibition reduces 
bone resorption. Therefore a drug, which could increase the estrogen levels in the OBs should 
result in a local increase of OB cell proliferation, OPG and ALP production, and should have 
beneficial effect on osteoporosis. While a decrease in estrogen and androgen levels can easily 
be obtained either systematically by the use of aromatase12 and CYP1713, 14 inhibitors or 
locally by inhibitors of 17β-HSD115-19 or 5α-reductase,20-22 an intracellular increase of both 
sex hormones should also be feasible.  
High levels of E2 and T should be obtained in bone cells only in order to avoid development 
of breast and prostate cancer. This goal could be achieved by inhibiting 17β-hydroxysteroid 
dehydrogenase type 2 (17β-HSD2, Chart 1) in the target tissues. 
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Chart 1. Interconversion of estradiol (E2) to estrone (E1) by 17β-HSD1 and 17β-HSD2 and 
of testosterone (T) to androstenedione (A-dione) by 17β-HSD2 and 17β-HSD3. 
O
OH
OH
OH
O
O
OH
O
17β-HSD1, NADPH
17β-HSD2, NAD+
E1E2
17β-HSD2, NAD+
T A-dione
17β-HSD3, NADPH
 
 
17β-HSD2 catalyses the conversion of active 17β-hydroxysteroid estrogen E2 and androgen T 
into their less active 17-ketosteroids using the cofactor NAD+. 17β-HSD2 is a trans-
membrane protein23 and its 3D-structure is unknown. It is mainly expressed in placenta, liver, 
small intestine, endometrium and osteoblastic cells.24 As 17β-HSD2 is present in bone cells24, 
25 and is responsible for the deactivation of active estrogens and androgens, inhibitors of 17β-
HSD2 could maintain a certain level in active sex steroids in bone tissue, and therefore could 
protect against bone loss and structure deterioration. Therefore 17β-HSD2 is a new attractive 
target for the treatment of osteoporosis. 
Only very few inhibitors of 17β-HSD2 (Chart 2) have been described until now.26-29 The 
steroidal spirolactone (Chart 2) was the first 17β-HSD2 inhibitor identified.26-28 Within the 
non-steroidal ones, some flavonoids like 3-hydroxyflavone have been described in the 
literature as 17β-HSD2 inhibitors.30 However, regarding 17β-HSD1 they were not very 
selective. The pyrrolidinone A is until now the most potent inhibitor described in the 
literature. It was evaluated in vivo in a monkey osteoporosis model by Bagi et al.31 In spite of 
the small effects observed at the highest dose and a strong variability when administrated 
orally, certainly due to an inappropriate pharmacokinetic profile, this study validates 17β-
HSD2 as potential target for the treatment of osteoporosis. Therefore there is a need for new 
potent inhibitors with good pharmacokinetic properties for further in vivo experiments. 
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Chart 2. Inhibitors of 17β-HSD2 
O
OH
O
NO
OH
S
F
C-18 spirolactone
62-66% at 1µM
Pyrrolidinone
IC50 = 10 nM
A  
 
In this report, the design of novel and selective inhibitors derived from substituted 1-
hydroxynaphthyl, 4-hydroxymethylphenyl and 4-hydroxyphenyl (Tables 1 and 2) as well as 
their synthesis and biological evaluation regarding inhibition of 17β-HSD2 and 17β-HSD1 
will be presented. 
 
Design of inhibitors 
 
As flavonoids are known to interact with several pharmacological targets, we refrained from 
using these structures as a starting point. A similar structure, 6-(3-hydroxyphenyl)-2-naphthol 
(compound B) was recently identified by Frotscher et al.15 as a highly potent 17β-HSD1 
inhibitor. In spite of the low sequence identity32 and homology32 (23% and 45%, 
respectively), the active site of 17β-HSD1 and 17β-HSD2 is considered to be very similar as 
the substrate of one enzyme is the product of the catalytic reaction of the other enzyme (Chart 
1). Taking advantage of our experience developing 17β-HSD1 inhibitors, the 
hydroxyphenylnaphthol scaffold of compound B was considered as promising starting point 
for the identification of new inhibitors of 17β-HSD2. To improve the activity of compound B 
in favour of 17β-HSD2 inhibition, the optimal position of the hydroxy groups was 
investigated first. In the second step, one hydroxy group was replaced by different 
substituents using the best scaffold. Subsequently, the naphthalene core was exchanged either 
by hydroxyphenyl or by hydroxymethylphenyl moiety.  
 
Chemistry 
 
Compounds 1-4 and 6 were synthesised following the procedure described by Frotscher et 
al.15 The synthesis of 5 started from the commercially available 6-methoxy-1-tetralone 5e, 
which is converted to the hydroxy analogue 5d by an ether cleavage using aluminium 
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trichloride33 and subsequently triflated34 to 5c. Bromination,35 followed by 
dehydrobromination35 gave the desired naphth-1-ol 5a in very good yield. Different 
substituted phenyl (5, 7-14, 19-24) or heteroaromatic rings (15-18) were introduced into the 6-
position of the naphthalene core via Suzuki coupling36 reaction (Scheme 1, Method A or B).  
 
Scheme 1. Synthesis of compounds 5 and 7-24a 
O
R1
O
OTf
Br
OH
OTf
OH
R
OH
R
a
b
c
5e R1: OCH3
5d R1: OH
5c R1: OTf
5b
d
e
3
4
5 R: H
7 R: 4-OCH3
8 R: 4-OH
9 R: 4-CH2OH
10 R: 4-F
11 R: 4-NO2
12 R: 4-CN
13 R: 4-COCH3
14 R: 4-COOH
19 R: 4-SO2NHCH3
20 R: 4-NHSO2CH3
21 R: 3-NHSO2CH3
22 R: 4-CONHCH3
23 R: 3-CONHCH3
24 R: 3-NHCOCH3
15 R: 4-pyridyl
16 R: 5-pyrimidyl
17 R: 4-OCH3-3-pyridyl
18 R: 3-furanyl
5a
e or f
aReagents and conditions: a. AlCl3, toluene, reflux, 2h; b. (CF3CO)2O, pyridine, 0°C, 30 min; c. Br2, CCl4, diethylether, 
0 °C, 4h; d. LiBr, Li2CO3, DMF, reflux, overnight; e. R-boronic acid, Pd(PPh3)4, Na2CO3, DME/EtOH 1:1, 85 °C, 2h for 5
and 7-18, Method A; f. R-boronic acid, Pd(PPh3)4, Na2CO3, DME/water 2:1, microwave irradiation (150°C, 150 W,  25
min) for 19-24, Method B.
 Synthesis of 25, 27 and 36 occurred in a two steps reaction: amidation (Method C) between 
benzoyl chloride and 3-aminophenylboronic acid37 afforded the intermediate 25a and a 
subsequent Suzuki coupling (Scheme 2) with the appropriate boronic acid led to the target 
compounds. 
 
Scheme 2. Synthesis of compounds 25, 27 and 36a 
ClO NH2
B(OH)2
N
H
O B(OH)2 N
H
O R
+
a b
25a 25 R: 5-hydroxy-2-naphthyl
27 R: 4-hydroxymethylphenyl
36 R: 4-hydroxyphenyl 
aReagents and conditions: a. Et3N, CH2Cl2, room temperature, 1h, Method C; b. R-Br or R-OTf, Pd(PPh3)4, Na2CO3, 
DME/EtOH 1:1, 85 °C, 2h, Method A.  
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Starting from 4-hydroxymethylbromophenyl or 4-bromophenol, compounds 26, 33, 35 and 43 
were obtained via a cross-coupling reaction under microwave assisted conditions (Scheme 3, 
Method B). 
 
Scheme 3. Synthesis of compounds 26, 33, 35 and 43a 
Br
OH n
 OH
n
 
R
a
4
3
26 R: 3-NHCOCH3, n=1
33 R: 4-NHSO2CH3, n=1
35 R: 3-NHCOCH3, n=0
43 R: 4-NHSO2CH3, n=0
aReagents and conditions: a. R-boronic acid, Pd(PPh3)4, Na2CO3, 
DME/Water 2:1, microwave irradiation 150 °C, 150 W, 15 bar,
 25 min, Method B.  
 
The synthesis of compounds 28-32 and 37-42 started from the 3-bromo-N-methylaniline 
which was coupled to different benzoyl chlorides following method C (Scheme 4) to form the 
amides 28a-32a. Subsequent Suzuki cross couplings with the appropriate boronic acids 
afforded 28-32, 37-40 and 42. Compound 40 was further demethylated38 with boron 
tribromide to give compound 41 in high yield. 
 
Scheme 4. Synthesis of compounds 28-32 and 37-42a 
N
H
Br
ClO
R1
N
O
n
 Br
R1
OR2
B(OH)2
OH
B(OH)2
R1
R1
N
O
n
 
OH
N
O
n
 
OR
+
28a R1: H, n= 0
29a R1: 3-OCH3, n= 0
30a R1: 4-OCH3, n= 0
31a R1: 3-OCH3, n= 1
32a R1: 4-OCH3, n= 1
3
4
28 R1: H, n= 0
29 R1: 3-OCH3, n= 0
30 R1: 4-OCH3, n= 0
31 R1: 3-OCH3, n= 1
32 R1: 4-OCH3, n= 1
3
4
4
3
37 R1: H, R2: H, n= 0
38 R1: 3-OCH3, R2: CH3, n= 0
39 R1: 4-OCH3, R2: CH3, n= 0
40 R1: 3-OCH3, R2: CH3, n= 1
41 R1: 3-OH, R2: H, n=1
42 R1: 4-OCH3, R2: CH3, n= 1
a
b b
aReagents and conditions: a. Et3N, CH2Cl2, room temperature, 1h, Method C; b. Pd(PPh3)4, 
Na2CO3, DME/Water 2:1, microwave irradiation, 150 °C, 150 W, 15 bar, 25 min, Method B;
c. BBr3, CH2Cl2, -78°C to room temperature, overnight.
2
c
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The synthesis37 of the sulfonamide derivative 34a was carried out by reaction of 4-
bromoaniline with 3-methylphenylsulfonylchloride (Scheme 5). Subsequent Suzuki coupling 
with the corresponding boronic acids afforded sulfonamides 34 and 44. 
 
Scheme 5. Synthesis of compounds 34 and 44a 
Br
NH2 SO O
Cl
Br
NH
S
O
O NH
S
O
O
R
+
34 R: CH2OH
44 R: OH
a b
34a
aReagents and conditions: a. pyridine, room temperature, overnight; b. R-phenylboronic acid, Pd(PPh3)4,
Na2CO3, DME/Water 2:1, microwave irradiation, 150 °C, 150 W, 15 bar, 25 min, Method B.  
 
Biological results 
 
Inhibition of human 17β-HSD2 and selectivity toward 17β-HSD1, ERα and β 
 
17β-HSD2 and 17β-HSD1 inhibitory activities of the synthesised compounds were evaluated 
in cell-free assays. As 17β-HSD1 catalyses the reduction of E1 to E2, it should not be affected 
by 17β-HSD2 inhibitors. Moreover, inhibitors of 17β-HSD2 should have no affinity for the 
estrogen receptors ERα and β, as it is expected that E2 effects are ER mediated. 
Human placental enzymes were used as source of enzymes for both assays and were obtained 
according to described methods.39-41 In the 17β-HSD2 assay, incubations were run with 
tritiated E2, cofactor and inhibitor.41 The separation of substrate and product was 
accomplished by HPLC. The 17β-HSD1 assay was performed similarly using tritiated E1 as 
substrate. The percent inhibition values of compounds 1-44 are shown in Tables 1 and 2, and 
the IC50 values of selected compounds are reported in Table 3. Compounds showing less than 
10% inhibition tested at a concentration of 1µM were considered to be inactive. The 6-(3-
hydroxyphenyl)-2-naphthol B identified in a previous work15 was used as internal reference 
(20% 17β-HSD2 inhibition vs. 100% 17β-HSD1 inhibition at 1µM). 
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To identify the best scaffold for a high 17β-HSD2 inhibition, the questions were examined 
whether two hydroxy substituents are necessary for inhibition and which positions on the 6-
phenylnaphthalene moiety were optimal. Compounds bearing only one hydroxy group, either 
on the naphthalene (compounds 3 and 5) or on the phenyl (compound 4) core turned out to 
have a weak 17β-HSD2 inhibitory activity (Table 1).  
 
Table 1. Inhibition of human 17β-HSD2 and 17β-HSD1 by compounds 1-25 
R
OH
R
R
15-18B, 1-14, 19-25
4´
3´
2
1
1
2
3
 
Cmpd R1 R2 R3 
Inhibition of 
17β-HSD2 [%]a 
at 1 µM 
Inhibition of 
17β-HSD1 [%]b 
at 1 µM 
B 2-OH 3´-OH - 20 100 
1 2-OH 2´-OH - n.i. n.i.c 
2 2-OH 4´-OH - n.d. n.i.c 
3 2-OH H - 17 44 
4 H 3´-OH - 12 61c 
5 1-OH H - 20 n.i. 
6 1-OH 3´-OH - 32 23c 
7 1-OH 4´-OCH3 - 20 28 
8 1-OH 4´-OH - 74 20 
9 1-OH 4´-CH2OH - 31 14 
10 1-OH 4´-F - n.i. n.i. 
11 1-OH 4´-NO2 - 13 15 
12 1-OH 4´-CN - 12 16 
13 1-OH 4´-COCH3 - n.i. 16. 
14 1-OH 4´-COOH - 16 n.i. 
15 - - 4-pyridyl 26 n.i. 
16 - - 5-pyrimidyl n.i. n.i. 
17 - - 
4-OCH3- 
3-pyridyl 
n.i. n.i. 
18 - - 3-furanyl 13 n.i. 
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Table 1 continued 
Cmpd R1 R2 R3 
Inhibition of 
17β-HSD2 [%]a 
at 1 µM 
Inhibition of 
17β-HSD1 [%]b 
at 1 µM 
19 1-OH 4´-SO2NHCH3 - 57 12 
20 1-OH 4´-NHSO2CH3 - 75 52 
21 1-OH 3´-NHSO2CH3 - 22 19 
22 1-OH 4´-CONHCH3 - 13 n.i. 
23 1-OH 3´-CONHCH3 - 43 n.i. 
24 1-OH 3´-NHCOCH3 - 64 12 
25 1-OH 3´-NHCOPh - n.i. n.i. 
a Human placenta, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], NAD+ [1.5 mM], mean value of 3 
determinations, relative standard deviation < 10%, b Human placenta, cytosolic fraction, substrate [3H]-E1 + E1 
[500 nM], NADH [0.5 mM], mean value of 3 determinations, relative standard deviation < 10%, crecombinant 
human 17β-HSD1, substrate [3H]-E1+ E1 [30 nM], cofactor NADPH [1 mM], mean value of two 
determinations, relative standard deviation < 20%, n.d. not determined, n.i.: no inhibition (inhibition < 10%).  
 
Compounds with two OH groups can be separated in two different groups depending on the 
position of the hydroxy moiety on the naphthalene ring: 2-naphthols (B, 1-2) and 1-naphthols 
(6-25). 2-naphthols are not appropriate as scaffold for 17β-HSD2 inhibitors as all compounds 
turned out to be inactive. 
Concerning the 1-naphthols, compounds 6 and 7 substituted with a meta-hydroxy (6) or a 
para-methoxy (7) group on the phenyl moiety displayed only very low activity. However, a 
para-hydroxy substituent (8) improved activity (74% inhibition at 1 µM) indicating that 1) the 
para-position is more appropriate than the meta-position and 2) H-bond interactions are likely 
to occur with the enzyme. 
Looking at these results, it appears that two hydroxy groups are crucial for the activity and the 
distance between them must be around 11Å as observed for E2 and 8. The structure of 
inactive B is very similar to the active 8: they both consist of a hydroxylated naphthol and a 
hydroxylated phenyl, and the distance between the two OH groups are identical. These 
compounds differ only in their hydroxy substitution pattern which seems to play a very 
important role for 17β-HSD2 or 17β-HSD1 inhibition. In order to better understand these 
results, 8 and B were superimposed using their hydroxy groups as fixed points (Chart 3). It 
can be observed that the central aromatic rings of B and 8 occupy a different space in the 
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enzyme. It is likely that the presence of at least one amino acid of the active site of 17β-HSD2 
around ring BB is responsible for the selectivity observed for 8 in favour of 17β-HSD2. 
 
Chart 3. Superimposition of compounds B and 8. 
 
 
 
The dihydroxylated compound 8 can be considered as a promising core structure. In order to 
improve its activity and to limit the number of hydroxy functions (often responsible for a fast 
metabolism as OH groups are substrates for phase II metabolism), either the hydroxy group of  
the phenyl moiety was replaced by different substituents (9-14, 19-25) or the 4-
hydroxyphenyl was exchanged by different heteroaromatic rings (15-18).  
Introduction of a methylene linker between the phenyl and the hydroxy group (9) led to a 
strong decrease in activity, possibly due to the flexibility of the OH group and a too long 
distance between the two hydroxy groups. 
Exchange of the hydroxy moiety by a withdrawing group like fluoro (10), nitro (11), cyano 
(12), acetyl (13) or carboxylic (14) led to inactive compounds, indicating that only electron 
donating groups are tolerated by the enzyme in this region or that a H-bond donor group is 
necessary for activity. A series of sulfonamides, reversed sulfonamides and amides in 
positions 3 or 4 were introduced as replacement of the hydroxy function. Amides were better 
tolerated in 3-position and sulfonamides in 4-position (64% 17β-HSD2 inhibition at 1 µM for 
amide 24; 57% and 75% for sulfonamide 19 and reverse sulfonamide 20). These results point 
out the importance of the H-bond donor group directly attached to the phenyl ring: good 
inhibition data were obtained in case of the amide (in 3-position 24) or sulfonamide (in 4-
position 20) which are linked to the ring by the NH and therefore able to mimic the OH group 
of 8. The inactivity of 25 is probably due to a steric clash between the large phenylamide 
group and amino acids from the active site.  
Various heteroaromatic rings were also introduced in 6-position of the naphthalene 
(compounds 15-18). None of them turned out to be active, proving that the hydroxy 
substituent on the phenyl of 8 can not be replaced by a pure H-bond acceptor group, a H-
donor in this position is essential for the activity. 
B 8 
BA 
BB 
8B 8A 
O H 
O H 
BA BB 
O H 
O H 
8A 8B 
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In order to simplify the rather lipophilic scaffold of the naphthalene, the 1-naphthol moiety 
was replaced either by 4-hydroxymethylphenyl or by 4-hydroxyphenyl groups. The exchange 
of the 1-naphthol for a 4-hydroxymethylphenyl was detrimental for the activity: the amide 26 
(to be compared to the 1-naphthol 24 64% inhibition at 1 µM) and sulfonamide 33 (to be 
compared to the 1-naphthol 20 75% inhibition at 1 µM) turned out to be completely inactive 
(Table 2). In order to gain activity in this class of compounds, different substituted amides 
(27-32) and sulfonamides (34) were introduced but also turned out to be either weakly active 
or inactive. Elimination of the methylene linker (compounds 35-44) leading to 4-
hydroxyphenyl derivatives was not appropriate to regain activity: the amide 35 (to be 
compared to the 1-naphthol 24 64% inhibition at 1 µM) and sulfonamide 43 (to be compared 
to the 1-naphthol 20 75% inhibition at 1 µM) were also inactive. These results emphasise the 
importance of the aromatic ring 8A of the 1-naphthol, which certainly stabilise the molecule 
in the active site via π-π-interactions. However, introduction of a methyl on the nitrogen of 
the phenyl amide 37 or of the benzylamide 41 led to a regain of activity (46% and 39% 
inhibition at 1µM for 37 and 41, respectively). All methoxy derivatives (38-40 and 42) were 
devoid of activity. 
 
Table 2. Inhibition of human 17β-HSD2 and 17β-HSD1 by compounds 26-44 
OR
n
 
N
R
R4
3
26-441
2
3
 
Cmpd n R1 
Position 
substi-
tution 
R2 R3 
Inhibition 
of 
17β-HSD2 
[%]a 
at 1 µM 
Inhibition 
of 
17β-HSD1 
[%]b 
at 1 µM 
26 1 H 3 H COCH3 n.i. n.i. 
27 1 H 3 H COPh n.i. n.i. 
28 1 H 3 CH3 COPh n.i. n.i. 
29 1 H 3 CH3 COPh(3´-OMe) 15 n.i. 
30 1 H 3 CH3 COPh(4´-OMe) 14 n.i. 
31 1 H 3 CH3 COCH2-Ph(3´-OMe) 12 n.i. 
32 1 H 3 CH3 COCH2-Ph(4´-OMe) n.i. n.i. 
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Table 2 continued 
Cmpd n R1 
Position 
substi-
tution 
R2 R3 
Inhibition 
of 
17β-HSD2 
[%]a 
at 1 µM 
Inhibition 
of 
17β-HSD1 
[%]b 
at 1 µM 
33 1 H 4 H SO2CH3 n.i. n.i. 
34 1 H 4 H SO2Ph(3´-CH3) 12 n.i. 
35 0 H 3 H COCH3 n.i. n.i. 
36 0 H 3 H COPh n.i. n.i. 
37 0 H 3 CH3 COPh 46 n.i. 
38 0 CH3 3 CH3 COPh(3´-OMe) 13 16 
39 0 CH3 3 CH3 COPh(4´-OMe) 20 n.i. 
40 0 CH3 3 CH3 COCH2-Ph(3´-OMe) n.i. n.i. 
41 0 H 3 CH3 COCH2-Ph(3´-OH) 39 n.i. 
42 0 CH3 3 CH3 COCH2-Ph(4´-OMe) 10 25 
43 0 H 4 H SO2CH3 n.i. n.i. 
44 0 H 4 H SO2Ph(3´-CH3) 14 n.i. 
a Human placenta, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], NAD+ [1.5 mM], mean value of 3 
determinations, relative standard deviation < 10%, b Human placenta, cytosolic fraction, substrate [3H]-E1 + E1 
[500 nM], NADH [0.5 mM], mean value of 3 determinations, relative standard deviation < 10%, n.i.: no 
inhibition (inhibition < 10%).  
 
In order to evaluate the selectivity profile of these compounds, all synthesised molecules were 
tested for their 17β-HSD1 inhibition (Table 1 and 2). For the most potent inhibitors identified 
in this report, IC50 data for 17β-HSD2 and 17β-HSD1 were determined as well as their 
binding affinity to ERα and β (Table 3). The most interesting compound identified in this 
study is the 4-hydroxyphenyl-1-naphthol 8, with an IC50 of 302 nM for 17β-HSD2 inhibition. 
A certain selectivity toward 17β-HSD1 has been achieved (selectivity factor: 8). Taking into 
account the structural similarity between E2 and compound 8, it was important to evaluate the 
affinity of 8 to the ERs, which is expressed as relative binding affinity 42.43 The RBA 
measured represents the ligand affinity to ER, relative to that of E2 which is arbitrarily set up 
at 100%. With a RBA value of 5% for ERα and β, compound 8, however, has a similar 
affinity as E1 which is weakly estrogenic.44  
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Table 3. IC50 values, selectivity factor and binding affinities for the estrogen receptors (ER) α 
and β for selected compounds. 
Cmpd 
Cell free assay 
ERα 
RBA (%)d 
ERβ 
RBA (%)d 
17β-HSD2 
IC50 [nM]a 
17β-HSD1 
IC50 [nM]b 
Selectivity 
factorc 
B 5641 116 0.02 0.2 0.8 
8 302 2425 8 5 5 
20 600 614 1 n.d. n.d. 
24 696 8516 12 n.d. n.d. 
a Human placenta, microsomal fraction, substrate [3H]-E2+ E2 [500 nM], cofactor NAD+ [1.5 mM], mean value 
of 3 determinations, relative standard deviation < 10%, b Human placenta, cytosolic fraction, substrate [3H]-E1 
+E1 [500 nM], cofactor NADH [0.5 mM], mean value of 3 determinations, relative standard deviation < 20%, c 
IC50 (17β-HSD1)/ IC50 (17β-HSD2), d RBA: Relative Binding Affinity, E2: 100%; n.d.: not determined. 
 
Discussion and conclusion 
 
The goal of this study was the identification of a new non-steroidal scaffold for 17β-HSD2 
inhibition. This was a difficult task, considering the structural similarities between 17β-HSD2 
and 17β-HSD1 in their active sites. Taking advantage of our experience developing 17β-
HSD1 inhibitors in the class of hydroxyphenylnaphthols,15, 16 compound 8 was identified as 
potent and selective 17β-HSD2 inhibitor while compound B showed a high inhibitory activity 
for 17β-HSD1 only. Compounds B and 8 share several structural similarities, they differ only 
in their hydroxy substitution pattern: in B, one OH is in 2-position of the naphthalene and the 
other is in meta on the phenyl while in 8, the naphthalene is hydroxylated in 1-position and 
the phenyl in para (Chart 3). Because of the different hydroxy substitution pattern not only 
activity for 17β-HSD2 could be gained but also selectivity toward 17β-HSD1 could be 
reached. A minor structural change in the ligand can completely reverse the activity and 
selectivity profile. This indicates that the small differences between the active sites of these 
two enzymes are very important and can lead to a radical ligand discrimination. Further 
studies about selectivity regarding other 17β-HSDs and SDR enzymes will be evaluated in the 
future. Selectivity toward the ER which is an important issue could be gained by introduction 
of large substituents into this scaffold. 
As neither a 3D-structure nor a good homology model of 17β-HSD2 exists, the information 
on the active site architecture is limited and identification of amino acids which could be 
important for interaction with the potential inhibitors is not possible. Therefore in this study, 
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drug design was focused on a ligand-based approach using the substrate E2 and other ligands 
like B (17β-HSD1 inhibitor). In case of 17β-HSD1, several X-ray structures of the enzyme 
with or without ligand are available.45 In a previous work we mentioned that the 
hydroxyphenyl moiety of B certainly mimics the steroidal A-ring.15 The superimposition 
between the OH moieties of B (17β-HSD1 inhibitor) and of 8 (17β-HSD2 inhibitor) (Chart 3) 
also indicates that the hydroxyphenyl moiety of B most likely does not overlap with the one 
of 8, thus the OH-phenyl of 8 would mimic the steroidal D-ring, interacting with the catalytic 
triad. It can be expected that in this area of the enzyme, close to the catalytic triad, there is 
more free space available than close to the A-ring for a large substituent. This results is indeed 
in accordance with the biological data obtained for 20 and 24, where the hydroxy moiety (8, 
74% inhibition at 1 µM) is replaced by the larger methylsulfonamide (20, 75% inhibition at 1 
µM) or acetamide (24, 64% inhibition at 1 µM) without loss in activity. This finding will be 
further validated by substitution of OH-naphthalene or by introduction of substituent close to 
this hydroxy moiety in 8.  
Attempts to simplify the scaffold of compound 8 failed: one hydroxy group is not enough to 
stabilise the compound in the active site. The aromatic ring 8A of the naphthalene, mimicking 
the steroidal A-ring seems to be necessary for inhibitory activity, it might interact with the 
enzyme via π-π-interactions. 
Exchange of the hydroxy group on the phenyl moiety by electron withdrawing groups or 
exchange of the hydroxyphenyl by heteroaromatic rings led to a complete loss in activity 
indicating the crucial role of the hydrogen bond donating properties of the OH-phenyl moiety 
to stabilise the compound in the active site. 
The structure-activity relationship which can be deduced from the biological data gives very 
useful informations to map the unknown enzyme active site of 17β-HSD2.  
In this report, a new scaffold for 17β-HSD2 inhibitors was identified: the 4-hydroxyphenyl-1-
naphthol 8, with a good inhibitory activity (IC50 = 302 nM), a selectivity factor of 8 toward 
17β-HSD1 and only weak estrogenicity. As hydroxynaphthyl and hydroxyphenyl compounds 
have been associated with the formation of reactive intermediates and DNA-adducts, the 
safety of compound 8 will be further evaluated and attempts to improve the biological profile 
(activity, selectivity) will be performed.  
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Experimental Section 
 
Chemical Methods 
 
1H NMR and 13C NMR spectra were recorded on a Bruker DRX-500 instrument in CDCl3, 
CD3OD and acetone-d6. Chemicals shifts are reported in δ values (ppm), the hydrogenated 
residues of deuteriated solvent were used as internal standard (CDCl3: δ = 7.26 ppm in 1H 
NMR and δ = 77 ppm in 13C NMR, CD3OD: δ = 3.35 ppm in 1H NMR and δ = 49.3 ppm in 
13C NMR, acetone-d6: δ = 2.05 ppm in 1H NMR and δ = 29.8 ppm and 206.3 ppm in 13C 
NMR). Signals are described as br, s, d, t, dd, ddd, dt, qt and m for broad, singlet, doublet, 
triplet, doublet of doublets, doublet of doublet of doublets, doublet of triplets, quintuplet and 
multiplet, respectively. All coupling constants (J) are given in Hertz.  
IR spectra were measured neat on a Bruker Vector 33FT-infrared spectrometer. 
Mass spectra (ESI) were measured on a TSQ Quantum (Thermo Electron Corporation) 
instrument. 
All microwave irradiation experiments were carried out in a CEM-Discover microwave 
apparatus. 
Flash chromatography was performed using silica gel 40 (35/40-63/70 μM) with hexane/ethyl 
acetate mixtures as eluents. Reaction progress was monitored by thin-layer chromatography 
analyses on Alugram SIL G/UV254 (Macherey-Nagel). Visualisation was accomplished with 
UV light. Purifications with preparative HPLC were carried out on a Agilent 1200 series 
HPLC system from Agilent Technologies, using a RP C18 Nucleodur 100-5 column (30∙100 
mm/50 µm – from Macherey-Nagel GmbH) as stationary phase with acetonitrile/water as 
solvent in a gradient from 20:80 to 100:0.  
Tested compounds show ≥ 95% chemical purity as measured by HPLC. The methods for 
HPLC analysis and a table of data for all tested compounds are provided in the supporting 
information. 
Chemical names follow IUPAC nomenclature. Starting materials were used as obtained from 
Aldrich, Acros and Combi-blocks without further purification. No attempts were made to 
optimise yields. 
The following compounds were prepared according to previously described procedures: 6-(2-
hydroxyphenyl)-2-naphthol 1,34 6-(4-hydroxyphenyl)-2-naphthol 2,34 6-phenyl-2-naphthol 
3,15 3-(2-naphthyl)phenol 4,46 6-(3-hydroxyphenyl)-1-naphthol 6,34 6-(4-hydroxyphenyl)-1-
naphthol 8,34 5-oxo-5,6,7,8-tetrahydro-2-naphthyl trifluoromethanesulfonate 5c,34 6-hydroxy-
1,2,3,4-tetrahydronapthalen-1-one 5d,33 3-benzamidophenylboronic acid 25a.47  
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General procedures for Suzuki coupling 
Method A. To a mixture of arylbromide (1 equiv) and tetrakis(triphenylphosphine) palladium 
(0) (0.02 equiv) in DME was added a 2M aqueous solution of caesium carbonate (2 equiv). 
The mixture was purged with N2 and stirred at room temperature for 5 min. Subsequently a 
solution of boronic acid (1.2 equiv) in EtOH was added. The mixture was heated to 90°C for 
2h. The reaction mixture was cooled to room temperature, quenched with water and extracted 
with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and 
concentrated to dryness under reduced pressure. The product was purified by column 
chromatography. 
 
Method B. A mixture of arylbromide (1 equiv), boronic acid (1.2 equiv), sodium carbonate (2 
equiv), and tetrakis(triphenylphosphine) palladium (0) (0.02 equiv) was suspended in an 
oxygen-free DME/water (2:1) solution. The reaction mixture was exposed to microwave 
irradiation (25 min, 150W, 150°C, 15 bar). After reaching room temperature, water was added 
and the aqueous layer was extracted with ethyl acetate. The combined organic layers were 
washed with brine, dried over sodium sulfate and concentrated to dryness under reduced 
pressure. The product was purified by column chromatography. 
 
General procedure for amide bound formation 
Method C. N-methylaniline derivative (1 equiv) was mixed with Et3N (2 equiv) in 
dichloromethane. The solution was cooled at 0°C. The acyl chloride (1.2 equiv) was slowly 
added and the mixture stirred at room temperature for 1h. The reaction mixture was extracted 
with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate and 
concentrated to dryness under reduced pressure. The product was purified by column 
chromatography. 
 
6-Bromo-5-oxo-5,6,7,8-tetrahydro-2-naphthyl trifluoromethanesulfonate (5b). A solution 
of Br2 (1.1 g, 0.35 mL, 6.9 mmol, 1.05 equiv) in CCl4 (6 mL) was added dropwise to a stirred 
solution of 5-oxo-5,6,7,8-tetrahydro-2-naphthyl trifluoromethanesulfonate 5c (2.0 g, 6.8 
mmol, 1 equiv) in dry ether (60 mL). The ether solution contained 0.3 mL of etheral hydrogen 
chloride (1 M) and was maintained at 0-5°C throughout the addition. After the complete 
addition of bromine, the reaction mixture was stirred for another 30 min at the same 
temperature and then water was added followed by ether. The organic layer was separated and 
washed with water. The solvent was removed under reduced pressure to afford the expected 
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product in quantitative yield (2.5 g). C11H8O4BrSF3; MW 373; 1H NMR (CDCl3): δ 8.26 (d, J 
= 8.7 Hz, 1H), 7.57-7.55 (m, 1H), 7.54 (dd, J = 2.5 Hz, J = 8.7 Hz, 1 H), 3.29-3.25 (m, 3H), 
3.21-3.18 (m, 2H). 
 
5-Hydroxy-2-naphthyl trifluoromethanesulfonate (5a). A solution of 6-bromo-5-oxo-
5,6,7,8-tetrahydro-2-naphthyl trifluoromethanesulfonate 5b (5.3 g, 14.1 mmol, 1 equiv) in 
DMF (100 mL) containing a mixture of lithium bromide (2.8 g, 32.4 mmol, 2.3 equiv) and 
lithium carbonate (2.1 g, 28.2 mmol, 2 equiv) was refluxed for 4h in an atmosphere of 
nitrogen. The solvent was removed under reduced pressure and the residue was treated with 
ice cold water followed by cold diluted hydrochloric acid. The mixture was extracted with 
ether and the combined organic layers were washed with 10% NaOH. The alkaline extract 
was acidified and again extracted with ether. The solvent was removed under vacuum and the 
crude product was purified using silica gel chromatography (hexane/ethyl acetate 9:1) to 
afford 65% (2.7 g) of the analytically pure product. C11H7SO4F3; MW 292; 1H NMR 
(acetone-d6): δ 9.35 (s, br, 1H), 8.38 (d, J = 9.2 Hz, 1H), 7.90 (d, J = 2.8 Hz, 1H), 7.80 (d, J = 
8.6 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.36-7.33 (m, 1H), 7.00 (dd, J = 1.0 Hz, J = 7.6 Hz, 
1H); 13C NMR (acetone-d6): δ 148.7, 136.0, 129.5, 128.0, 126.8, 126.4, 123.0, 120.0, 119.7, 
118.5, 110.4; IR: 3243, 3111, 1422, 1137 cm-1. 
 
6-Phenyl-1-naphthol (5). The title compound was prepared by reaction of 5-hydroxy-2-
naphthyl trifluoromethanesulfonate 5a (200 mg, 0.68 mmol, 1 equiv) with phenylboronic acid 
(108 mg, 0.89 mmol, 1.3 equiv) according to method A. The analytically pure compound was 
obtained after purification by column chromatography (gradient hexane/ethyl acetate 10:0 to 
9:1) in 42% yield (63 mg) as a brown powder. C16H12O; MW 220; m.p.: 108-110°C; 1H NMR 
(acetone-d6): δ 9.00 (s, br, 1H), 8.33 (d, J = 9.2 Hz, 1H), 8.09 (d, J = 2.2 Hz, 1H), 7.81-7.77 
(m, 3H), 7.55-7.46 (m, 3H), 7.41-7.37 (m, 1H), 7.36-7.32 (m, 1H), 6.93 (dd, J = 1.0 Hz, J = 
7.4 Hz, 1H); 13C NMR (acetone-d6): δ 154.0, 141.8, 139.4, 136.3, 130.7, 129.8, 128.2, 128.1, 
127.6, 126.1, 125.0, 123.7, 120.4, 109.2; IR: 3370, 3060, 1582, 1259 cm-1; GC/MS m/z: 220 
(M)+. 
 
6-(4-Methoxyphenyl)-1-naphthol (7). The title compound was prepared by reaction of 5-
hydroxy-2-naphthyl trifluoromethanesulfonate 5a (200 mg, 0.68 mmol, 1 equiv) with 3-
methoxyphenylboronic acid (135 mg, 0.89 mmol, 1.3 equiv) according to method A. The 
analytically pure compound was obtained after purification by column chromatography 
(gradient hexane/ethyl acetate 10:0 to 9:1) in 54% yield (91 mg) as an orange oil. C17H14O2; 
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MW 250; 1H NMR (acetone-d6): δ 8.96 (s, br, 1H), 8.30 (d, J = 8.8 Hz, 1H), 8.03 (d, J = 2.0 
Hz, 1H), 7.76-7.72 (m, 3H), 7.43 (d, J = 8.0 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.08-7.04 (m, 
2H), 6.91 (dd, J = 0.9 Hz, J = 7.4 Hz, 1H), 3.86 (s, 3H); 13C NMR (acetone-d6): δ 160.5, 
154.0, 139.1, 136.3, 134.1, 129.0, 127.5, 125.2, 124.7, 123.6, 120.3, 115.2, 108.9, 55.6; IR: 
3386, 3051, 2986, 1522, 1238 cm-1; LC/MS m/z: 251 (M+H)+. 
 
6-[4-(Hydroxymethyl)phenyl]-1-naphthol (9). The title compound was prepared by reaction 
of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (70 mg, 0.24 mmol, 1 equiv) with 4-
(hydroxymethyl)phenylboronic acid (44 mg, 0.29 mmol, 1.2 equiv) according to method A. 
The product was purified by column chromatography (hexane/ethyl acetate 1:1). Yield: 49% 
(27 mg). Brown powder. C17H14O2; MW 250; m.p.: 183-185°C; 1H NMR (acetone-d6): δ 9.03 
(s, br, 1H), 8.32 (d, J = 8.8 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 7.80-7.75 (m, 3H), 7.52-7.45 
(m, 3H), 7.35-7.31 (m, 1H), 6.93 (dd, J = 0.7 Hz, J = 7.5 Hz, 1H), 4.71 (s, 2H); 13C NMR 
(acetone-d6): δ 154.0, 142.7, 140.3, 139.3, 136.3, 128.0, 127.8, 127.6, 125.9, 125.0, 124.8, 
123.7, 120.3, 109.1, 64.4; IR: 3199, 3063, 1345 cm-1; LC/MS m/z: 251 (M+H)+. 
 
6-(4-Fluorophenyl)-1-naphthol (10). The title compound was prepared by reaction of 5-
hydroxy-2-naphthyl trifluoromethanesulfonate 5a (150 mg, 0.51 mmol, 1 equiv) with 4-
fluorophenylboronic acid (86 mg, 0.62 mmol, 1.2 equiv) according to method A. The 
analytically pure product was obtained after purification by column chromatography 
(hexane/ethyl acetate 9:1) in 56% yield (68 mg) as an orange oil. C16H11FO; MW 238; 1H 
NMR (acetone-d6): δ 8.70 (s, br, 1H), 7.71 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 9.2 Hz, 1H), 7.51-
7.47 (m, 2H), 7.44 (dd, J = 6.9 Hz, J = 8.2 Hz, 1H), 7.30-7.25 (m, 3H), 7.19 (dd, J = 1.3 Hz, J 
= 7.0 Hz, 1H), 7.12 (dd, J = 2.5 Hz, J = 9.2 Hz, 1H); 13C NMR (acetone-d6): δ 164.1, 156.2, 
139.9, 138.1, 136.6, 132.5, 132.4, 128.0, 127.3, 127.1, 126.7, 125.0, 119.4, 116.0, 115.8, 
110.4; LC/MS m/z: 239 (M+H)+. 
 
6-(4-Nitrophenyl)-1-naphthol (11). The title compound was prepared by reaction of 5-
hydroxy-2-naphthyl trifluoromethanesulfonate 5a (276 mg, 0.94 mmol, 1 equiv) with 4-
nitrophenylboronic acid (205 mg, 1.13 mmol, 1.2 equiv) according to method A. The product 
was purified by column chromatography (hexane/ethyl acetate 6:4). Yield: 23% (57 mg). 
Yellow oil. C16H11NO3; MW 265; 1H NMR (acetone-d6): δ 9.15 (s, br, 1H), 8.40-8.37 (m, 
3H), 8.27 (dd, J = 1.9 Hz, J = 8.7 Hz, 1H), 8.12-8.10 (m, 2H), 7.88 (dd, J = 1.9 Hz, J = 8.6 
Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.39 (t, J = 7.6 Hz, 1H), 6.99 (dd, J = 0.6 Hz, J = 7.6 Hz, 
1H); 13C NMR (acetone-d6): δ 154.1, 148.8, 148.3, 148.1, 131.9, 129.0, 128.2, 127.7, 127.4, 
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126.7, 124.9, 124.4, 124.3, 124.2, 120.6, 120.0; IR: 3244, 3023, 1605, 1517, 1391 cm-1; 
GC/MS m/z: 265 (M)+. 
 
4-(5-Hydroxy-2-naphthyl)benzonitrile (12). The title compound was prepared by reaction 
of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (146 mg, 0.50 mmol, 1 equiv) with 4-
cyanophenylboronic acid (91 mg, 0.60 mmol, 1.2 equiv) according to method A. The product 
was purified by column chromatography (hexane/ethyl acetate 7:3) to afford 33 mg of the 
analytically pure product (27%) as a beige powder. C17H11NO; MW 245; m.p.: 174-176°C; 1H 
NMR (acetone-d6): δ 9.11 (s, br, 1H), 8.36 (d, J = 8.8 Hz, 1H), 8.22 (d, J = 1.8 Hz, 1H), 8.05-
8.02 (m, 2H), 7.93-7.90 (m, 2H), 7.84 (dd, J = 1.9 Hz, J = 8.8 Hz, 1H), 7.51 (d, J = 8.3 Hz, 
1H), 7.40-7.36 (m, 1H), 6.98 (d, J = 7.6 Hz, 1H); 13C NMR (acetone-d6): δ 156.4, 154.0, 
133.6, 133.1, 131.7, 128.9, 127.9, 127.7, 127.1, 126.7, 125.1, 124.4, 120.6, 119.8, 110.5, 
109.8; IR: 3199, 3063, 1345 cm-1; LC/MS m/z: 244 (M-H)-. 
 
1-[4-(5-Hydroxy-2-naphthyl)phenyl]ethanone (13). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (100 mg, 0.34 mmol, 1 equiv) 
with 4-acetylphenylboronic acid (67 mg, 0.41 mmol, 1.2 equiv) according to method A. The 
product was purified by column chromatography (hexane/ethyl acetate 6:4). Yield: 33% (40 
mg). Yellow powder. C18H14O2; MW 262; m.p.: 155-157°C; 1H NMR (acetone-d6): δ 8.70 (s, 
br, 1H), 8.15-8.12 (m, 2H), 7.75 (d, J = 8.3 Hz, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.63-7.60 (m, 
2H), 7.50-7.45 (m, 1H), 7.30 (d, J = 2.5 Hz, 1H), 7.24 (dd, J = 0.9 Hz, J = 7.0 Hz, 1H), 7.13 
(dd, J = 2.6 Hz, J = 9.1 Hz, 1H), 2.66 (s, 3H); 13C NMR (acetone-d6): δ 197.6, 156.3, 146.6, 
139.9, 137.1, 136.6, 130.9, 129.8, 129.2, 128.2, 127.9, 127.6, 126.9, 126.7, 124.9, 119.6, 
110.5, 26.8; IR: 3250, 3096, 1655, 1397, 1270 cm-1; LC/MS m/z: 263 (M+H)+. 
 
4-(5-Hydroxy-2-naphthyl)benzoic acid (14). The title compound was prepared by reaction 
of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (200 mg, 0.68 mmol, 1 equiv) with 4-
boronobenzoic acid (147 mg, 0.82 mmol, 1.2 equiv) according to method A. The product was 
purified by column chromatography (hexane/ethyl acetate 1:1) to give 77% of the analytically 
pure product (142 mg) as a yellow powder. C17H12O3; MW 264; m.p.: 234-236°C; 1H NMR 
(acetone-d6): δ 11.03 (s, br, 1H), 9.07 (s, br, 1H), 8.36 (d, J = 8.8 Hz, 1H), 8.20 (d, J = 1.7 Hz, 
1H), 8.18-8.16 (m, 2H), 7.96-7.94 (m, 2H), 7.85 (dd, J = 1.9 Hz, J = 8.8 Hz, 1H), 7.51 (d, J = 
8.4 Hz, 1H), 7.39-7.34 (m, 1H), 6.97 (d, J = 7.4 Hz, 1H); 13C NMR (acetone-d6): δ 167.5, 
154.0, 146.2, 138.2, 136.1, 132.7, 131.4, 130.4, 128.0, 127.9, 126.8, 125.4, 124.6, 124.0, 
120.6, 116.0, 109.6; IR: 3241, 3102, 1682, 1608, 1297 cm-1; LC/MS m/z: 265 (M+H)+. 
RESULTS   
 - 38 - 
 
6-(Pyridin-4-yl)-1-naphthol (15). The title compound was prepared by reaction of 5-
hydroxy-2-naphthyl trifluoromethanesulfonate 5a (200 mg, 0.68 mmol, 1 equiv) with 4-
pyridylboronic acid (100 mg, 0.82 mmol, 1.2 equiv) according to method A. The product was 
purified by column chromatography (hexane/ethyl acetate 9:1) and then recrystallised in ethyl 
acetate to afford 54% (81 mg) of the analytically pure product as a yellow powder. C15H11NO; 
MW 221; m.p.: 85.4 °C; 1H NMR (acetone-d6): δ 7.93-7.91 (m, 2H), 7.58 (d, J = 8.7 Hz, 1H), 
7.53-7.51 (m, 1H), 7.13-7.10 (m, 3H), 6.76 (d, J = 8.0 Hz, 1H), 6.66-6.62 (m, 1H), 6.21-6.18 
(m, 1H); 13C NMR (acetone-d6): δ 148.7, 126.1, 124.9, 122.2, 121.7, 120.6, 118.2, 107.9; IR: 
3054, 1577, 1239 cm-1; LC/MS m/z: 222 (M+H)+. 
 
6-(Pyrimidin-5-yl)-1-naphthol (16). The title compound was prepared by reaction of 5-
hydroxy-2-naphthyl trifluoromethanesulfonate 5a (200 mg, 0.68 mmol, 1 equiv) with 5-
pyrimidinylboronic acid (102 mg, 0.82 mmol, 1.2 equiv) according to method A. The product 
was purified by column chromatography (hexane/ethyl acetate 3:1) to afford 65 mg (43%) of 
the analytically pure product as a yellow powder. C14H10N2O; MW 222; m.p.: 242-243°C; 1H 
NMR (CD3OD): δ 9.25 (s, 2H), 9.21 (s, 1H), 8.41 (d, J = 5.1 Hz, 1H), 8.26 (d, J = 1.8 Hz, 
1H), 7.86 (dd, J = 2.0 Hz, J = 8.8 Hz, 1H), 7.52 (d, J = 8.3 Hz, 1H), 7.43-7.39 (m, 1H), 6.97 
(d, J = 7.8 Hz, 1H); 13C NMR (CD3OD): δ 158.3, 156.4, 136.6, 135.8, 133.0, 128.6, 127.4, 
125.0, 124.3, 120.7, 119.0, 110.2; IR: 3022, 1278 cm-1; LC/MS m/z: 223 (M+H)+. 
 
6-(4-Methoxypyridin-3-yl)-1-naphthol (17). The title compound was prepared by reaction 
of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (50 mg, 0.17 mmol, 1 equiv) with 4-
methoxy-3-pyridylboronic acid (67 mg, 0.44 mmol, 2.6 equiv) according to method A. The 
desired product was obtained after purification by column chromatography (hexane/ethyl 
acetate 7:3) and by preparative HPLC. Yield: 47% (10 mg). Brown solid. C17H13NO2; MW 
251; m.p.: 165-166°C; 1H NMR (CDCl3): δ 8.10 (dd, J = 0.6 Hz, J = 2.5 Hz, 1H), 7.61 (dd, J 
= 2.4 Hz, J = 8.6 Hz, 1H), 7.57-7.54 (m, 2H), 7.32-7.28 (m, 1H), 7.09 (d, J = 2.5 Hz, 1H), 
7.05 (dd, J = 1.1 Hz, J = 7.0 Hz, 1H), 6.95 (dd, J = 2.4 Hz, J = 9.3 Hz, 1H), 6.76 (dd, J = 0.9 
Hz, J = 8.5 Hz, 1H), 3.88 (s, 3H); 13C NMR (CDCl3): δ 163.4, 154.9, 146.8, 140.6, 136.0, 
135.4, 130.0, 127.0, 126.6, 126.5, 125.8, 124.4, 118.5, 110.2, 109.6, 53.5; IR: 3215, 1579, 
1498, 1286 cm-1; LC/MS m/z: 252 (M+H)+. 
 
6-(3-Furyl)-1-naphthol (18). The title compound was prepared by reaction of 5-hydroxy-2-
naphthyl trifluoromethanesulfonate 5a (200 mg, 0.68 mmol, 1 equiv) with 3-furylboronic acid 
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(91 mg, 0.82 mmol, 1.2 equiv) according to method A. The product was purified by column 
chromatography (hexane/ethyl acetate 9:1). Yield: 40% (57 mg). Brown oil. C14H10O2; MW 
210; 1H NMR (acetone-d6): δ 8.16 (d, J = 8.8 Hz, 1H), 7.82 (d, J = 1.5 Hz, 1H), 7.80-7.78 (m, 
1H), 7.55 (dd, J = 1.6 Hz, J = 8.6 Hz, 1H), 7.47-7.45 (m, 1H), 7.36-7.33 (m, 1H), 7.26-7.22 
(m, 1H), 6.78-6.75 (m, 2H), 6.60 (s, 1H); 13C NMR (acetone-d6): δ 171.5, 152.0, 143.7, 138.9, 
135.1, 130.2, 126.5, 126.4, 123.7, 123.5, 122.5, 120.1, 108.8, 108.4; IR:  3320, 1368 cm-1; 
LC/MS m/z: 211 (M+H)+. 
 
4-(5-Hydroxy-2-naphthyl)-N-methylbenzenesulfonamide (19). The title compound was 
prepared by reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (100 mg, 0.34 
mmol, 1 equiv) with 4-[(methylamino)sulfonyl]phenylboronic acid (88 mg, 0.41 mmol, 1.2 
equiv) according to method B. The product was purified by column chromatography (gradient 
hexane/ethyl acetate 1:0 to 3:1) to afford the analytically pure compound in 90% yield (84 
mg) as a yellow powder. C17H15NO3S; MW 313; m.p.: 204-207°C; 1H NMR (acetone-d6): δ 
9.10 (s, 1H), 8.36 (d, J = 8.6 Hz, 1H), 8.21 (d, J = 1.8 Hz, 1H), 8.04-8.01 (m, 2H), 7.99-7.95 
(m, 2H), 7.85-7.84 (m, 1H), 7.51 (d, J = 8.4 Hz, 1H), 7.39-7.35 (m, 1H), 6.97 (dd, J = 1.0 Hz, 
J = 7.6 Hz, 1H), 6.36 (qt, J = 5.1 Hz, 1H), 2.64 (d, J = 5.1 Hz, 3H); 13C NMR (acetone-d6): δ 
154.0, 145.7, 139.6, 137.7, 136.1, 133.2, 129.9, 128.6, 127.9, 127.8, 126.9, 125.4, 124.6, 
124.1, 120.6, 109.7; IR: 3259, 2971, 1378 cm-1; LC/MS m/z: 314 (M+H)+. 
 
N-[4-(5-Hydroxy-2-naphthyl)phenyl]methanesulfonamide (20). The title compound was 
prepared by reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (100 mg, 0.34 
mmol, 1 equiv) with 4-[(methylsulfonyl)amino]phenylboronic acid (88 mg, 0.41 mmol, 1.2 
equiv) according to method B. The product was purified by column chromatography 
(hexane/ethyl acetate 3:1) to give the analytically pure compound in 57% yield (61 mg) as an 
orange powder. C17H15NO3S; MW 313; m.p.: 194-195°C; 1H NMR (acetone-d6): δ 9.33 (s, 
1H), 8.92 (s, 1H), 8.53 (d, J = 8.8 Hz, 1H), 8.30 (d, J = 1.6 Hz, 1H), 8.05-8.01 (m, 2H), 8.00 
(dd, J = 1.6 Hz, J = 8.8 Hz, 1H), 7.72-7.69 (m, 2H), 7.67 (d, J = 8.8 Hz, 1H), 7.57-7.55 (m, 
1H), 7.16-7.13 (m, 1H), 3.27 (s, 3H); 13C NMR (acetone-d6): δ 154.1, 138.9, 138.6, 137.8, 
136.3, 131.6, 128.9, 127.7, 125.7, 125.0, 124.6, 123.8, 121.5, 120.9, 120.3, 109.1, 39.5; IR: 
3384, 2934, 1692, 1519, 1322 cm-1; LC/MS m/z: 314 (M+H)+. 
 
N-[3-(5-Hydroxy-2-naphthyl)phenyl]methanesulfonamide (21). The title compound was 
prepared by reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (100 mg, 0.34 
mmol, 1 equiv) with 3-[(methylsulfonyl)amino]phenylboronic acid (88 mg, 0.41 mmol, 1.2 
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equiv) according to method B. The product was purified by column chromatography 
(hexane/ethyl acetate 3:1) to give the analytically pure compound in 39% yield (41 mg) as an 
orange oil. C17H15NO3S; MW 313; 1H NMR (acetone-d6): δ 9.08 (s, 1H), 8.66 (s, br, 1H), 
8.33 (d, J = 8.8 Hz, 1H), 8.09 (d, J = 1.9 Hz, 1H), 7.78-7.75 (m, 2H), 7.60-7.58 (m, 1H), 7.52-
7.46 (m, 2H), 7.41-7.38 (m, 1H), 7.34 (t, J = 8.1 Hz, 1H), 6.95 (dd, J = 1.0 Hz, J = 7.3 Hz, 
1H), 3.07 (s, 3H); 13C NMR (acetone-d6): δ 154.1, 143.1, 140.1, 138.9, 136.2, 130.8, 127.8, 
126.2, 125.2, 124.7, 124.0, 123.9, 120.4, 120.1, 119.9, 109.3, 39.5; IR: 3259, 1705, 1601, 
1275 cm-1; LC/MS m/z: 314 (M+H)+. 
 
4-(5-Hydroxy-2-naphthyl)-N-methylbenzamide (22). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (200 mg, 0.68 mmol, 1 equiv) 
with 4-(N-methylaminocarbonyl)phenylboronic acid (147 mg, 0.82 mmol, 1.2 equiv) 
according to method B. The analytically pure product was obtained after column 
chromatography (hexane/ethyl acetate 3:1) in 68% yield (128 mg) as a brown oil. C18H15NO2; 
MW 277; 1H NMR (acetone-d6): δ 9.13 (s, 1H), 8.33 (d, J = 8.9 Hz, 1H), 8.17 (d, J = 1.9 Hz, 
1H), 8.10 (s, br, 1H), 8.07-8.04 (m, 2H), 7.91-7.88 (m, 2H), 7.82 (dd, J = 1.9 Hz, J = 8.7 Hz, 
1H), 7.48 (d, J = 8.4 Hz, 1H), 7.35 (t, J = 8.1 Hz, 1H), 6.95 (dd, J = 1.0 Hz, J = 7.4 Hz, 1H), 
2.98 (s, 3H); 13C NMR (acetone-d6): δ 154.1, 144.6, 138.2, 136.1, 133.0, 132.9, 128.9, 127.9, 
127.8, 126.5, 125.3, 124.6, 123.9, 120.5, 109.5, 27.0; IR: 3483, 1643, 1336 cm-1; LC/MS m/z: 
278 (M+H)+. 
 
3-(5-Hydroxy-2-naphthyl)-N-methylbenzamide (23). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (100 mg, 0.34 mmol, 1 equiv) 
with 3-(N-methylaminocarbonyl)phenylboronic acid (74 mg, 0.41 mmol, 1.2 equiv) according 
to method B. The analytically pure product was obtained after column chromatography 
(gradient dichloromethane/methanol 1:0 to 20:1) in 54% yield (51 mg) as a brown oil. 
C18H15NO2; MW 277; 1H NMR (acetone-d6): δ 9.14 (s, 1H), 8.34 (d, J = 8.6 Hz, 1H), 8.30 (t, 
J = 1.9 Hz, 1H), 8.14 (d, J = 1.9 Hz, 1H), 7.95-7.93 (m, 1H), 7.92-7.90 (m, 1H), 7.88 (s, 1H), 
7.82 (dd, J = 1.9 Hz, J = 8.6 Hz, 1H), 7.60-7.57 (m, 1H), 7.48 (d, J = 8.2 Hz, 1H), 7.35 (t, J = 
7.7 Hz, 1H), 6.95 (dd, J = 0.9 Hz, J = 7.6 Hz, 1H), 2.95 (d, J = 4.7 Hz, 3H); 13C NMR 
(acetone-d6): δ 154.2, 141.9, 132.8, 132.7, 130.5, 129.8, 129.5, 129.4, 127.8, 127.0, 126.6, 
126.3, 124.7, 123.9, 120.3, 109.4, 26.7; IR: 3166, 1574, 1272 cm-1; LC/MS m/z: 278 (M+H)+. 
 
N-[3-(5-Hydroxy-2-naphthyl)phenyl]acetamide (24). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (100 mg, 0.34 mmol, 1 equiv) 
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with 3-acetamidophenylboronic acid (74 mg, 0.41 mmol, 1.2 equiv) according to method B. 
The analytically pure product was obtained after column chromatography (gradient 
dichloromethane/methanol 1:0 to 20:1) in 42% yield (40 mg) as a yellow powder. C18H15NO2; 
MW 277; m.p.: 105-106°C; 1H NMR (acetone-d6): δ 9.24 (s, 1H), 9.04 (s, 1H), 8.32 (d, J = 
8.6 Hz, 1H), 8.10-8.08 (m, 1H), 8.05 (d, J = 1.6 Hz, 1H), 7.75 (dd, J = 1.8 Hz, J = 8.8 Hz, 
1H), 7.69 (d, J = 7.5 Hz, 1H), 7.49-7.45 (m, 2H), 7.42 (t, J = 7.9 Hz, 1H), 7.33 (t, J = 7.9 Hz, 
1H),  6.93 (dd, J = 1.0 Hz, J = 7.4 Hz, 1H), 2.13 (s, 3H); 13C NMR (acetone-d6): δ 154.0, 
147.6, 136.3, 130.1, 127.7, 126.0, 124.8, 123.7, 122.8, 120.3, 119.0, 118.7, 109.2, 24.3; IR: 
3208, 3082, 2944, 1670 cm-1; LC/MS m/z: 278 (M+H)+. 
 
N-[3-(5-Hydroxy-2-naphthyl)phenyl]benzamide (25). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 5a (100 mg, 0.34 mmol, 1 equiv) 
with 3-benzamidophenylboronic acid 25a (99 mg, 0.41 mmol, 1.2 equiv) according to method 
A. The product was purified by column chromatography (hexane/ethyl acetate 3:1) then 
recrystallised in ethyl acetate. Yield: 28% (32 mg). White powder. C23H17NO2; MW 339; 
m.p.: 159.4°C; 1H NMR (acetone-d6): δ 9.66 (s, br, 1H), 9.39 (s, 1H), 8.21 (t, J = 1.8 Hz, 1H), 
8.06-8.03 (m, 1H), 7.98-7.95 (m, 2H), 7.90 (dt, J = 1.7 Hz, J = 7.7 Hz, 1H), 7.59-7.55 (m, 
1H), 7.54-7.52 (m, 2H), 7.52-7.48 (m, 2H), 7.46 (d, J = 7.7 Hz, 1H), 7.43 (dt, J = 1.6 Hz, J = 
7.9 Hz, 1H), 7.25 (ddd, J = 1.0 Hz, J = 2.0 Hz, J = 7.9 Hz, 1H), 7.15 (t, J = 7.9 Hz, 1H), 6.60 
(ddd, J = 1.0 Hz, J = 2.4 Hz, J = 8.0 Hz, 1H); 13C NMR (acetone-d6): δ 179.7, 166.4, 158.6, 
142.3, 141.5, 140.9, 136.5, 136.3, 132.4, 132.2, 130.2, 130.1, 129.5, 129.3, 129.2, 128.4, 
128.3, 123.1, 120.1, 119.6, 112.1, 111.6, 108.2; IR: 3297, 3076, 1646, 1603, 1579, 1404, 
1286 cm-1; GC/MS m/z: 339 (M)+. 
 
N-[4'-(Hydroxymethyl)biphenyl-3-yl]acetamide (26). The title compound was prepared by 
reaction of (4-bromophenyl)methanol (100 mg, 0.53 mmol, 1 equiv) with 3-
acetamidophenylboronic acid (115 mg, 0.64 mmol, 1.2 equiv) according to method B. The 
analytically pure product was obtained after column chromatography (hexane/ethyl acetate 
3:1) in 31% yield (40 mg) as a beige powder. C15H15NO2; MW 241; m.p.: 140-142°C; 1H 
NMR (acetone-d6): δ 9.96 (s, 1H), 9.15 (s, br, 1H), 7.96 (s, 1H), 7.89-7.86 (m, 2H), 7.73-7.70 
(m, 2H), 7.56-7.53 (m, 1H), 7.30-7.28 (m, 2H), 2.70 (s, 2H), 1.99 (s, 3H); 13C NMR (acetone-
d6): δ 192.5, 169.1, 147.5, 141.3, 141.0, 136.7, 130.9, 130.3, 128.4, 122.8, 119.9, 118.7, 24.3; 
IR: 3458, 3098, 2986, 1699, 1657 cm-1; LC/MS m/z: 240 (M-H)-. 
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N-[4'-(Hydroxymethyl)biphenyl-3-yl]benzamide (27). The title compound was prepared by 
reaction of (4-bromophenyl)methanol (100 mg, 0.53 mmol, 1 equiv) with N-(3-phenylboronic 
acid)benzamide 25a (154 mg, 0.64 mmol, 1.2 equiv) according to method A. The product was 
obtained after column chromatography (hexane/ethyl acetate 3:1) in 50% yield (80 mg) as a 
beige powder. C20H17NO2; MW 303; m.p.: 167-168°C; 1H NMR (acetone-d6): δ 9.67 (s, br, 
1H), 8.27 (t, J = 1.9 Hz, 1H), 8.13-8.10 (m, 2H), 7.97 (dt, J = 1.8 Hz, J = 7.6 Hz, 1H), 7.74-
7.71 (m, 2H), 7.69-7.65 (m, 1H), 7.63-7.59 (m, 2H), 7.57-7.54 (m, 2H), 7.52 (d, J = 7.5 Hz, 
1H), 7.50 (dt, J = 1.6 Hz, J = 7.8 Hz, 1H), 4.78 (s, 2H); 13C NMR (acetone-d6): δ 170.9, 
168.4, 142.8, 142.3, 140.9, 140.3, 136.3, 132.4, 130.0, 129.3, 128.3, 127.9, 127.5, 123.0, 
119.8, 119.4, 64.4; IR: 3490, 3185, 2973, 1607, 1550, 1316 cm-1; LC/MS m/z: 304 (M+H)+.  
 
N-(3-Bromophenyl)-N-methylbenzamide (28a). The title compound was prepared by 
reaction of 3-bromo-N-methylaniline (200 mg, 0.14 mL, 1.07 mmol, 1 equiv) with benzoyl 
chloride (273 mg, 0.15 mL, 1.28 mmol, 1.2 equiv) according to method C. The product was 
purified by column chromatography (hexane/ethyl acetate 8:2) to afford 295 mg of product 
(yield: 95%). C14H12BrNO; MW 290; 1H NMR (acetone-d6): δ 7.39 (t, J = 1.8 Hz, 1H), 7.32-
7.28 (m, 3H), 7.28-7.25 (m, 1H), 7.23-7.19 (m, 2H), 7.17 (t, J = 7.9 Hz, 1H), 7.14-7.11 (m, 
1H), 3.39 (s, 3H); 13C NMR (acetone-d6): δ 170.5, 147.7, 137.3, 131.4, 130.9, 130.4, 130.1, 
129.3, 128.7, 127.0, 122.6, 38.3; IR: 3422, 3067, 1647, 1477, 1355 cm-1. 
 
N-[4'-(Hydroxymethyl)biphenyl-3-yl]-N-methylbenzamide (28). The title compound was 
prepared by reaction of N-(3-bromophenyl)-N-methylbenzamide 28a (100 mg, 0.34 mmol, 1 
equiv) with 4-(hydroxymethyl)phenylboronic acid (62 mg, 0.41 mmol, 1.2 equiv) according 
to method B. The product was purified by column chromatography (hexane/ethyl acetate 6:4) 
to give the analytically pure compound in 70% yield (75 mg) as a yellow oil. C21H19NO2; 
MW 317; 1H NMR (acetone-d6): δ 7.44-7.42 (m, 3H), 7.41-7.38 (m, 3H), 7.37-7.33 (m, 3H), 
7.26 (dt, J = 2.5 Hz, J = 7.2 Hz, 1H), 7.24-7.20 (m, 2H), 7.18-7.15 (m, 1H), 4.65 (d, J = 5.7 
Hz, 2H),  4.25 (t, J = 5.7 Hz, 1H), 3.49 (s, 3H); 13C NMR (acetone-d6): δ 170.7, 146.6, 143.1, 
142.7, 139.4, 137.9, 130.4, 130.1, 129.4, 128.5, 127.9, 127.5, 126.7, 126.3, 125.4, 64.3, 38.2; 
IR: 3410, 1632, 1599, 1369 cm-1; LC/MS m/z: 318 (M+H)+. 
 
N-(3-Bromophenyl)-3-methoxy-N-methylbenzamide (29a). The title compound was 
prepared by reaction of 3-bromo-N-methylaniline (200 mg, 0.14 mL, 1.07 mmol, 1 equiv) 
with 3-methoxybenzoyl chloride (218 mg, 0.17 mL, 1.28 mmol, 1.2 equiv) according to 
method C. The product was purified by column chromatography (hexane/ethyl acetate 7:3) to 
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give the analytically pure compound in 99% yield (340 mg). C15H14BrNO2; MW 320; 1H 
NMR (acetone-d6): δ 7.46 (t, J = 2.0 Hz, 1H), 7.35 (ddd, J = 1.3 Hz, J = 2.0 Hz, J = 7.9 Hz, 
1H), 7.22 (t, J = 7.7 Hz, 1H), 7.19-7.16 (m, 1H), 7.14 (t, J = 7.9 Hz, 1H), 6.90-6.87 (m, 2H), 
6.85 (dd, J = 1.4 Hz, J = 8.5 Hz, 1H), 3.69 (s, 3H), 3.42 (s, 3H); 13C NMR (acetone-d6): δ 
170.3, 160.1, 147.7, 138.6, 131.5, 130.8, 130.1, 129.8, 127.0, 122.6, 121.6, 116.4, 114.6, 55.6, 
38.3; IR: 3474, 2836, 1659, 1583, 1478, 1257 cm-1. 
 
N-[4'-(Hydroxymethyl)biphenyl-3-yl]-3-methoxy-N-methylbenzamide (29). The title 
compound was prepared by reaction of N-(3-bromophenyl)-3-methoxy-N-methylbenzamide 
29a (100 mg, 0.31 mmol, 1 equiv) with 4-hydroxymethylphenylboronic acid (58 mg, 0.38 
mmol, 1.2 equiv) according to method B. The analytically pure compound was obtained after 
column chromatography (hexane/ethyl acetate 6:4) in 74% yield (80 mg) as a yellow oil. 
C22H21NO3; MW 347; 1H NMR (acetone-d6): δ 7.34-7.30 (m, 4H), 7.29-7.26 (m, 2H), 7.22 (t, 
J = 7.8 Hz, 1H), 7.04 (d, J = 7.4 Hz, 1H), 7.00 (t, J = 7.9 Hz, 1H), 6.80 (d, J = 7.7 Hz, 1H), 
6.79-6.77 (m, 1H), 6.68 (dd, J = 2.0 Hz, J = 8.3 Hz, 1H), 4.52 (d, J = 5.8 Hz, 2H), 3.51 (s, 
3H), 3.35 (s, 3H); 13C NMR (acetone-d6): δ 170.4, 159.9, 146.7, 143.1, 142.7, 139.4, 139.0, 
130.4, 129.6, 127.9, 127.5, 126.6, 126.3, 125.5, 121.7, 116.2, 114.6, 64.3, 55.5, 38.2; IR: 
3408, 3225, 1632, 1581, 1373, 1257 cm-1; LC/MS m/z: 348 (M+H)+. 
 
N-(3-Bromophenyl)-4-methoxy-N-methylbenzamide (30a). The title compound was 
prepared by reaction of 3-bromo-N-methylaniline (200 mg, 0.14 mL, 1.07 mmol, 1 equiv) 
with 4-methoxybenzoyl chloride (218 mg, 0.17 mL, 1.28 mmol, 1.2 equiv) according to 
method C. The product was purified by column chromatography (hexane/ethyl acetate 7:3) to 
afford the analytically pure compound in quantitative yield (340 mg). C15H14BrNO2; MW 
320; 1H NMR (acetone-d6): δ 7.42 (t, J = 2.1 Hz, 1H), 7.35 (ddd, J = 1.2 Hz, J = 1.9 Hz, J = 
8.0 Hz, 1H), 7.31-7.28 (m, 2H), 7.22 (t, J = 8.1 Hz, 1H), 7.13 (ddd, J = 0.9 Hz, J = 2.1 Hz, J = 
8.0 Hz, 1H),  6.80-6.76 (m, 2H), 3.76 (s, 3H), 3.41 (s, 3H); 13C NMR (acetone-d6): δ 170.1, 
161.8, 148.3, 131.5, 131.4, 130.6, 129.8, 129.1, 126.9, 122.6, 113.9, 55.6, 38.5. 
 
N-[4'-(Hydroxymethyl)biphenyl-3-yl]-4-methoxy-N-methylbenzamide (30). The title 
compound was prepared by reaction of N-(3-bromophenyl)-4-methoxy-N-methylbenzamide 
30a (100 mg, 0.31 mmol, 1 equiv) with 4-hydroxymethylphenylboronic acid (58 mg, 0.38 
mmol, 1.2 equiv) according to method B. The product was purified by column 
chromatography (hexane/ethyl acetate 7:3) to give the analytically pure compound in 65% 
yield (70 mg) as a white powder. C22H21NO3; MW 347; m.p.: 147-149°C; 1H NMR (acetone-
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d6): δ 7.56-7.52 (m, 1H), 7.49-7.46 (m, 2H), 7.45 (ddd, J = 1.0 Hz, J = 1.9 Hz, J = 7.9 Hz, 
1H), 7.42-7.40 (m, 3H), 7.36 (t, J = 7.9 Hz, 1H), 7.34-7.31 (m, 2H), 7.13 (ddd, J = 1.0 Hz, J = 
2.2 Hz, J = 7.8 Hz, 1H), 6.77-6.74 (m, 2H), 4.66 (d, J = 5.3 Hz, 2H), 3.74 (s, 3H), 3.47 (s, 
3H); 13C NMR (acetone-d6): δ 170.3, 161.5, 147.2, 143.1, 142.7, 139.4, 132.7, 131.5, 130.4, 
129.5, 129.4, 127.9, 127.5, 126.5, 126.3, 125.2, 113.8, 64.3, 55.6, 38.4; LC/MS m/z: 348 
(M+H)+. 
 
N-(3-Bromophenyl)-2-(3-methoxyphenyl)-N-methylacetamide (31a). The title compound 
was prepared by reaction of 3-bromo-N-methylaniline (200 mg, 0.14 mL, 1.07 mmol, 1 equiv) 
with 3-methoxyphenylacetyl chloride (218 mg, 0.20 mL, 1.28 mmol, 1.2 equiv) according to 
method C. The product was purified by column chromatography (hexane/ethyl acetate 7:3) to 
give the analytically pure compound in 98% yield (350 mg). C16H16BrNO2; MW 334; 1H 
NMR (acetone-d6): δ 7.55 (d, J = 7.5 Hz, 1H), 7.47-7.45 (m, 1H), 7.41 (t, J = 8.0 Hz, 1H), 
7.31 (ddd, J = 0.9 Hz, J = 2.1 Hz, J = 7.9 Hz, 1H), 7.14 (t, J = 8.0 Hz, 1H), 6.76 (dd, J = 2.1 
Hz, J = 8.2 Hz, 1H), 6.67-6.62 (m, 2H), 3.74 (s, 3H), 3.45 (s, 2H), 3.23 (s, 3H); 13C NMR 
(acetone-d6): δ 180.6, 146.8, 138.1, 132.0, 129.9, 122.1, 115.5, 112.8, 60.5, 55.4, 41.6; IR: 
3447, 2980, 1659, 1587, 1257 cm-1. 
 
N-[4'-(Hydroxymethyl)biphenyl-3-yl]-2-(3-methoxyphenyl)-N-methylacetamide (31). The 
title compound was prepared by reaction of N-(3-bromophenyl)-2-(3-methoxyphenyl)-N-
methylacetamide 31a (90 mg, 0.27 mmol, 1 equiv) with 4-hydroxymethylphenylboronic acid 
(52 mg, 0.34 mmol, 1.2 equiv) according to method B. The analytically pure product was 
obtained after column chromatography (hexane/ethyl acetate 6:4) in 51% yield (50 mg) as a 
yellow oil. C23H23NO3; MW 361; 1H NMR (acetone-d6): δ 7.53-7.49 (m, 1H), 7.44-7.37 (m, 
3H), 7.33 (s, 1H), 7.30 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 7.7 Hz, 1H), 6.99-6.94 (m, 1H), 6.59 
(d, J = 7.7 Hz, 1H), 6.52-6.46 (m, 2H), 4.53 (d, J = 5.7 Hz, 2H), 3.53 (s, 3H), 3.34 (s, 2H), 
3.13 (s, 3H); 13C NMR (acetone-d6): δ 181.1, 170.7, 160.5, 145.8, 143.2, 139.3, 129.9, 127.9, 
127.6, 127.1, 122.1, 115.5, 112.7, 64.3, 55.3, 49.8, 41.6; IR: 3417, 3076, 2927, 1636, 1599, 
1436, 1258 cm-1; LC/MS m/z: 362 (M+H)+. 
 
N-(3-Bromophenyl)-2-(4-methoxyphenyl)-N-methylacetamide (32a). The title compound 
was prepared by reaction of 3-bromo-N-methylaniline (200 mg, 0.14 mL, 1.07 mmol, 1 equiv) 
with 4-methoxyphenylacetyl chloride (218 mg, 0.18 mL, 1.28 mmol, 1.2 equiv) according to 
method C. The product was purified by column chromatography (hexane/ethyl acetate 7:3) to 
give the analytically pure compound in quantitative yield (358 mg). C16H16BrNO2; MW 334; 
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1H NMR (acetone-d6): δ 7.55 (d, J = 7.4 Hz, 1H), 7.45 (t, J = 1.7 Hz, 1H), 7.41 (t, J = 7.9 Hz, 
1H), 7.31 (ddd, J = 0.9 Hz, J = 2.0 Hz, J = 7.9 Hz, 1H), 6.98 (s, 2H), 6.80 (d, J = 8.6 Hz, 2H), 
3.75 (s, 3H), 3.42 (s, 2H), 3.22 (s, 3H); 13C NMR (acetone-d6): δ 170.9, 159.4, 146.9, 132.0, 
131.6, 130.9, 128.5, 114.7, 114.4, 55.5, 40.6. 
 
N-[4'-(Hydroxymethyl)biphenyl-3-yl]-2-(4-methoxyphenyl)-N-methylacetamide (32). The 
title compound was prepared by reaction of N-(3-bromophenyl)-2-(4-methoxyphenyl)-N-
methylacetamide 32a (90 mg, 0.27 mmol, 1 equiv) with 4-hydroxymethylphenylboronic acid 
(52 mg, 0.34 mmol, 1.2 equiv) according to method B. The product was purified by column 
chromatography (hexane/ethyl acetate 6:4) to give the analytically pure compound in 64% 
yield (62 mg) as a white oil. C23H23NO3; MW 361; 1H NMR (acetone-d6): δ 7.60-7.57 (m, 
2H), 7.56-7.52 (m, 2H), 7.48-7.44 (m, 3H), 7.26 (ddd, J = 1.0 Hz, J = 2.2 Hz, J = 7.8 Hz, 1H), 
6.97 (d, J = 5.6 Hz, 2H), 6.76 (d, J = 8.4 Hz, 2H), 4.69 (d, J = 5.7 Hz, 2H), 3.73 (s, 3H), 3.44 
(s, 2H), 3.26 (s, 3H); 13C NMR (acetone-d6): δ 171.0, 159.3, 145.9, 143.2, 139.2, 134.9, 
132.7, 132.6, 130.9, 129.5, 129.4, 128.9, 127.9, 127.6, 127.2, 114.4, 64.3, 55.4, 40.7; LC/MS 
m/z: 362 (M+H)+. 
 
N-[4'-(Hydroxymethyl)biphenyl-4-yl]methanesulfonamide (33). The title compound was 
prepared by reaction of (4-bromophenyl)methanol (100 mg, 0.53 mmol, 1 equiv) with 4-
methylsulfonylaminophenylboronic acid (138 mg, 0.64 mmol, 1.2 equiv) according to method 
B. The analytically pure product was obtained after column chromatography (hexane/ethyl 
acetate 7:3) in 24% yield (35 mg) as a white powder. C14H15NO3S; MW 277; m.p.: 204-
205°C; 1H NMR (acetone-d6): δ 8.61 (s, br, 1H), 7.68-7.64 (m, 2H), 7.63-7.60 (m, 2H), 7.46-
7.41 (m, 4H), 4.68 (d, J = 5.8 Hz, 2H), 4.20 (t, J = 5.8 Hz, 1H), 3.03 (s, 3H); 13C NMR 
(acetone-d6): δ 142.5, 139.6, 138.7, 137.8, 128.5, 128.0, 127.2, 121.5, 64.4, 39.5; IR: 3371, 
3248, 1646, 1498, 1320, 1302 cm-1; GC/MS m/z: 277 (M)+. 
 
N-(4-Bromophenyl)-3-methylbenzenesulfonamide (34a). Under nitrogen, 3-
methylphenylsulfonylchloride (221 mg, 0.17 mL, 1.16 mmol, 1 equiv) was added to a 
solution of 4-bromoaniline (200 mg, 1.16 mmol, 1 equiv) in pyridine at 0°C. The mixture was 
stirred at room temperature overnight. The solvent was removed under reduced pressure and 
the crude product was used in the next step without any purification and characterisation. 
 
N-[4´-(Hydroxymethyl)biphenyl-4-yl]-3-methylbenzenesulfonamide (34). The title 
compound was prepared by reaction of N-(4-bromophenyl)-3-methylbenzenesulfonamide 34a 
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(60 mg, 0.18 mmol, 1 equiv) with 4-hydroxymethylphenylboronic acid (34 mg, 0.22 mol, 1.2 
equiv) according to method B. The product was purified by column chromatography 
(hexane/ethyl acetate 7:3) to afford the analytically pure compound in 47% yield (30 mg) as 
an orange oil. C20H19NO3S; MW 353; 1H NMR (acetone-d6): δ 9.02 (s, 1H), 7.67-7.65 (m, 
1H), 7.65-7.62 (m, 1H), 7.57-7.53 (m, 4H), 7.43-7.40 (m, 4H), 7.31-7.28 (m, 2H), 4.66 (d, J = 
5.8 Hz, 2H), 2.36 (s, 3H); 13C NMR (acetone-d6): δ 142.5, 140.1, 139.5, 138.1, 137.8, 134.3, 
129.8, 128.3, 128.2, 127.9, 127.2, 125.1, 121.9, 64.4, 21.2; LC/MS m/z: 354 (M+H)+. 
 
N-(4'-Hydroxybiphenyl-3-yl)acetamide (35). The title compound was prepared by reaction 
of 4-bromophenol (100 mg, 0.58 mmol, 1 equiv) with 3-acetamidophenylboronic acid (124 
mg, 0.69 mmol, 1.2 equiv) according to method B. The product was purified by column 
chromatography (hexane/ethyl acetate 3:1) to give the analytically pure compound in 23% 
yield (30 mg) as a beige powder. C14H13NO2; MW 227; m.p.: 205-206°C; 1H NMR (acetone-
d6): δ 9.22 (s, br, 1H), 8.49 (s, 1H), 7.97 (s, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.56-7.53 (m, 2H), 
7.39 (t, J = 8.0 Hz, 1H), 7.34-7.31 (m, 1H), 7.02-6.98 (m, 2H), 2.17 (s, 3H); 13C NMR 
(acetone-d6): δ 168.9, 158.1, 142.4, 141.0, 133.1, 130.0, 128.8, 122.0, 118.0, 117.9, 116.5, 
24.3; IR: 3495, 3028, 2964, 1606, 1554, 1266 cm-1; LC/MS m/z: 228 (M+H)+. 
 
N-(4'-Hydroxybiphenyl-3-yl)benzamide (36). The title compound was prepared by reaction 
of 4-bromophenol (100 mg, 0.58 mmol, 1 equiv) with N-(3-phenylboronic acid)benzamide 
25a (169 mg, 0.70 mmol, 1.2 equiv) according to method A. The product was purified by 
column chromatography (hexane/ethyl acetate 3:1) to afford the analytically pure compound 
in 30% yield (50 mg) as a beige oil. C19H15NO2; MW 289; 1H NMR (acetone-d6): δ 9.55 (s, 
br, 1H), 8.44 (s, 1H), 8.12 (t, J = 1.9 Hz, 1H), 8.04-8.01 (m, 2H), 7.82 (ddd, J = 0.9 Hz, J = 
2.1 Hz, J = 8.0 Hz, 1H), 7.57 (dt, J = 1.3 Hz, J = 7.5 Hz, 1H), 7.54-7.50 (m, 4H), 7.39 (t, J = 
8.0 Hz, 1H), 7.34 (dt, J = 1.3 Hz, J = 8.0 Hz, 1H), 6.97-6.93 (m, 2H); 13C NMR (acetone-d6): 
δ 166.4, 158.1, 142.4, 140.8, 136.4, 133.1, 132.3, 129.9, 129.3, 128.8, 128.3, 122.5, 119.1, 
119.0, 116.6; IR: 3293, 3015, 1651, 1545, 1258 cm-1; LC/MS m/z: 290 (M+H)+. 
 
N-(4'-Hydroxybiphenyl-3-yl)-N-methylbenzamide (37). The title compound was prepared 
by reaction of N-(3-bromophenyl)-N-methylbenzamide 28a (100 mg, 0.34 mmol, 1 equiv) 
with 4-hydroxyphenylboronic acid (56 mg, 0.41 mmol, 1.2 equiv) according to method B. 
The analytically pure product was obtained after column chromatography (hexane/ethyl 
acetate 6:4) in 19% yield (20 mg) as a beige powder. C20H17NO2; MW 303; m.p.: 175-176°C; 
1H NMR (acetone-d6): δ 8.51 (s, 1H), 7.34-7.31 (m, 3H), 7.30-7.29 (m, 2H), 7.28 (s, 1H), 7.26 
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(t, J = 8.0 Hz, 1H), 7.23-7.20 (m, 1H), 7.19-7.15 (m, 2H), 3.44 (s, 3H); 13C NMR (acetone-
d6): δ 170.7, 158.4, 146.6, 142.7, 137.9, 132.1, 130.2, 130.1, 129.4, 128.8, 128.5, 126.1, 
125.6, 124.9, 116.6, 38.2; IR: 3380, 3080, 1696, 1598, 1379, 1257 cm-1; LC/MS m/z: 304 
(M+H)+. 
 
3-Methoxy-N-(4'-methoxybiphenyl-3-yl)-N-methylbenzamide (38). The title compound 
was prepared by reaction of N-(3-bromophenyl)-3-methoxy-N-methylbenzamide 29a (90 mg, 
0.28 mmol, 1 equiv) with 4-methoxyphenylboronic acid (52 mg, 0.34 mmol, 1.2 equiv) 
according to method B. The analytically pure product was obtained after column 
chromatography (hexane/ethyl acetate 7:3) in 82% yield (80 mg) as a white powder. 
C22H21NO3; MW 347; m.p.: 128-129°C; 1H NMR (acetone-d6): δ 7.45-7.42 (m, 2H), 7.41-
7.38 (m, 2H), 7.34-7.30 (m, 1H), 7.15-7.10 (m, 2H), 6.99-6.96 (m, 2H), 6.93 (dt, J = 1.2 Hz, J 
= 7.7 Hz, 1H), 6.91-6.90 (m, 1H), 6.81 (ddd, J = 1.0 Hz, J = 2.7 Hz, J = 8.3 Hz, 1H), 3.82 (s, 
3H), 3.64 (s, 3H), 3.47 (s, 3H); 13C NMR (acetone-d6): δ 170.4, 160.6, 160.0, 146.7, 142.5, 
139.1, 136.7, 133.2, 130.3, 129.6, 128.8, 126.2, 125.8, 125.1, 121.7, 116.2, 115.1, 114.7, 55.6, 
55.5, 38.2; IR: 3446, 2937, 1644, 1583, 1290 cm-1; LC/MS m/z: 348 (M+H)+. 
 
4-Methoxy-N-(4'-methoxybiphenyl-3-yl)-N-methylbenzamide (39). The title compound 
was prepared by reaction of N-(3-bromophenyl)-4-methoxy-N-methylbenzamide 30a (90 mg, 
0.28 mmol, 1 equiv) with 4-methoxyphenylboronic acid (52 mg, 0.34 mmol, 1.2 equiv) 
according to method B. The analytically pure product was obtained after column 
chromatography (hexane/ethyl acetate 7:3) in 69% yield (67 mg) as a white oil. C22H21NO3; 
MW 347; 1H NMR (acetone-d6): δ 7.47-7.44 (m, 2H), 7.40 (ddd, J = 1.0 Hz, J = 1.9 Hz, J = 
7.8 Hz, 1H), 7.36 (t, J = 1.8 Hz, 1H), 7.34-7.30 (m, 3H), 7.08 (ddd, J = 1.2 Hz, J = 2.2 Hz, J = 
7.9 Hz, 1H), 6.99-6.96 (m, 2H), 6.76-6.73 (m, 2H), 3.82 (s, 3H), 3.73 (s, 3H), 3.46 (s, 3H); 
13C NMR (acetone-d6): δ 170.2, 161.5, 160.6, 147.2, 142.5, 133.4, 131.5, 130.3, 129.7, 128.8, 
126.0, 125.8, 124.8, 115.1, 113.7, 55.6, 55.5, 38.4; LC/MS m/z: 348 (M+H)+. 
 
N-(4'-Methoxybiphenyl-3-yl)-2-(3-methoxyphenyl)-N-methylacetamide (40). The title 
compound was prepared by reaction of N-(3-bromophenyl)-2-(3-methoxyphenyl)-N-
methylacetamide 31a (90 mg, 0.27 mmol, 1 equiv) with 4-methoxyphenylboronic acid (52 
mg, 0.34 mmol, 1.2 equiv) according to method B. The product was purified by column 
chromatography (hexane/ethyl acetate 7:3) to give the analytically pure compound in 77% 
yield (75 mg) as a yellow oil. C23H23NO3; MW 361; 1H NMR (acetone-d6): δ 7.65-7.61 (m, 
1H), 7.60-7.55 (m, 2H), 7.53 (t, J = 7.7 Hz, 1H), 7.47-7.44 (m, 1H), 7.25 (d, J = 7.2 Hz, 1H), 
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7.14 (t, J = 7.4 Hz, 1H), 7.05-7.00 (m, 2H), 6.78-6.74 (m, 1H), 6.70-6.60 (m, 2H), 3.87 (s, 
3H), 3.71 (s, 3H), 3.50 (s, 2H), 3.29 (s, 3H); 13C NMR (acetone-d6): δ 160.7, 145.8, 136.7, 
130.9, 129.9, 128.9, 122.1, 115.6, 115.1, 113.8, 112.6, 55.6, 55.3, 41.5; IR: 3401, 3258, 2935, 
1653, 1600, 1485, 1377, 1252 cm-1; LC/MS m/z: 362 (M+H)+. 
 
N-(4'-Hydroxybiphenyl-3-yl)-2-(3-hydroxyphenyl)-N-methylacetamide (41). To a solution 
of N-(4'-methoxybiphenyl-3-yl)-2-(3-methoxyphenyl)-N-methylacetamide 40 (30 mg, 0.083 
mmol, 1 equiv) in anhydrous dichloromethane cooled at -78°C under nitrogen was slowly 
added boron tribromide (0.83 mL, 0.83 mmol, 10 equiv). The reaction mixture was stirred at -
78°C for 1h and allowed to warm up to room temperature overnight. The reaction was 
quenched by addition of water and extracted with ethyl acetate. The combined organic layers 
were washed with brine and dried over sodium sulfate evaporated to dryness under reduced 
pressure and purified by column chromatography (dichloromethane/methanol 20:1) to give 
the analytically pure compound in 72% yield (20 mg) as a yellow oil. C21H19NO3; MW 333; 
1H NMR (acetone-d6): δ 8.51 (s, 1H), 8.16 (s, 1H), 7.58 (d, J = 7.3 Hz, 1H), 7.49-7.45 (m, 
3H), 7.42 (t, J = 1.8 Hz, 1H), 7.19 (ddd, J = 0.9 Hz, J = 2.0 Hz, J = 7.9 Hz, 1H), 7.05-7.00 (m, 
1H), 6.94-6.90 (m, 2H), 6.68-6.64 (m, 2H), 6.50 (s, 1H), 3.43 (s, 2H), 3.27 (s, 3H); 13C NMR 
(acetone-d6): δ 158.4, 158.2, 150.9, 145.8, 130.8, 129.9, 129.0, 126.3, 121.0, 116.9, 116.6, 
114.2, 41.4; LC/MS m/z: 334 (M+H)+. 
 
N-(4'-Methoxybiphenyl-3-yl)-2-(4-methoxyphenyl)-N-methylacetamide (42). The title 
compound was prepared by reaction of N-(3-bromophenyl)-2-(4-methoxyphenyl)-N-
methylacetamide 32a (90 mg, 0.27 mmol, 1 equiv) with 4-methoxyphenylboronic acid (52 
mg, 0.34 mmol, 1.2 equiv) according to method B. The analytically pure product was 
obtained after column chromatography (hexane/ethyl acetate 7:3) in 62% yield (60 mg) as a 
yellow oil. C23H23NO3; MW 361; 1H NMR (acetone-d6): δ 7.61 (d, J = 7.8 Hz, 1H), 7.58-7.54 
(m, 2H), 7.50 (t, J = 7.6 Hz, 1H), 7.42 (t, J = 1.8 Hz, 1H), 7.21 (ddd, J = 1.0 Hz, J = 2.2 Hz, J 
= 7.8 Hz, 1H), 7.04-7.00 (m, 2H), 7.00-6.93 (m, 2H), 6.77 (d, J = 8.6 Hz, 2H), 3.85 (s, 3H), 
3.73 (s, 3H), 3.44 (s, 2H), 3.26 (s, 3H); 13C NMR (acetone-d6): δ 171.0, 160.7, 159.3, 145.9, 
136.7, 133.0, 130.9, 129.0, 128.9, 126.7, 126.6, 126.4, 115.2, 114.4, 113.9, 55.7, 55.4, 55.3, 
40.6; LC/MS m/z: 362 (M+H)+. 
 
N-(4'-Hydroxybiphenyl-4-yl)methanesulfonamide (43). The title compound was prepared 
by reaction of 4-bromophenol (100 mg, 0.58 mmol, 1 equiv) with 4-
methylsulfonylaminophenylboronic acid (149 mg, 0.69 mmol, 1.2 equiv) according to method 
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B. The analytically pure product was obtained after column chromatography (hexane/ethyl 
acetate 7:3) in 20% yield (30 mg) as a beige powder. C13H13NO3S; MW 263; m.p.: 168-
169°C; 1H NMR (acetone-d6): δ 8.60 (s, br, 1H), 7.68-7.63 (m, 4H), 7.48-7.42 (m, 4H), 7.33-
7.32 (m, 1H), 3.03 (s, 3H); 13C NMR (acetone-d6): δ 141.1, 138.8, 137.8, 129.7, 128.6, 128.1, 
127.5, 121.4, 39.5; IR: 3376, 2930, 1643, 1396 cm-1. 
 
N-(4'-Hydroxybiphenyl-4-yl)-3-methyl-benzenesulfonamide (44). The title compound was 
prepared by reaction of N-(4-bromophenyl)-3-methylbenzenesulfonamide 34a (70 mg, 0.21 
mmol, 1 equiv) with 4-hydroxyphenylboronic acid (36 mg, 0.26 mmol, 1.2 equiv) according 
to method B. The product was purified by column chromatography (hexane/ethyl acetate 7:3) 
to give the analytically pure compound in 63% yield (45 mg) as an orange oil. C19H17NO3S; 
MW 339; 1H NMR (acetone-d6): δ 8.94 (s, 1H), 8.39 (s, 1H), 7.65-7.64 (m, 1H), 7.63-7.60 
(m, 1H), 7.49-7.46 (m, 2H), 7.45-7.42 (m, 2H), 7.41-7.39 (m, 2H), 7.26-7.23 (m, 2H), 6.90-
6.87 (m, 2H), 2.36 (s, 3H); 13C NMR (acetone-d6): δ 157.9, 141.0, 140.0, 138.1, 137.3, 134.3, 
132.3, 129.7, 128.5, 128.2, 127.7, 125.1, 122.1, 116.6, 21.2; LC/MS m/z: 338 (M-H)-. 
 
Biological Assays 
 
[2,4,6,7-3H]-E2 and [2,4,6,7-3H]-E1 were bought from Perkin-Elmer, Boston. Quickszint 
Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. 17β-HSD2 and 17β-
HSD1 were obtained from human placenta according to previously described procedures.39-41, 
48 Fresh human placenta was homogenised and centrifuged. The pellet fraction contains the 
microsomal 17β-HSD2, while 17β-HSD1 was obtained after precipitation with ammonium 
sulfate from the cytosolic fraction. 
 
1. Inhibition of 17β-HSD2 
Inhibitory activities were evaluated by a well established method with minor modifications.39 
Briefly, the enzyme preparation was incubated with NAD+ [1500 μM] in the presence of 
potential inhibitors at 37°C in a phosphate buffer (50 mM) supplemented with 20% of 
glycerol and EDTA 1 mM. Inhibitor stock solutions were prepared in DMSO. Final 
concentration of DMSO was adjusted to 1% in all samples. The enzymatic reaction was 
started by addition of a mixture of unlabeled- and [2,4,6,7-3H]-E2 (final concentration: 500 
nM, 0.11 μCi). After 20 min at 37°C, the incubation was stopped with HgCl2 and the mixture 
was extracted with ether. After evaporation, the steroids were dissolved in acetonitrile. E1 and 
E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 rp 
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chromatography column (Nucleodur C18 Gravity, 3 μm, Macherey-Nagel, Düren) connected 
to a HPLC-system (Agilent 1100 Series, Agilent Technologies, Waldbronn). Detection and 
quantification of the steroids were performed using a radioflow detector (Berthold 
Technologies, Bad Wildbad). The conversion rate was calculated according to following 
equation: %conversion = (%E1/(%E1 + %E2) × 100). Each value was calculated from at least 
three independent experiments. 
 
2. Inhibition of 17β-HSD1 
The 17β-HSD1 inhibition assay was performed similarly to the 17β-HSD2 procedure. The 
cytosolic fraction was incubated with NADH [500 μM], test compound and a mixture of 
unlabeled- and [2,4,6,7-3H]-E1 (final concentration: 500 nM, 0.15 μCi) for 10 min. Further 
treatment of the samples and HPLC separation was carried out as mentioned above. 
 
3. ER affinity 
The binding affinity of selected compounds to the ERα and ERβ was determined according to 
Zimmermann et al.49 using recombinant human proteins. Briefly, 0.25 pmoles of ERα or ERβ, 
respectively, were incubated with [3H]-E2 (10 nM) and test compound for 1h at room 
temperature. The potential inhibitors were dissolved in DMSO (5% final concentration). Non-
specific-binding was performed with diethylstilbestrol (10 µM). After incubation, ligand-
receptor complexes were selectively bound to hydroxyapatite (5 g/ 60 mL TE-buffer). The 
formed complex was separated, washed and resuspended in ethanol. For radiodetection, 
scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was added and samples 
were measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, Turku). From 
these results the percentage of [3H]-E2 displacement by the compounds was calculated. The 
plot of % displacement versus compound concentration resulted in sigmoidal binding curves. 
The compound concentration to displace 50% of the receptor bound [3H]-E2 were determined. 
Unlabelled E2 was used as a reference. For determination of the relative binding affinity 42 the 
ratio was calculated according to the following equation: [ ] ( )( ) 100
2%
50
50
•=
compoundIC
EICRBA .50 
This results in an RBA value of 100% for E2. After the assay was established and validated a 
modification was made to increase throughput. Compounds were tested at concentrations of 
1000∙IC50(E2) and 10000∙IC 50(E2). Results were reported as RBA ranges. Compounds with 
less than 50% displacement of [3H]-E2 at a concentration of 10000∙IC50(E2) were classified as 
RBA <0.01%, compounds that displace more than 50% at 10000∙IC 50(E2) but less than 50% 
at 1000∙IC50(E2) were classified as 0.01%<RBA<0.1%.  
RESULTS   
 - 51 - 
Acknowledgements 
 
We are grateful to the Deutsche Forschungsgemeinschaft for financial support (HA1315/8-1). 
We thank Jannine Ludwig, Jeannine Jung and Jörg Haupenthal for their help in performing 
the enzyme inhibition tests (17β-HSD2, 17β-HSD1) and the ER tests. 
 
References 
 
1. Compston, J. E. Physiol. Rev. 2001, 81, 419. 
2. Frenkel, B.; Hong, A.; Baniwal, S. K.; Coetzee, G. A.; Ohlsson, C.; Khalid, O.; Gabet, 
Y. J. Cell. Physiol. 2010, 224, 305. 
3. Liberman, U. A.; Weiss, S. R.; Broll, J.; Minne, H. W.; Quan, H.; Bell, N. H.; 
Rodriguez-Portales, J.; Downs, R. W., Jr.; Dequeker, J.; Favus, M.; Seeman, E.; Recker, R. 
R.; Capizzi, T.; Santora, A. C. I.; Lombardi, A.; Shah, R. V.; Hirsch, L. J.; Karpf, D. B. N. 
Engl. J. Med. 1995, 333, 1437. 
4. Bauer, D. C.; Black, D. M.; Garnero, P.; Hochberg, M.; Ott, S.; Orloff, J.; Thompson, 
D. E.; Ewing, S. K.; Delmas, P. D. J. Bone Miner. Res. 2004, 19, 1250. 
5. Orwoll, E.; Ettinger, M.; Weiss, S.; Miller, P.; Kendler, D.; Graham, J.; Adami, S.; 
Weber, K.; Lorenc, R.; Pietschmann, P.; Vandormael, K.; Lombardi, A. N. Engl. J. Med. 
2000, 343, 604. 
6. Ettinger, B.; Black, D. M.; Mitlak, B. H.; Knickerbocker, R. K.; Nickelsen, T.; 
Genant, H. K.; Christiansen, C.; Delmas, P. D.; Zanchetta, J. R.; Stakkestad, J.; Glüer, C. C.; 
Krueger, K.; Cohen, F. J.; Eckert, S.; Ensrud, K. E.; Avioli, L. V.; Lips, P.; Cummings, S. R. 
Jama 1999, 282, 637. 
7. Barrett-Connor, E.; Mosca, L.; Collins, P.; Geiger, M. J.; Grady, D.; Kornitzer, M.; 
McNabb, M. A.; Wenger, N. K. N. Engl. J. Med. 2006, 355, 125. 
8. Turner, R. T.; Riggs, B. L.; Spelsberg, T. C. Endocr. Rev. 1994, 15, 275. 
9. Chen, X.; Deng, Y.; Zhou, Z.; Tao, Q.; Zhu, J.; Li, X.; Chen, J.; Hou, J. Vet. Res. 
Commun. 2010, 34, 143. 
10. Mok, S. K.; Chen, W. F.; Lai, W. P.; Leung, P. C.; Wang, X. L.; Yao, X. S.; Wong, M. 
S. Br. J. Pharmacol. 2010, 159, 939. 
11. Eastell, R.; Blumsohn, A. J. Rheumatol. 1997, 24, 1215. 
12. Le Borgne, M.; Marchand, P.; Duflos, M.; Delevoye-Seiller, B.; Piessard-Robert, S.; 
Le Baut, G.; Hartmann, R. W.; Palzer, M. Arch. Pharm. 1997, 330, 141. 
RESULTS   
 - 52 - 
13. Haidar, S.; Ehmer, P. B.; Barassin, S.; Batzl-Hartmann, C.; Hartmann, R. W. J. Steroid 
Biochem. Mol. Biol. 2003, 84, 555. 
14. Leroux, F.; Hutschenreuter, T. U.; Charrière, C.; Scopelliti, R.; Hartmann, R. W. Helv. 
Chim. Acta 2003, 86, 2671. 
15. Frotscher, M.; Ziegler, E.; Marchais-Oberwinkler, S.; Kruchten, P.; Neugebauer, A.; 
Fetzer, L.; Scherer, C.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. J. Med. 
Chem. 2008, 51, 2158. 
16. Marchais-Oberwinkler, S.; Kruchten, P.; Frotscher, M.; Ziegler, E.; Neugebauer, A.; 
Bhoga, U.; Bey, E.; Müller-Vieira, U.; Messinger, J.; Thole, H.; Hartmann, R. W. J. Med. 
Chem. 2008, 51, 4685. 
17. Bey, E.; Marchais-Oberwinkler, S.; Werth, R.; Negri, M.; Al-Soud, Y. A.; Kruchten, 
P.; Oster, A.; Frotscher, M.; Birk, B.; Hartmann, R. W. J. Med. Chem. 2008, 51, 6725. 
18. Bey, E.; Marchais-Oberwinkler, S.; Negri, M.; Kruchten, P.; Oster, A.; Klein, T.; 
Spadaro, A.; Werth, R.; Frotscher, M.; Birk, B.; Hartmann, R. W. J. Med. Chem. 2009, 52, 
6724. 
19. Oster, A.; Klein, T.; Werth, R.; Kruchten, P.; Bey, E.; Negri, M.; Marchais-
Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. Bioorg. Med. Chem. 2010, 18, 3494. 
20. Baston, E.; Hartmann, R. W. Bioorg. Med. Chem. Lett. 1999, 9, 1601. 
21. Picard, F.; Baston, E.; Reichert, W.; Hartmann, R. W. Bioorg. Med. Chem. 2000, 8, 
1479. 
22. Picard, F.; Schulz, T.; Hartmann, R. W. Bioorg. Med. Chem. 2002, 10, 437. 
23. Lu, M. L.; Huang, Y. W.; Lin, S. X. J. Biol. Chem. 2002, 277, 22123. 
24. Dong, Y.; Qiu, Q. Q.; Debear, J.; Lathrop, W. F.; Bertolini, D. R.; Tamburini, P. P. J. 
Bone Miner. Res. 1998, 13, 1539. 
25. van der Eerden, B. C.; Lowik, C. W.; Wit, J. M.; Karperien, M. J. Endocrinol. 2004, 
180, 457. 
26. Sam, K.; Labrie, F.; Poirier, D. Eur. J. Med. Chem. 2000, 35, 217. 
27. Poirier, D.; Bydal, P.; Tremblay, M. R.; Sam, K. M.; Luu-The, V. Mol. Cell. 
Endocrinol. 2001, 171, 119. 
28. Bydal, P.; Auger, S.; Poirier, D. Steroids 2004, 69, 325. 
29. Wood, J.; Bagi, C. M.; Akuche, C.; Bacchiocchi, A.; Baryza, J.; Blue, M. L.; Brennan, 
C.; Campbell, A. M.; Choi, S.; Cook, J. H.; Conrad, P.; Dixon, B. R.; Ehrlich, P. P.; Gane, T.; 
Gunn, D.; Joe, T.; Johnson, J. S.; Jordan, J.; Kramss, R.; Liu, P.; Levy, J.; Lowe, D. B.; 
RESULTS   
 - 53 - 
McAlexander, I.; Natero, R.; Redman, A. M.; Scott, W. J.; Town, C.; Wang, M.; Wang, Y.; 
Zhang, Z. Bioorg. Med. Chem. Lett. 2006, 16, 4965. 
30. Kristan, K.; Krajnc, K.; Konc, J.; Gobec, S.; Stojan, J.; Lanišnik Rižner, T. Steroids 
2005, 70, 626. 
31. Bagi, C. M.; Wood, J.; Wilkie, D.; Dixon, B. J. Musculoskelet. Neuronal Interact. 
2008, 8, 267. 
32. Wu, L.; Einstein, M.; Geissler, W. M.; Chan, H. K.; Elliston, K. O.; Andersson, S. J. 
Biol. Chem. 1993, 268, 12964. 
33. Woo, L. W. L.; Howarth, N. M.; Purohit, A.; Hejaz, H. A. M.; Reed, M. J.; Potter, B. 
V. L. J. Med. Chem. 1998, 41, 1068. 
34. Mewshaw, R. E.; Edsall, R. J., Jr.; Yang, C.; Manas, E. S.; Xu, Z. B.; Henderson, R. 
A.; Keith, J. C., Jr.; Harris, H. A. J. Med. Chem. 2005, 48, 3953. 
35. Kasturi, T. R.; Arunachalam, T. Can. J. Chem. 1968, 46, 3625. 
36. Koubachi, J.; El Kazzouli, S.; Berteina-Raboin, S.; Mouaddib, A.; Guillaumet, G. J. 
Org. Chem. 2007, 72, 7650. 
37. Herrero, M. T.; Tellitu, I.; Domínguez, E.; Hernández, S.; Moreno, I.; SanMartín, R. 
Tetrahedron 2002, 58, 8581. 
38. Bhatt, M. V.; Kulkarni, S. U. Synthesis 1983, 1983, 249. 
39. Lin, S. X.; Yang, F.; Jin, J. Z.; Breton, R.; Zhu, D. W.; Luu-The, V.; Labrie, F. J. Biol. 
Chem. 1992, 267, 16182. 
40. Zhu, D. W.; Lee, X.; Breton, R.; Ghosh, D.; Pangborn, W.; Duax, W. L.; Lin, S. X. J. 
Mol. Biol. 1993, 234, 242. 
41. Kruchten, P.; Werth, R.; Marchais-Oberwinkler, S.; Frotscher, M.; Hartmann, R. W. 
Mol. Cell. Endocrinol. 2009, 301, 154. 
42. Dominguez, L. J.; Scalisi, R.; Barbagallo, M. Acta Biomed. 2010, 81, 55. 
43. Minutolo, F.; Macchia, M.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. Med. 
Res. Rev. 2009. 
44. Zhu, B. T.; Han, G. Z.; Shim, J. Y.; Wen, Y.; Jiang, X. R. Endocrinology 2006, 147, 
4132. 
45. Mazumdar, M.; Fournier, D.; Zhu, D. W.; Cadot, C.; Poirier, D.; Lin, S. X. Biochem. 
J. 2009, 424, 357. 
46. Chen, W.; Lin, Z.; Ning, M.; Yang, C.; Yan, X.; Xie, Y.; Shen, X.; Wang, M. W. 
Bioorg. Med. Chem. 2007, 15, 5828. 
RESULTS   
 - 54 - 
47. Cusack, K. S.-G., J. A.; Gordon, T. D.; Barberis, C. E.; Allen, H. J.; Bischoff, A. K.; 
Ericsson, A. M.; Friedman, M. M.; George, D. M.; Roth, G. P.; Talanian, R. V.; Thomas, C.; 
Wallace, G. A.; Wishart, N.; Yu, Z. 2007, WO 2005110410 (A2). 
48. Qiu, W.; Campbell, R. L.; Gangloff, A.; Dupuis, P.; Boivin, R. P.; Tremblay, M. R.; 
Poirier, D.; Lin, S. X. Faseb J. 2002, 16, 1829. 
49. Zimmermann, J.; Liebl, R.; von Angerer, E. J. Steroid Biochem. Mol. Biol. 2005, 94, 
57. 
50. Hartmann, R. W. J. Med. Chem. 1986, 29, 1668. 
 
 
 
RESULTS   
 - 55 - 
3.2. Introduction of an electron withdrawing group on 
the hydroxyphenylnaphthol scaffold improves the 
potency of 17β-hydroxysteroid dehydrogenase type 2 
(17β-HSD2) inhibitors 
 
Marie Wetzel
 
, Sandrine Marchais-Oberwinkler, Enrico Perspicace, Gabriele 
Möller, Jerzy Adamski and Rolf W. Hartmann  
This manuscript has been submitted in the journal  
Journal of Medicinal Chemistry, 2011,  
 
Paper II 
 
Abstract 
 
Estrogen deficiency in postmenopausal women or elderly men is often associated with the 
skeletal disease osteoporosis. The supplementation of estradiol (E2) in osteoporotic patients is 
known to prevent bone fracture but can not be administered because of adverse effect. As 
17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) oxidises E2 to its inactive form 
estrone (E1) and has been found in osteoblastic cells, it is an attractive target for the treatment 
of osteoporosis. Twenty one novel, naphthalene-derived compounds have been synthesised 
and evaluated for their 17β-HSD2 inhibition and their selectivity toward 17β-HSD1 and the 
estrogen receptors (ERs) α and β. Compound 19 turned out to be the most potent and selective 
inhibitor of 17β-HSD2 in cell free assays and had a very good cellular activity in MDA-MB-
231 cells, expressing naturally 17β-HSD2. It also showed marked inhibition of the E1-
formation by the rat and mouse orthologous enzymes and strong inhibition of monkey 17β-
HSD2. It is thus an appropriate candidate to be further evaluated in a disease-oriented model. 
 
Introduction 
 
17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyses the conversion of the 
biologically active sex steroids estradiol (E2) and testosterone (T) into their inactive forms 
using NAD+ as cofactor (Chart 1). It is a trans-membrane protein1 and no crystal structure is 
available yet. This enzyme is abundantly expressed in placenta, liver, small intestine, 
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endometrium and to a lesser extend also in kidney, pancreas, colon, uterus, breast and 
prostate. It was also found in osteoblastic cells1-4.  
 
Chart 1. Interconversion of estradiol (E2) to estrone (E1) by 17β-HSD2, 17β-HSD4, 17β-
HSD1, and of testosterone (T) to androstenedione (A-dione) by 17β-HSD2, 17β-HSD4, 17β-
HSD3 and 17β-HSD5. 
O
OH
OH
OH
O
O
OH
O
17β-HSD1, NADPH
17β-HSD2,4, NAD+
E1E2
17β-HSD2,4, NAD+
T A-dione
17β-HSD3,5 NADPH
 
 
In bone physiology osteoblastic cells 5 are responsible for bone formation and 
mineralisation and osteoclastic cells (OCs) for bone resorption. The subtle remodelling 
balance maintained between the OB and OC activities is crucial for bone stability.  
Osteoporosis6 is a systemic skeletal disease characterised by low bone mass and 
deterioration of bone tissue. Symptoms of this disease include bone fragility6 and increase in 
fractures6, often at the hips, spine and wrist. Osteoporosis occurs especially in 
postmenopausal women and elderly men, when the levels in active sex steroids (E2 and T)7 
drop. 
Only few drugs are efficient for the treatment of osteoporosis. Among them, the 
antiresorptive agent bisphosphonate alendronate8 is the most potent drug but the risk of 
fractures in postmenopausal women8-10 and elderly men11 is only reduced by 50%. Estrogens 
stop bone loss in osteoporotic patients but are no longer used, because of several non-skeletal 
effects such as an increased risk of deep vein thrombosis, pulmonary embolism and breast 
cancer12. Furthermore, low dose of synthetic estrogens, like ethinylestradiol, has no practical 
application. Raloxifene13, a selective estrogen receptor modulator (SERM) is frequently used 
to treat osteoporosis. Drawbacks of this therapy are the increased risks of thromboembolism14, 
hot flushes15 and leg cramps15. Therefore, there is a need to develop novel drugs, more 
efficient and selective for osteoporosis. 
RESULTS   
 - 57 - 
Estrogens are known to play a key role in bone physiology. They act directly on OBs, 
which regulate the ability of the OC precursors to differentiate to OCs (osteoclastogenesis). 
The mode of action of estrogens on bone mass is not yet well understood. 17β-HSD2, which 
is expressed in OBs, can be considered as a molecular switch, as it is involved in the 
regulation of the level of active E2 and T in the target cell. Therefore, a local intracellular 
enhancement of E2 and T in bones should be feasible. This strategy has already been 
successfully applied for several enzymes like aromatase16-18, CYP1719-22, 17β-HSD123-35 and 
5α-reductase36-40. 
Among the few 17β-HSD2 inhibitors described in the literature41-50 there is only one class 
of non-steroidal compounds46-48: the cis-pyrrolidinones. Applying a non-steroidal inhibitor 
from this class in a monkey osteoporosis model, 17β-HSD2 has been validated as target for 
the treatment of osteoporosis by Bagi et al.51. Treatment with this compound led to a slight 
decrease in bone resorption and increase in bone formation resulting in maintenance of bone 
balance and bone strength50. As only small effects were observed, there is a need to develop 
new potent 17β-HSD2 inhibitors with better in vivo efficacy. Additionally, these compounds 
should show a high selectivity toward 17β-HSD1, the isoenzyme catalysing the reverse 
reaction, the reduction of estrone (E1) to E2.  
In a previous work52, focusing on the design of new non-steroidal 17β-HSD2 inhibitors, 
6-(4´-hydroxyphenyl)-1-naphthol (compound A - Table 1) has been identified as a promising 
scaffold with an IC50 value of 302 nM for 17β-HSD2 and a selectivity factor (SF) of 8 toward 
17β-HSD1. This hit needed to be improved regarding activity and selectivity. According to 
our hypothesis52, the OH substituted benzene ring of the naphthalene moiety in A mimics the 
A-ring of E2 and the OH-phenyl the D-ring, leading to a close binding of the OH-phenyl to 
the catalytic triad and the cofactor. As the substrate of one enzyme (17β-HSD2 in this case) is 
the product of the catalytic reaction of the other enzyme (17β-HSD1 in this case), it can be 
concluded that their active sites must be very similar too. Therefore, with analysing 17β-
HSD1 from which in contrast to 17β-HSD2 the crystal structure is known, it becomes 
apparent that there is some space available around the OH-phenyl for substituents. 
 In this work, first the hypothesis concerning the binding mode of hydroxyphenyl 
naphthol derivatives to 17β-HSD2 was validated. Afterwards, the available space for the 
inhibitors in the active site of the enzyme was explored by synthesis of several derivatives 
where the size of substituents at position 2’ and 3’ of the hydroxyphenyl ring was varied. 
Expecting that electronic effects play an important role, electron donating (EDG) and electron 
withdrawing (EWG) groups were also introduced into the OH-phenyl moiety. 
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Chemistry 
 Synthesis of 1 to 8 and 10 to 20 (Scheme 1) started from the commercially available 6-
methoxy-1-tetralone which was triflated and aromatised in 1a in very good yield according to 
the method described by us52. The cross-coupling reaction53 of the triflate 1a with the 
appropriate methoxy phenylboronic acid led to compounds 1, 3a, 4, 6, 8, 10, 12, 14, 16 to 18 
and 20 (method A or B). Ether cleavage was performed using boron tribromide for 
compounds 2, 7 and 13 (method C), boron trifluoride dimethylsulfide complex for compounds 
3, 5 and 15 (method D) or pyridinium hydrochloride for compounds 11 and 19 (method E). 
 
Scheme 1. Synthesis of compounds 1 to 8 and 10 to 20a 
OH
OTf
OH
OMe
R2
OH
OH
R2
OH
OH
R2
1: R2: 2´-CH3
3a: R2: 3´-CH3
4: R2: 2´-OCH3
6: R2: 3´-OCH3
10: R2: 2´-F
12: R2: 3´-F
14: R2: 2´, 5´-diF
18: R2: 3´-CF3
1a
a or b
8: R2: 3´-OCH3
16: R2: 2´, 6´-diF
17: R2: 2´-CF3
20: R2: 3´-Cl
2´
3´
2´
3´
2´
3´
2: R2: 2´-CH3
3: R2: 3´-CH3
5: R2: 2´-OH
7: R2: 3´-OH
11: R2: 2´-F
13: R2: 3´-F
15: R2: 2´, 5´-diF
19: R2: 3´-CF3
aReagents and conditions: a. boronic acid, Pd(PPh3)4, aq. Na2CO3, DME/EtOH, 90°C, 2h for 1, 3a, 4, 6, 12 and 17,
Method A; b. boronic acid, Pd(PPh3)4, Cs2CO3, DME/water, microwave irradiation (150°C, 150 W,  25 min) for 8, 10,
14, 16, 18 and 20, Method B; c. BBr3, CH2Cl2, -78°C to rt, overnight, for 2, 7 and 13, Method C; d. BF3.SMe2, CH2Cl2,
rt, overnight, for 3, 5 and 15, Method D; e. pyridinium hydrochloride, 220°C, 3h for 11 and 19, Method E.
6´
5´
5´
a or b
c, d or e
 Compound 9 bearing an additional phenyl ring on the hydroxyphenyl moiety was 
synthesised according to the route described in Scheme 2. Compound 1a was first methylated 
using methyliodide54 and subsequently the triflate group was exchanged by a boronic ester 
group (intermediate 9c) with bis(neopentylglycolato)diboron and a crown-ether under basic 
conditions according to the method of Xu et al.55 In parallel, compound 9b was synthesised 
by a Suzuki coupling with 4-bromo-2-iodo-1-methoxybenzene 9e and phenylboronic acid.  
Subsequent Suzuki coupling (method B) between compounds 9c and 9b led to compound 9a. 
Demethylation using boron tribromide (method C) afforded compound 9. 
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 The synthesis of 21 was carried out by palladium-catalysed Suzuki coupling reaction 
using the intermediate 9c (method A) and the commercially available 5-bromo-2-
hydroxybenzonitrile, followed by ether cleavage with boron trifluoride dimethylsulfide 
complex (method D, Scheme 2). 
 
Scheme 2. Synthesis of compounds 9 and 21a 
OR
OTf
B
O
O
OMe
Br
OMe
R
OR
OR
OH
Br
CN
OH
CN
OR
1a: R3: H
9d: R3: CH3
9c
9a: R1: CH3
9: R1: H
b
c
d
d
e
aReagents and conditions: a. MeI, K2CO3, 18-Crown-6, acetone, reflux, overnight; b. bis(neopentylglycolato)diboron,
PdCl2(dppf), dppf, KOAc, 1,4-dioxane, 85°C, 4h; c. PhI(OAc)2, I2, EtOAc, 60°C, dark conditions, 4h; d. boronic acid, 
Pd(PPh3)4, Cs2CO3, DME/water, microwave irradiation (150°C, 150 W, 25 min), Method B; e. BBr3, CH2Cl2, -78°C
to rt, overnight, Method C; f. boronic acid, Pd(PPh3)4, aq. Na2CO3, DME/EtOH, 90°C, 2h, Method A; g. BF3.SMe2, 
CH2Cl2, rt, overnight, Method D.
9f: R: H
9e: R: I
9b: R: phenyl
a
3
3
1
f
21a: R3: CH3
21: R3: H
g
3
 
Biological characterisation 
Inhibition of human 17β-HSD2 
 17β-HSD2 inhibitory activity of the synthesised compounds was first evaluated in a 
cell-free assay. Human placental microsomal enzyme was used as source. The incubation was 
performed with tritiated E2, cofactor and inhibitor. The separation of substrate and product 
was accomplished by HPLC with a subsequent quantification by peak integration56. The 
percent inhibition values of compounds 1 to 21 are shown in Table 1, and the IC50 values of 
the most active compounds are reported in Table 2. Compounds showing less than 10% 
inhibition at 1µM concentration were considered to be inactive. Compound A, identified in a 
previous work52, was used as internal reference (74% 17β-HSD2 inhibition vs. 20% 17β-
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HSD1 inhibition at 1µM) and a spiro-δ-lactone (compound 10 published by Poirier et al.43) 
was taken as external control (68% at 1µM in our test; 62-66% at 1µM in their test43). 
 For selected substituents (R2 = 2´-CH3, 2´-OCH3, 3´-OCH3, 2´-F, 3´-F, 2´,5´-diF, 3´-
CF3), both hydroxyphenyl 2, 5, 8, 11, 13, 15, 19 and corresponding methoxyphenyl 
derivatives 1, 4, 6, 10, 12, 14, 18 were synthesised and tested for 17β-HSD2 inhibitory 
activity. As observed for the unsubstituted compound A, the hydroxylated molecules (2, 8, 11, 
13, 15 and 19) were always more potent than the respective methoxylated analogues except 
for the compound pair 4 (R2 = 2´-OCH3) and 5. For compounds 3, 9, 16, 17, 20 and 21, the 
hydroxylated derivatives only were therefore tested. 
 Introduction of a lipophilic group like methyl (compounds 2 and 3) led to good 17β-HSD2 
inhibitory activity (65% inhibition for 2 and 79% for 3 when tested at 1 µM), which was at 
the level of unsubstituted A (74% inhibition at 1 µM). This indicates that there is space 
around the hydroxyphenyl moiety for introduction of a small substituent in 2´- or 3´-position 
but the methyl is certainly not able to achieve any specific interactions as no gain in activity is 
observed compared to the parent hydroxyphenylnaphthol A. 
 Exchange of the methyl group for a hydrophilic hydroxy substituent was detrimental for 
activity in 2´-position (5, inactive) but tolerated in 3´-position (8, similar activity as the 
unsubstituted A). It can therefore be hypothesised that there is no polar amino acid in the 
active site close to the 2´-position of the inhibitor. Furthermore, the 3´-OH group of 
compound 8 did not show specific interactions with the enzyme, as no increase in activity was 
observed compared to A. It is striking that an exchange of hydroxy (8) by methoxy (7) in 3´-
position decreased the inhibitory activity strongly. 
 A phenyl ring was also introduced into the 3´-position (9). This compound displayed a 
slight increase in activity (84% inhibition at 1 µM for 9 vs. 74% inhibition at 1 µM for A), 
confirming our previous hypothesis that there is space available around the hydroxyphenyl 
core.  
 In order to evaluate the influence of electron withdrawing groups (EWGs) or electron 
donating groups (EDGs) on the 17β-HSD2 inhibitory activity, compounds 10 to 21 bearing 
EWGs were synthesised to be compared to compounds with EDGs like methyl (3) or phenyl 
(9) groups. All methoxy derivatives (10, 12, 14 and 18) showed lower activity than the 
corresponding hydroxy compounds (11, 13, 15 and 19). Most of the hydroxy compounds 
exhibited identical or better potency than the parent compound A except 21. Compound 11, 
substituted with a fluoro group in 2´- position turned out to be highly active (87% inhibition at 
1µM, IC50 = 132 nM). Disubstituted fluorine compounds (2´, 5´-diF: 15 and 2´, 6´-diF: 16) 
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resulted in highly active inhibitors, but slightly weaker than the monofluoro 11 (IC50: 238 nM 
for 15 vs. 132 nM for 11). Compounds 17 (R2 = 2´-CF3) and 19 (R2 = 3´-CF3) showed high 
(17) and very high (19) activity (84% and 98% inhibition at 1µM, respectively), resulting in 
IC50 values of 19 nM for 19 vs. 156 nM for 17. However, exchange of the trifluoromethyl 
group for bioisosteric chloro (20) or cyano (21) groups was detrimental for the activity (74% 
and 45% inhibition for 20 and 21, respectively) when compared with inhibitory efficiency of 
19 (98% at 1μM). 
Table 1. Inhibition of human 17β-HSD2 and 17β-HSD1 by compounds 1 to21 
OH
OR
R2
1
A, B, 1-21
2´
3´
5´
6´
 
Compd R1 R2 
Inhibition of 
17β-HSD2a [%] 
at 1 µM 
Inhibition of 
17β-HSD1b [%] 
at 1 µM 
LogPc 
Spiro-δ-
lactone - - 68 n.i. - 
A H H 74 20 3.93 
B CH3 H 20 28 - 
1 CH3 2´-CH3 25 20 4.68 
2 H 2´-CH3 65 25 4.41 
3 H 3´-CH3 79 48 4.41 
4 CH3 2´-OCH3 37 15 4.06 
5 H 2´-OH 11 10 3.54 
6 CH3 3´-OCH3 49 45 4.06 
7 H 3´-OCH3 36 24 3.80 
8 H 3´-OH 69 31 3.54 
9 H 3´-phenyl 84 47 5.60 
10 CH3 2´-F 32 41 4.35 
11 H 2´-F 87 36 4.09 
12 CH3 3´-F 51 66 4.35 
13 H 3´-F 78 62 4.09 
14 CH3 2´, 5´-diF 26 73 4.51 
15 H 2´, 5´-diF 83 74 4.24 
16 H 2´, 6´-diF 69 73 4.24 
17 H 2´-CF3 84 52 4.85 
18 CH3 3´-CF3 44 69 5.11 
19 H 3´-CF3 98 60 4.85 
20 H 3´-Cl 74 43 4.49 
21 H 3´-CN 45 n.i. 3.96 
a Human placenta, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], NAD+ [1500 µM], mean value of three 
determinations, relative standard deviation < 10%, b Human placenta, cytosolic fraction, substrate [3H]-E1 + E1 
[500 nM], NADH [500 µM], mean value of three determinations, relative standard deviation < 10%, c calculated 
logP data; n.i.: no inhibition (inhibition < 10%).  
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Selectivity and cellular activity 
 17β-HSD1, as the main enzyme implicated in the reduction of estrone (E1) to E2 in sex 
steroid metabolism57, should not be affected by inhibitors of 17β-HSD2. Furthermore, 
inhibitors of 17β-HSD2 should have none or little affinity for the estrogen receptors α and β 
(ERα and ERβ), as most of the E2 effects are ER mediated. Therefore all compounds were 
tested for selectivity toward 17β-HSD1 and a selection of the most potent inhibitors for 
binding affinity to ERα and β. 
 The assay for 17β-HSD1 inhibition was performed in a similar way as for the 17β-HSD2. 
Human placental cytosolic 17β-HSD1 was incubated with tritiated E1, cofactor and inhibitor. 
The amount of labelled E2 formed was determined after HPLC separation. For the most 
potent compounds, IC50 values were determined and selectivity factors (SFs) calculated (SF = 
IC50 17β-HSD1 / IC50 17β-HSD2, Table 2). All compounds except 15 showed selectivity 
toward 17β-HSD1. The most selective one, with a selectivity factor of 32, was compound 19 
(R2: 3´-CF3), which was also the most potent one exhibiting an IC50 value of 19 nM. The 2´-F 
compound 11 also showed a high SF of 17 toward 17β-HSD1. 
For the determination of ER binding affinity, a competition assay was used, with tritiated 
E2. Receptor bound and free E2 were separated by means of hydroxyapatite. Compounds 3, 9, 
11 and 19 showed a relative binding affinity (RBA) of less than 0.1% to ERα, compared to 
the affinity of E2, which is arbitrarily set to 100%. The indicated compounds are therefore 
classified as low affinity ligands of the ERα.  
The logP values were calculated using the ChemDrawPro 11.0 program in order to get 
insight into the lipophilicity of this class of compounds and are shown in Table 1. The values 
for all compounds except 9 and 18 are lower than 5, fulfilling the criteria of Lipinski´s rule of 
five. It therefore can be expected that they are able to easily permeate cell membranes. 
 The most interesting compounds 11, 17 and 19 with IC50 values below 200 nM were 
further investigated in a cellular assay, using the human breast cancer cell line MDA-MB-
23158, which endogenously expresses 17β-HSD2. Cells were incubated with tritiated E2 and 
inhibitor for 3.5h. Separation was performed by HPLC similar as in the cell-free inhibition 
assays. Compounds 17 and 19 showed very similar inhibitory activity in MDA-MB-231 cells 
as in the cell-free assay, i.e. IC50 of 171 nM for 17 and 31 nM for 19 in cellular assay vs. 156 
nM and 19 nM, respectively, in the cell-free assay. Interestingly, compound 11 showed an 
IC50 of 1227 nM in the cellular assay compared to 132 nM in the cell-free assay, indicating 
that this compound is less appropriate to permeate the cell membrane or is metabolically 
unstable.  
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Table 2. IC50 values, selectivity factor and binding affinities for the estrogen receptors α and 
β for selected compounds. 
Compd 
Cell free assay 
ERα 
RBAd (%) 
ERβ 
RBAd (%) 
17β-
HSD2 
IC50a 
[nM] 
17β-
HSD1 
IC50b 
[nM] 
Selectivity 
factorc 
Spiro- δ-
lactone 34 n.d. n.d. n.d. n.d. 
A 302 2425 8 5 5 
3 275 1748 6 < 0.1 0.1-1.0 
9 261 919 4 < 0.1 < 0.1 
11 132 2245 17 < 0.1 < 0.1 
13 292 713 2 0.1-1.0 0.1-1.0 
15 238 309 1 0.1-1.0 0.1-1.0 
17 156 926 6 1.0-10 1.0-10 
19 19 611 32 < 0.1 0.1-1.0 
20 307 1130 4 0.1-1.0 0.1-1.0 
a Human placenta, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], cofactor NAD+ [1500 μM], mean 
value of three determinations, relative standard deviation < 10%, b Human placenta, cytosolic fraction, substrate 
[3H]-E1 + E1 [500 nM], cofactor NADH [500 μM], mean value of three determinations, relative standard 
deviation < 20%, c IC50 (17β-HSD1)/ IC50 (17β-HSD2), d RBA: Relative Binding Affinity, E2: 100%; n.d.: not 
determined. 
 
Further in vitro assays 
In order to refine the profile of the most potent compound 19, it was further tested for 
selectivity on other enzymes, namely 17β-HSDs type 4 and 5. 17β-HSD4 catalyses the same 
reaction as 17β-HSD2 (Chart 1)57, and 17β-HSD5 (beside 17β-HSD3) is responsible for the 
reduction of the androgen A-dione to T57. Both enzymes should not be inhibited by 17β-
HSD2 inhibitors. To investigate this important issue, experiments were performed with E.coli 
bacteria expressing human 17β-HSD4 and 17β-HSD556, 59. These cells were incubated with 
cofactor, inhibitor and tritiated E2 in case of 17β-HSD4 and A-dione in case of 17β-HSD5. 
After RP-HPLC separation of substrate and product, the amount of labelled E1 or T formed 
was quantified. Compound 19 was found to be selective toward 17β-HSD4 and 17β-HSD5 
(40% 17β-HSD4 inhibition and 21% 17β-HSD5 inhibition at 1μM). 
According to the potency of compound 19 in cell-free and cellular assays and its 
selectivity toward 17β-HSD1, 17β-HSD4, 17β-HSD5 and ERs, it can be considered as 
potential candidate for further development. Before evaluation in an animal model of the 
efficacy of this new 17β-HSD2 inhibitor 19, it is reasonable to determine its profile on 
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orthologous enzymes from different species. Compound 19 was therefore tested for inhibition 
of 17β-HSD2/E1-formation (activity) and 17β-HSD1/E2-formation (selectivity) using rat, 
mouse and monkey enzymes. 
In rat and mouse assays, liver enzymes were used, while in monkey assay, placental 
enzymes were employed. Compound 19 showed good inhibition of the rat and mouse 17β-
HSD2 enzymes and very good inhibition on the monkey enzyme. In this case, the efficacy 
was in the same range as for the human enzyme (Table 3). In addition, selectivity toward 17β-
HSD1/E2-formation in monkey seems to be similar to that observed in human.  
 
Table 3. Inhibition of rat, mouse and monkey E1- and E2-formation by compound 19. 
Compound 19 
Inhibition of E1-formationa 
[%] 
Inhibition of E2-formationb  
[%] 
1μM 100 nM 1μM 100 nM 
Human 98c 87c 60d 27d 
Rat 77e n.d. 52f n.d. 
Mouse 72g n.d. 26h n.d. 
Monkey 99i 75i 75j 55 j 
a Substrate [3H]-E2 + E2 [500 nM], NAD+ [1500 µM], mean value of three determinations, relative standard 
deviation < 10%, b Substrate [3H]-E1 + E1 [500 nM], NADH [500 µM], mean value of three determinations, 
relative standard deviation < 10%, c Human placenta, microsomal fraction, d Human placenta, cytosolic fraction, 
e Rat liver, microsomal fraction, f Rat liver, cytosolic fraction, g Mouse liver, microsomal fraction, h Mouse liver, 
cytosolic fraction, i Monkey placenta, microsomal fraction, j Monkey placenta, cytosolic fraction, n.d.: not 
determined. 
 
Discussion and Conclusion 
Compound A, identified by us in a previous study52 represents a promising scaffold as 
17β-HSD2 inhibitor: substituted by two hydroxy groups (polar), the naphthalene and phenyl 
cores (hydrophobic) mimicking the substrate E2. We have previously shown52 that an 
exchange of the hydroxy group on the phenyl moiety by a sulfonamide did not affect the 
activity toward 17β-HSD2 (74% vs. 75% inhibition at 1µM, respectively), indicating that 
some space is available around the phenyl core. We hypothesised therefore that the phenyl 
ring mimics the D-ring of E2 and thus that introduction of additional substituents on this 
phenyl moiety would be tolerated and would allow an increase of the 17β-HSD2 inhibitory 
activity. In this paper, we aimed at verifying whether this hypothesis is correct and whether 
introduction of various substituents on the phenyl ring could improve this activity. 
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The biological activity of the phenyl-substituted compound 9 confirms that the compound 
can indeed bind in the active site according to the previous hypothesis (the hydroxy 
naphthalene mimics the A-ring and the hydroxyphenyl the D-ring). The additional phenyl 
might be accommodated between cofactor and steroid where space is available.  
The electronic effects of the substituents on the 17β-HSD2 inhibitory activity were 
further elucidated. No matter where being introduced, EDGs (Me, OH, Ph) in either 2´- or 3´-
position did not lead to significant differences in activity except for the hydroxy group where 
position 3´ was better (compounds 5 and 8). None of the synthesised compounds (2, 3, 8 and 
9) reached a better activity compared to reference A indicating that these substituents are 
tolerated (there is space available) but not able to establish specific interactions with amino 
acid residues. The position of the substituent on the phenyl ring will induce either a 
pronounced rotation of the phenyl toward the naphthalene (position 2´, ortho effect) or a weak 
rotation (position 3´). In both cases, only the 4´-hydroxy substituent stays at the same position 
and anchors the molecule into its binding site. Our finding that there is no difference in 
activity between 2´- and 3´-substituted compounds indicates that the phenyl ring is not able to 
establish π- π stacking interactions with amino acid side chains of the protein. 
When the substituent was an EWG (F, CF3, Cl, CN), the highest potency was observed 
for compound 19 (R2: 3´-CF3) in which the additional group was located in the 3´-position. 
Exchange of the trifluoromethyl group by the bioisosteric groups like chloro (20) and cyano 
(21) decreased inhibition. In case of the CN group, the different activities might be due to the 
fact that CN is hydrophilic whereas CF3 is lipophilic. The linear shape of CN giving steric 
hindrance might also explain the moderate activity of 21.  
As shown in many other cases5 and also observed for compound 11, the substitution with 
F results in an increase in inhibitory activity. However, the introduction of a second fluorine 
as in 15 or 16 does not further enhance activity, indicating that the effects are not additive. 
In our previous study52, it was observed that the hydroxy group bound to the phenyl 
moiety was important for activity (74% at 1µM for A with OH vs. 20% inhibition for B with 
OMe). This is confirmed in this study as all methoxy compounds displayed lower 17β-HSD2 
inhibitory activity than their corresponding hydroxy analogues. Contrary to our compounds, 
the other described non-steroidal 17β-HSD2 inhibitor46-48, the cis-pyrrolidinones, do not need 
any hydrophilic group to be active, letting us to presume that they might have a different 
binding mode compared to ours.  
As other 17β-HSD enzymes of the short-chain dehydrogenase/reductase (SDR) and the 
aldo-ketoreductases (AKR) family participate in steroid interconversions60, the development 
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of enzyme-specific inhibitors is a challenge. We therefore tested the compounds on other 17β-
HSDs, like 17β-HSD type 1, 2, 4 and 5. Selectivity toward 17β-HSD1 was low with nearly all 
of the tested hydroxyphenylnaphthol derivatives, however, the most potent 17β-HSD2 
inhibitors 11 and 19 showed the highest selectivity toward 17β-HSD1, exhibiting promising 
selectivity factors (SFs) of 17 and 32, respectively. Although some inhibition of 17β-HSD4 
and 5 was observed with the best inhibitor compound 19, the substance can be assumed to be 
selective toward both enzymes. We were surprised by the fact, that the compound 19 showed 
some minor inhibition of 17β-HSD4. In our previous projects we have not seen any effect on 
this particular enzyme with steroidal or non-steroidal inhibitors56, 61. Nevertheless, the 
observed inhibition of compound 19 is fairly low and the impact on the ubiquitously 
expressed 17β-HSD4 contributing to the peroxisomal β-oxidation of fatty acids62 is most 
probably negligible.  
Compounds 11 and 19 also displayed very little binding affinity to ERα, which is 
responsible for cell proliferation.  Only compound 19 showed a very good cellular activity 
(IC50 = 31 nM in MDA-MB-231 cells). Thus it is able to permeate the cell membrane and is 
not quickly metabolised.  
An osteoblastic cell-line, expressing 17β-HSD2 and the ERs like SV-HFO should be 
promising to prove our concept that 17β-HSD2 inhibition is able to induce bone formation 
and inhibit osteoclastogenesis. For further in vivo experiments, species differences have to be 
taken into consideration63, 64, and compound 19 should inhibit the enzyme of the chosen 
species. Pursuing this, 19 was tested on rat, mouse and monkey enzymes, and revealed a high 
(72% to 77% inhibition at 1μM in mouse and rat enzymes, respectively) to very high (99% 
inhibition at 1μM in monkey enzyme) inhibitory activity for 17β-HSD2/E1-formation. 
Showing a better activity and selectivity in marmoset (Callithrix jacchus) enzymes, this 
species should be appropriate for proving our concept. 
In the present study, we describe the synthesis of substituted 6-phenyl-1-naphthols as 
inhibitors of 17β-HSD2 and the evaluation of their biological activities. A new highly potent 
inhibitor of 17β-HSD2 has been discovered (compound 19), with a very good cellular activity 
and good selectivity toward 17β-HSD1, 17β-HSD4, 17β-HSD5 and ERs. Compound 19 is 
also able to inhibit E1-formation in rat, mouse and monkey. Further biological analyses still 
need to be investigated to get information on the efficacy of the compound, to demonstrate 
that 17β-HSD2 inhibitors are able to inhibit osteoclastogenesis and induce bone formation. 
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Experimental section 
 
Chemical methods.  
1H NMR and 13C NMR spectra were recorded on a Bruker DRX-500 instrument in 
CDCl3 and acetone-d6. Chemicals shifts are reported in δ values (ppm), the hydrogenated 
residues of deuteriated solvent were used as internal standard (CDCl3: δ = 7.26 ppm in 1H 
NMR and δ = 77.0 ppm in 13C NMR, acetone-d6: δ = 2.05 ppm in 1H NMR and δ = 30.8 ppm 
and 206.3 ppm in 13C NMR). Signals are described as s, br, d, t, dd, dt, qt and m for singlet, 
broad, doublet, triplet, doublet of doublets, doublet of triplets, quintuplet and multiplet, 
respectively. All coupling constants (J) are given in Hertz. IR spectra were measured neat on 
a Bruker Vector 33FT-infrared spectrometer. Melting points (mp) were determined in open 
capillaries on a Stuart Scientific SMP3 apparatus and are uncorrected. 
Mass spectra (GC/MS) were measured on a GCD Series G1800A (Hewlett Packard) 
instrument with an Optima-5-MS (0.25 μM, 30 m) column (Macherey Nagel). All microwave 
irradiation experiments were carried out in a CEM-Discover monomode microwave 
apparatus. 
Flash chromatography was performed on silica gel 40 (35/40-63/70 μM) with 
hexane/ethyl acetate mixtures as eluents and the reaction progress was determined by thin-
layer chromatography analyses on Alugram SIL G/UV254 (Macherey-Nagel). Visualization 
was accomplished with UV light. 
Tested compounds are ≥ 95 % chemical purity as measured by LC/MS. A table of data 
for all tested compounds are provided in the supporting information. The Surveyor®-LC-
system consisted of a pump, an autosampler, and a PDA detector. Mass spectrometry was 
performed on a MSQ® electro spray mass spectrometer (ThermoFisher, Dreieich, Germany). 
The system was operated by the standard software Xcalibur®. 
A RP-C18 NUCLEODUR® 100-5 (125x3 mm) column (Macherey-Nagel GmbH, Dühren, 
Germany) was used as stationary phase. All solvents were HPLC grade. 
In a gradient run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) in 0.1 % 
trifluoroacetic acid was increased from an initial concentration of 0 % at 0 min to 100 % at 15 
min and kept at 100 % for 5 min. The injection volume was 15 µL and flow rate was set to 
800 µL/min. MS analysis was carried out at a spray voltage of 3800 V and a capillary 
temperature of 350 °C and a source CID of 10 V. Spectra were acquired in positive mode 
from 100 to 1000 m/z at 254 nm for the UV trace. 
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Starting materials (different boronic acids and compounds 1e, 9f and 21b) were 
purchased from Aldrich, Alfa Aeser, Acros and Combi-blocks and were used without further 
purification. No attempts were made to optimise yields. 
The following compounds were prepared according to previously described procedures: 
5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a52, 4-bromo-2-iodo-1-methoxybenzene 
9e27. 
 
General procedures for Suzuki coupling 
Method A. To a mixture of arylbromide (1 equiv) and tetrakis(triphenylphosphine) palladium 
(0) (0.02 equiv) in DME was added a 2N aqueous solution of sodium carbonate (2 equiv) and 
the mixture (oxygen free) was purged with N2. The resultant solution was stirred at room 
temperature for 5 min and a solution of boronic acid (1.3 equiv) in EtOH was added. The 
mixture was heated to 90°C and stirred for 2h. The reaction mixture was cooled to room 
temperature, quenched by water and extracted with ethyl acetate. The organic layer was 
washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The 
product was purified by column chromatography. 
 
Method B. A mixture of arylbromide (1 equiv), boronic acid (1 equiv), caesium carbonate (3 
equiv), and tetrakis(triphenylphosphine) palladium (0) (0.02 equiv) was suspended in an 
oxygen-free DME/water (2:1) solution. The reaction mixture was exposed to microwave 
irradiation (25 min, 150W, 150°C, 15 bar). After reaching room temperature, water was added 
and the aqueous layer was extracted with ethyl acetate. The combined organic layers were 
washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The 
product was purified by column chromatography. 
 
General procedures for ether cleavage 
Method C. To a solution of methoxy derivative (1 equiv) in dry dichloromethane cooled at          
-78°C under nitrogen was slowly added boron tribromide (1M solution in dichloromethane,   
5 equiv to 10 equiv per methoxy function). The reaction mixture was stirred at -78°C for 1h 
and then allowed to warm to room temperature overnight. The reaction was quenched by 
water and extracted with ethyl acetate. The combined organic layers were washed with brine 
and dried over sodium sulfate, evaporated to dryness under reduced pressure and purified by 
column chromatography. 
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Method D. To a solution of methoxy derivative (1 equiv) in dry dichloromethane, 
borontrifluoride dimethyl sulfide complex (75 equiv per methoxy function) was added drop 
wise at room temperature. The reaction mixture was stirred at room temperature overnight. 
Water was added to quench the reaction and the aqueous layer was extracted with ethyl 
acetate. The combined organic layers were washed with brine, dried over sodium sulfate, 
evaporated to dryness under reduced pressure and purified by column chromatography. 
 
Method E. To pyridinium hydrochloride (100 equiv) at 190°C was added methoxy derivative 
(1 equiv), and the solution was stirred for 2h. The reaction mixture was cooled to room 
temperature and was stirred with 1N HCl. The mixture was dissolved in ethyl acetate and the 
combined organic layers were washed with water, dried over sodium sulfate, filtered, 
evaporated to dryness under reduced pressure and purified by column chromatography. 
 
6-(4-Methoxy-2-methylphenyl)-1-naphthol (1). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (150 mg, 0.51 mmol, 1 equiv) 
with 4-methoxy-2-methylphenylboronic acid (110 mg, 0.66 mmol, 1.3 equiv) according to 
method A. The product was purified by column chromatography (hexane/ethyl acetate 9:1) to 
give 90 mg (63%) of the analytically pure compound as a yellow oil. C18H16O2; MW 264; 1H 
NMR (acetone-d6): δ 9.00 (s, br, 1H), 8.28 (d, J = ca. 9.3 Hz, 1H), 7.72 (d, J = ca. 1.5 Hz, 
1H), 7.45-7.40 (m, 2H), 7.35-7.31 (m, 1H), 7.24 (d, J = ca. 8.4 Hz, 1H), 6.94 (dd, J = ca. 0.7 
Hz, J = ca. 7.4 Hz, 1H), 6.91 (d, J = ca. 2.6 Hz, 1H), 6.86 (dd, J = ca. 2.6 Hz, J = ca.  8.3 Hz, 
1H), 3.84 (s, 3H), 2.30 (s, 3H); 13C NMR (acetone-d6): δ 160.0, 154.0, 140.4, 137.5, 135.9, 
135.3, 131.7, 128.2, 127.5, 127.4, 124.5, 122.7, 120.1, 116.6, 112.1, 108.9, 55.5, 20.9; IR: 
3354, 2956, 1502, 1240 cm-1; GC/MS m/z: 264 (M)+.  
 
6-(4-Hydroxy-2-methylphenyl)-1-naphthol (2). The title compound was prepared by 
reaction of 6-(4-methoxy-2-methylphenyl)-1-naphthol 1 (20 mg, 0.08 mmol, 1 equiv) with 
boron tribromide (0.40 mmol, 5 equiv) according to method C. The product was purified by 
column chromatography (hexane/ethyl acetate 1:1) to give 9 mg (43%) of the analytically 
pure compound as a yellow oil. C17H14O2; MW 250; 1H NMR (acetone-d6): δ 8.93 (s, br, 1H), 
8.22 (s, br, 1H), 8.22-8.20 (m, 1H), 7.66 (d, J = ca. 1.6 Hz, 1H), 7.40-7.34 (m, 2H), 7.30-7.25 
(m, 1H), 7.11 (d, J = ca. 8.3 Hz, 1H), 6.88 (dd, J = ca. 0.9 Hz, J = ca. 7.4 Hz, 1H), 6.77 (d, J = 
ca. 2.5 Hz, 1H), 6.73 (dd, J = ca. 2.5 Hz, J = ca. 8.3 Hz, 1H), 2.78 (s, 3H); 13C NMR (acetone-
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d6): δ 157.9, 154.0, 140.7, 138.7, 136.0, 131.8, 128.2, 127.6, 127.4, 124.5, 122.6, 120.0, 
117.9, 116.7, 113.7, 108.8, 20.8; IR: 3378, 2924, 1691, 1235 cm-1; GC/MS m/z: 250 (M)+. 
 
6-(4-Methoxy-3-methylphenyl)-1-naphthol (3a). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (75 mg, 0.26 mmol, 1 equiv) 
with 4-methoxy-3-methylphenylboronic acid (55 mg, 0.33 mmol, 1.3 equiv) according to 
method A. The product was purified by column chromatography (hexane/ethyl acetate 9:1) to 
afford 70 mg (49%) of the analytically pure compound. C18H16O2; MW 264; 1H NMR 
(acetone-d6): δ 8.96 (s, br, 1H), 8.28 (d, J = ca. 9.3 Hz, 1H), 8.02 (d, J = ca. 2.3 Hz, 1H), 7.74 
(dd, J = ca. 1.9 Hz, J = ca. 8.7 Hz, 1H), 7.61-7.58 (m, 2H), 7.45-7.42 (m, 1H), 7.33-7.28 (m, 
1H), 7.06-7.02 (m, 1H), 6.89 (dd, J = ca. 0.8 Hz, J = ca. 7.5 Hz, 1H), 3.89 (s, 3H), 2.28 (s, 
3H); 13C NMR (acetone-d6): δ 158.5, 154.0, 139.3, 136.4, 130.1, 127.5, 126.5, 125.2, 124.7, 
123.5, 120.2, 118.5, 113.3, 112.1, 111.3, 108.8, 55.8, 16.5; IR: 3404, 2955, 1503, 1245, 1219 
cm-1. 
 
6-(4-Hydroxy-3-methylphenyl)-1-naphthol (3). The title compound was prepared by 
reaction of 6-(4-methoxy-3-methylphenyl)-1-naphthol 3a (20 mg, 0.08 mmol, 1 equiv) with 
boron trifluoride dimethylsulfide complex (6.00 mmol, 75 equiv) according to method D. The 
product was purified by column chromatography (hexane/ethyl acetate 1:1) to give 12 mg 
(60%) of the analytically pure compound as a brown solid. C17H14O2; MW 250; mp: 164-
166°C; 1H NMR (acetone-d6): δ 8.90 (s, br, 1H), 8.26 (s, br, 1H), 8.23 (d, J = ca. 8.5 Hz, 1H), 
7.96 (d, J = ca. 1.9 Hz, 1H), 7.69 (dd, J = ca. 2.0 Hz, J = ca. 8.5 Hz, 1H), 7.53 (d, J = ca. 1.9 
Hz, 1H), 7.43 (dd, J = ca. 2.0 Hz, J = ca. 8.5 Hz, 1H), 7.40-7.37 (m, 1H), 7.28-7.24 (m, 1H), 
6.91 (d, J = ca. 8.5 Hz, 1H), 6.84 (dd, J = ca. 0.8 Hz, J = ca. 7.4 Hz, 1H), 2.27 (s, 3H); 13C 
NMR (acetone-d6): δ 156.1, 154.0, 139.6, 136.4, 133.0, 130.4, 127.4, 126.4, 125.6, 124.9, 
124.7, 123.5, 120.2, 118.2, 116.0, 108.7, 16.3; IR: 3337, 2952, 1506, 1274 cm-1; GC/MS m/z: 
250 (M)+. 
 
6-(2,4-Dimethoxyphenyl)-1-naphthol (4). The title compound was prepared by reaction of 
5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (75 mg, 0.26 mmol, 1 equiv) with 2,4-
dimethoxyphenylboronic acid (60 mg, 0.33 mmol, 1.3 equiv) according to method A. The 
product was purified by column chromatography (hexane/ethyl acetate 7:3) to afford 38 mg 
(49%) of the analytically pure compound as an orange oil. C18H16O3; MW 280; 1H NMR 
(acetone-d6): δ 8.88 (s, br, 1H), 8.18 (d, J = ca. 8.7 Hz, 1H), 7.84 (s, 1H), 7.58 (dd, J = ca. 1.8 
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Hz, J = ca. 8.7 Hz, 1H), 7.36-7.30 (m, 2H), 7.27-7.23 (m, 1H), 6.86 (d, J = ca. 7.5 Hz, 1H), 
6.66 (d, J = ca. 2.5 Hz, 1H), 6.61 (dd, J = ca. 2.5 Hz, J = ca. 8.4 Hz, 1H), 3.83 (s, 3H), 3.79 (s, 
3H); 13C NMR (acetone-d6): δ 161.7, 158.7, 153.9, 137.5, 136.0, 132.2, 128.2, 127.8, 127.1, 
124.4, 124.1, 122.2, 120.1, 108.7, 106.1, 99.8, 55.9, 55.7; IR: 3388, 2982, 1610, 1507, 1206 
cm-1; GC/MS m/z: 280 (M)+. 
 
4-(5-Hydroxy-2-naphthyl)benzene-1,3-diol (5). The title compound was prepared by 
reaction of 6-(2,4-dimethoxyphenyl)-1-naphthol 4 (60 mg, 0.21 mmol, 1 equiv) with boron 
trifluoride dimethylsulfide complex (32 mmol, 150 equiv) according to method D. The 
product was purified by column chromatography (hexane/ethyl acetate 1:1) to afford 30 mg 
(55%) of the analytically pure compound as a yellow solid. C16H12O3; MW 252; mp: 152-
154°C; 1H NMR (acetone-d6): δ 8.99 (s, br, 1H), 8.40 (s, br, 1H), 8.31 (s, br, 1H), 8.29 (s, 
1H), 8.02 (d, J = ca. 1.7 Hz, 1H), 7.77 (dd, J = ca. 1.7 Hz, J = ca. 8.5 Hz, 1H), 7.46 (d, J = ca. 
8.5 Hz, 1H), 7.37 (d, J = ca. 7.6 Hz, 1H), 7.33 (d, J = ca. 8.5 Hz, 1H), 6.96 (dd, J = ca. 1.0 Hz, 
J = ca. 7.6 Hz, 1H), 6.65 (d, J = ca. 2.4 Hz, 1H), 6.58 (dd, J = ca. 2.4 Hz. J = ca. 8.5 Hz, 1H); 
13C NMR (acetone-d6): δ 157.6, 156.9, 151.5, 135.0, 134.2, 130.0, 126.5, 125.4, 124.9, 120.8, 
116.4, 108.8, 108.7, 103.4; IR: 3363, 1689, 1598, 1358, 1260 cm-1.  
 
6-(3,4-Dimethoxyphenyl)-1-naphthol (6). The title compound was prepared by reaction of 
5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (75 mg, 0.26 mmol, 1 equiv) with 3,4-
dimethoxyphenylboronic acid (60 mg, 0.33 mmol, 1.3 equiv) according to method A. The 
product was purified by column chromatography (hexane/ethyl acetate 8:2) to give 46 mg 
(60%) of the analytically pure compound as a yellow solid. C18H16O3; MW 280; mp: 139-
141°C; 1H NMR (acetone-d6): δ 8.97 (s, br, 1H), 8.28 (d, J = ca. 8.5 Hz, 1H), 8.06 (d, J = ca. 
2.0 Hz, 1H), 7.77 (dd, J = ca. 2.0 Hz, J = ca. 8.9 Hz, 1H), 7.43 (d, J = ca. 8.5 Hz, 1H), 7.39 (d, 
J = ca. 2.0 Hz, 1H), 7.34-7.31 (m, 2H), 7.08 (d, J = ca. 8.5 Hz, 1H), 6.90 (dd, J = ca. 0.8 Hz, J 
= ca. 7.5 Hz, 1H), 3.94 (s, 3H), 3.87 (s, 3H); 13C NMR (acetone-d6): δ 154.0, 150.8, 150.3, 
139.4, 136.3, 134.6, 127.5, 125.4, 124.8, 123.5, 120.3, 120.2, 113.3, 112.0, 108.9, 56.3, 56.2; 
IR: 3424, 2934, 1516, 1247 cm-1; GC/MS m/z: 280 (M)+. 
 
4-(5-Hydroxy-2-naphthyl)benzene-1,2-diol (7). The title compound was prepared by 
reaction of 6-(3,4-dimethoxyphenyl)-1-naphthol 6 (20 mg, 0.07 mmol, 1 equiv) with boron 
tribromide (0.70 mmol, 10 equiv) according to method C. The product was purified by 
column chromatography (hexane/ethyl acetate 1:1) to afford 8 mg (40%) of the analytically 
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pure product as an orange oil. C16H12O3; MW 252; 1H NMR (acetone-d6): δ 8.94 (s, br, 1H), 
8.26 (d, J = ca. 9.1 Hz, 1H), 8.01 (s, br, 1H), 7.98-7.96 (m, 2H), 7.70 (dd, J = ca. 2.0 Hz, J = 
ca. 8.5 Hz, 1H), 7.42 (d, J = ca. 8.5 Hz, 1H), 7.31-7.28 (m, 2H), 7.16 (dd, J = ca. 2.0 Hz, J = 
ca. 8.1 Hz, 1H), 6.95 (d, J = ca. 8.1 Hz, 1H), 6.89 (dd, J = ca. 0.9 Hz, J = ca. 7.6 Hz, 1H); 13C 
NMR (acetone-d6): δ 166.8, 159.2, 154.0, 146.4, 136.3, 134.0, 127.4, 125.1, 124.7, 123.5, 
120.2, 119.6, 118.4, 116.7, 115.1, 108.7; IR: 3325, 1602, 1576, 1363, 1274 cm-1. 
 
6-(4-Hydroxy-3-methoxyphenyl)-1-naphthol (8). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (200 mg, 0.68 mmol, 1 equiv) 
and 4-hydroxy-3-methoxyphenylboronic acid (150 mg, 0.89 mmol, 1.3 equiv) according to 
method B. The product was purified by column chromatography (hexane/ethyl acetate 8:2) to 
give 150 mg (52%) of the analytically pure compound as a brown solid. C17H14O3; MW 266; 
mp: 146-147°C; 1H NMR (CDCl3): δ 8.22 (d, J = ca. 8.5 Hz, 1H), 7.91 (d, J = ca. 1.8 Hz, 1H), 
7.68 (dd, J = ca. 1.8 Hz, J = ca. 8.7 Hz, 1H), 7.44 (d, J = ca. 8.2 Hz, 1H), 7.32-7.28 (m, 1H), 
7.22 (dd, J = ca. 2.1 Hz, J = ca. 8.2 Hz, 1H), 7.19 (d, J = ca. 2.1 Hz, 1H), 7.02 (d, J = ca. 8.0 
Hz, 1H), 6.79 (dd, J = ca. 1.0 Hz, J = ca. 7.4 Hz, 1H), 3.98 (s, 3H); 13C NMR (CDCl3): δ 
151.7, 146.9, 145.4, 139.0, 135.1, 133.6, 126.4, 124.9, 124.8, 123.3, 122.3, 120.6, 120.5, 
114.8, 110.0, 108.4, 56.1; IR: 3250, 2987, 1520, 1273 cm-1; GC/MS m/z: 266 (M)+. 
 
5-Methoxy-2-naphthyl trifluoromethanesulfonate (9d). To a solution of 5-hydroxy-2-
naphthyl trifluoromethanesulfonate 1a (400 mg, 1.37 mmol, 1 equiv) in 7 mL acetone were 
added K2CO3 (186 mg, 1.66 mmol, 1.3 equiv) and 18-Crown-6 (4 mg, 0.01 mmol, 0.01 
equiv). The mixture was stirred for 15 min at room temperature before methyliodide (250 mg, 
0.12 mL, 1.66 mmol, 1.3 equiv) was added dropwise and then refluxed overnight. After 
cooling to room temperature, the mixture was filtered through a pad of Celite® and 
concentrated. The residue was taken up in ethyl acetate and washed twice with 1N NaOH, 
water and brine, dried over sodium sulfate and concentrated to dryness. The solid was 
recrystallised in hexane/ethyl acetate 10:1 to afford 315 mg (75%) of the analytically pure 
product as a beige solid. C12H9F3O4S; MW 306; mp: 134-135°C; 1H NMR (CDCl3): δ 8.33 (d, 
J = ca. 9.3 Hz, 1H), 7.67 (d, J = ca. 2.5 Hz, 1H), 7.49-7.44 (m, 1H), 7.41 (d, J = ca. 8.3 Hz, 
1H), 7.31 (dd, J = ca. 2.5 Hz, J = ca. 9.3 Hz, 1H), 6.86 (d, J = ca. 7.6 Hz, 1H), 4.00 (s, 3H). 
 
2-(5-Methoxy-2-naphthyl)-5,5-dimethyl-1,3,2-dioxaborinane (9c). A flask was flushed 
with nitrogen and charged with PdCl2(dppf) (50 mg, 0.07 mmol, 0.1 equiv), dppf (38 mg, 0.07 
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mmol, 0.1 equiv), KOAc (200 mg, 2.04 mmol, 3 equiv) and bis(neopentylglycolato)diboron 
(169 mg, 0.75 mmol, 1.1 equiv). A solution of 5-methoxy-2-naphthyl 
trifluoromethanesulfonate 9d (200 mg, 0.68 mmol, 1 equiv) in 1,4-dioxane (16 mL) was 
added and the mixture was stirred for 4h at 85°C. The reaction was worked up by filtration of 
the mixture through a silica gel pad, and washed with ethyl acetate. The combined solvent 
was concentrated under vacuum to give the crude boronic acid purified by column 
chromatography (hexane/ethyl acetate 10:1) to afford 121 mg (66%) of the analytically pure 
compound as a white solid. C16H19BO3; MW 270; mp: 148-149°C; 1H NMR (CDCl3): δ 8.22 
(s, 1H), 8.14 (d, J = ca. 8.0 Hz, 1H), 7.77 (dd, J = ca. 0.9 Hz, J = ca. 8.3 Hz, 1H), 7.39 (d, J = 
ca. 8.3 Hz, 1H), 7.31-7.27 (m, 1H), 6.76 (d, J = ca. 8.0 Hz, 1H), 3.93 (s, 3H), 3.76 (s, 4H), 
0.99 (s, 6H); 13C NMR (CDCl3): δ 155.2, 134.5, 133.9, 129.4, 127.0, 125.5, 121.0, 120.8, 
104.5, 72.4, 55.5, 31.9, 21.9. 
 
2-Methoxy-5-(5-methoxy-2-naphthyl)biphenyl (9a). The title compound was prepared by 
reaction of 5-bromo-2-methoxybiphenyl 9b (100 mg, 0.38 mmol, 1 equiv) with 2-(5-
methoxy-2-naphthyl)-5,5-dimethyl-1,3,2-dioxaborinane 9c (103 mg, 0.38 mmol, 1 equiv) 
according to method B. The product was purified by column chromatography (hexane/ethyl 
acetate 8:2) to give 80 mg (62%) of the analytically pure compound as a white oil. C24H20O2; 
MW 340; 1H NMR (acetone-d6): δ 8.20 (d, J = ca. 8.5 Hz, 1H), 7.89-7.87 (m, 1H), 7.60-7.59 
(m, 1H), 7.57 (d, J = ca. 8.5Hz, 1H), 7.45 (dd, J = ca. 2.0 Hz, J = ca. 8.8 Hz, 2H), 7.35-7.30 
(m, 3H), 7.27-7.23 (m, 3H), 6.90 (d, J = ca. 8.8 Hz, 1H), 6.67 (d, J = ca. 8.0 Hz, 1H), 3.94 (s, 
3H), 3.92 (s, 3H); 13C NMR (acetone-d6): δ 162.0, 156.4, 136.6, 135.0, 134.4, 129.5, 129.3, 
129.2, 127.4, 127.3, 127.2, 126.4, 125.6, 124.4, 123.9, 122.5, 120.1, 116.1, 103.5, 56.4, 56.3; 
IR: 3001, 2963, 1389 cm-1; LC/MS m/z: 341 (M+H)+. 
 
5-(5-Hydroxy-2-naphthyl)biphenyl-2-ol (9). The title compound was prepared by reaction 
of 2-methoxy-5-(5-methoxy-2-naphthyl)biphenyl 9a (75 mg, 0.22 mmol, 1 equiv) with boron 
tribromide (2.2 mmol, 10 equiv) according to method C. The product was purified by column 
chromatography (hexane/ethyl acetate 8:2), then by preparative HPLC (gradient 
acetonitrile/water 20:80 to 100:0) to give 10 mg (15%) of the analytically pure compound as 
an orange oil. C22H16O2; MW 312; 1H NMR (acetone-d6): δ 8.16 (d, J = ca. 8.5 Hz, 1H), 7.96 
(d, J = ca. 2.0 Hz, 1H), 7.67 (dd, J = ca. 2.0 Hz, J = ca. 8.5 Hz, 1H), 7.61 (d, J = ca. 2.0 Hz, 
1H), 7.59-7.55 (m, 2H), 7.51 (dd, J = ca. 2.0 Hz, J = ca. 8.5 Hz, 1H), 7.32-7.28 (m, 3H), 7.22-
7.16 (m, 2H), 7.00 (d, J = ca. 8.5 Hz, 1H), 6.76 (d, J = ca. 7.6 Hz, 1H); 13C NMR (acetone-
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d6): δ 154.8, 153.9, 139.7, 139.2, 136.4, 133.7, 130.3, 128.9, 128.1, 127.7, 127.5, 125.2, 
124.7, 124.6, 123.6, 120.2, 117.5, 108.7; GC/MS m/z: 312 (M)+. 
 
6-(2-Fluoro-4-methoxyphenyl)-1-naphthol (10). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (200 mg, 0.68 mmol, 1 equiv) 
and 2-fluoro-4-methoxyphenylboronic acid (151 mg, 0.89 mmol, 1.3 equiv) according to 
method B. The product was purified by column chromatography (hexane/ethyl acetate 9:1) to 
afford 110 mg (60%) of the analytically pure product as a beige solid. C17H13FO2; MW 268; 
mp: 133-135°C; 1H NMR (CDCl3): δ 8.20 (d, J = ca. 8.8 Hz, 1H), 7.92 (s, br, 1H), 7.64 (dd, J 
= ca. 2.0 Hz, J = ca. 8.6 Hz, 1H), 7.47-7.43 (m, 2H), 7.33-7.29 (m, 1H), 6.82-6.78 (m, 2H), 
6.74 (dd, J = ca. 2.0 Hz, J = ca. 8.6 Hz, 1H), 5.20 (s, 1H), 3.85 (s, 3H); 13C NMR (CDCl3): δ 
162.8, 161.5, 160.2, 151.7, 134.8, 131.3, 131.2, 127.3, 126.3, 123.4, 121.8, 120.6, 110.4, 
108.7, 102.2, 102.0, 55.6; IR: 3202, 3027, 1585 cm-1; GC/MS m/z: 268 (M)+. 
 
6-(2-Fluoro-4-hydroxyphenyl)-1-naphthol (11). The title compound was prepared by 
reaction of 6-(2-fluoro-4-methoxyphenyl)-1-naphthol 10 (100 mg, 0.09 mmol, 1 equiv) with 
pyridinium hydrochloride (9 mmol, 100 equiv) according to method E. The product was 
purified by column chromatography (hexane/ethyl acetate 7:3) to afford 48 mg (54%) of the 
analytically pure product as a beige solid. C16H11FO2; MW 254; mp: 145-146°C; 1H NMR 
(acetone-d6): δ 9.15 (s, br, 1H), 9.07 (s, br, 1H), 8.28 (d, J = ca. 8.5 Hz, 1H), 7.83 (d, J = ca. 
8.5 Hz, 2H), 7.62 (dt, J = ca. 1.8 Hz, J = ca. 8.5 Hz, 1H), 7.50-7.46 (m, 1H), 7.42 (d, J = ca. 
8.5 Hz, 1H), 7.327.31 (m, 1H), 6.92 (dd, J = ca. 1.0 Hz, J = ca. 7.3 Hz, 1H), 6.84-6.81 (m, 
1H); 13C NMR (acetone-d6): δ 162.7, 154.0, 148.1, 136.0, 132.4, 130.1, 127.8, 127.5, 126.5, 
123.1, 120.2, 115.1, 115.0, 112.9, 109.1, 104.2; IR: 3225, 1623, 1214 cm-1; GC/MS m/z: 254 
(M)+. 
 
6-(3-Fluoro-4-methoxyphenyl)-1-naphthol (12). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (75 mg, 0.26 mmol, 1 equiv) 
with 3-fluoro-4-methoxyphenylboronic acid (57 mg, 0.33 mmol, 1 equiv) according to 
method A. The product was purified by column chromatography (hexane/ethyl acetate 7:3) to 
afford 44 mg (60%) of the analytically pure compound as a brown oil. C17H13FO2; MW 268; 
1H NMR (acetone-d6): δ 8.97 (s, br, 1H), 8.26 (d, J = ca. 8.4 Hz, 1H), 8.04 (s, 1H), 7.72 (d, J 
= ca. 8.4 Hz, 1H), 7.58-7.54 (m, 2H), 7.41 (d, J = ca. 8.9 Hz, 1H), 7.31-7.27 (m, 1H), 7.24-
7.20 (m, 1H), 6.91-6.87 (m, 1H), 3.91 (s, 3H); 13C NMR (acetone-d6): δ 154.0, 148.2, 137.9, 
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136.2, 134.9, 128.1, 127.7, 125.6, 124.9, 124.4, 123.9, 123.8, 120.3, 115.4, 115.0, 109.1, 56.6; 
IR: 3445, 2937, 1521, 1246 cm-1; GC/MS m/z: 268 (M)+. 
 
6-(3-Fluoro-4-hydroxyphenyl)-1-naphthol (13). The title compound was prepared by 
reaction of 6-(3-fluoro-4-methoxyphenyl)-1-naphthol 12 (20 mg, 0.08 mmol, 1 equiv) with 
boron tribromide (0.80 mmol, 10 equiv) according to method C. The product was purified by 
column chromatography (hexane/ethyl acetate 1:1) to give 8 mg (40%) of the analytically 
pure compound as a yellow oil. C16H11O2F; MW 254; 1H NMR (acetone-d6): δ 8.99 (s, br, 
1H), 8.74 (s, br, 1H), 8.29 (d, J = ca. 8.8 Hz, 1H), 8.05 (d, J = ca. 2.0 Hz, 1H), 7.74 (dd, J = 
ca. 2.1 Hz, J = ca. 8.7 Hz, 1H), 7.57 (dd, J = ca. 2.1 Hz, J = ca. 8.7 Hz, 1H), 7.50-7.47 (m, 
1H), 7.44 (d, J = ca. 8.3 Hz, 1H), 7.34-7.30 (m, 1H), 7.15-7.11 (m, 1H), 6.91 (dd, J = ca. 0.9 
Hz, J = ca. 7.6 Hz, 1H); 13C NMR (acetone-d6): δ 154.2, 136.3, 127.6, 125.4, 124.4, 124.0, 
123.7, 120.3, 119.1, 115.5, 109.0; IR: 3247, 1692, 1524, 1277 cm-1; GC/MS m/z: 254 (M)+. 
 
6-(2,5-Difluoro-4-methoxyphenyl)-1-naphthol (14). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (200 mg, 0.68 mmol, 1 equiv) 
with 2,5-difluoro-4-methoxyphenylboronic acid (154 mg, 0.82 mmol, 1.3 equiv) according to 
method B. The product was purified by column chromatography (hexane) to afford 70 mg 
(36%) of the analytically pure compound as a yellow solid. C17H12F2O2; MW 286; mp: 185-
187°C; 1H NMR (CDCl3): δ 8.21 (d, J = ca. 8.8 Hz, 1H), 7.91 (s, br, 1H), 7.61 (dt, J = ca. 1.8 
Hz, J = ca. 8.8 Hz, 1H), 7.45 (d, J = ca. 8.0 Hz, 1H), 7.32 (d, J = ca. 8.0 Hz, 1H), 7.30 (d, J = 
ca. 2.6 Hz, 1H), 7.29-7.25 (m, 1H), 6.83-6.78 (m, 1H), 5.32 (s, 1H), 3.92 (s, 3H); 13C NMR 
(CDCl3): δ 151.4, 134.8, 127.5, 126.4, 126.0, 123.5, 122.0, 120.9, 117.1, 109.0, 56.6; IR: 
3237, 3098, 2978, 1525, 1445 cm-1; GC/MS m/z: 286 (M)+. 
 
6-(2, 5-Difluoro-4-hydroxyphenyl)-1-naphthol (15). The title compound was prepared by 
reaction of 6-(2,5-difluoro-4-methoxyphenyl)-1-naphthol 14 (40 mg, 0.14 mmol, 1 equiv) 
with boron trifluoride dimethylsulfide complex (10.5 mmol, 75 equiv) according to method D. 
The product was purified by column chromatography (hexane/ethyl acetate 8:2) to afford 20 
mg (50%) of the analytically pure product as a beige solid. C16H10F2O2; MW 272; mp: 178-
181°C; 1H NMR (acetone-d6): δ 9.22 (s, br, 1H), 9.05 (s, br, 1H), 8.29 (d, J = ca. 8.8 Hz, 1H), 
7.99-7.97 (m, 1H), 7.63 (dt, J = ca. 1.9 Hz, J = ca. 8.8 Hz, 1H), 7.44 (d, J = ca. 8.4 Hz, 1H), 
7.42-7.39 (m, 1H), 7.36-7.32 (m, 1H), 6.96-6.90 (m, 2H); 13C NMR (acetone-d6): δ 162.4, 
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159.6, 154.4, 153.2, 135.2, 134.5, 126.6, 125.9, 125.1, 123.5, 122.0, 120.8, 117.9, 117.5, 
108.9, 104.6; IR: 3427, 1641, 1522, 1268 cm-1; GC/MS m/z: 272 (M)+. 
 
6-(2, 6-Difluoro-4-hydroxyphenyl)-1-naphthol (16). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (100 mg, 0.34 mmol, 1 equiv) 
with 2,5-difluoro-4-hydroxyphenylboronic acid (71 mg, 0.41 mmol, 1.2 equiv) according to 
method B. The product was purified by column chromatography (hexane/ethyl acetate 3:1) to 
afford 43 mg (47%) of the analytically pure compound as a beige solid. C16H10F2O2; MW 
272; mp: 164-166°C; 1H NMR (acetone-d6): δ 9.20 (s, br, 1H), 8.93 (s, br, 1H), 8.16 (d, J = 
ca. 8.9 Hz, 1H), 7.74 (s, 1H), 7.35 (dd, J = ca. 1.4 Hz, J = ca. 8.4 Hz, 1H), 7.29 (d, J = ca. 8.4 
Hz, 1H), 7.20 (m, 1H), 6.82 (d, J = ca. 7.7 Hz, 1H), 6.52-6.46 (m, 2H); 13C NMR (acetone-
d6): δ 162.7, 162.6, 160.7, 160.6, 159.4, 154.0, 135.7, 130.0, 128.2, 127.7, 127.6, 125.0, 
122.9, 120.1, 109.4, 100.5; IR: 3220, 3112, 1640, 1280 cm-1; GC/MS m/z: 272 (M)+. 
 
6-[4-Hydroxy-2-(trifluoromethyl)phenyl]-1-naphthol (17). The title compound was 
prepared by reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (100 mg, 0.34 
mmol, 1 equiv) with 4-hydroxy-2-trifluoromethylphenylboronic acid (98 mg, 0.44 mmol, 1.3 
equiv) according to method A. The product was purified by column chromatography 
(hexane/ethyl acetate 8:2) to give 70 mg (68%) of the analytically pure compound as a brown 
solid. C17H11F3O2; MW 304; mp: 140-142°C; 1H NMR (acetone-d6): δ 9.03 (s, br, 1H), 9.01 
(s, br, 1H), 8.25 (d, J = ca. 8.8 Hz, 1H), 7.73 (s, 1H), 7.42-7.39 (m, 2H), 7.36-7.31 (m, 2H), 
7.28 (d, J = ca. 2.5 Hz, 1H), 7.18 (dd, J = ca. 2.5 Hz, J = ca. 8.6 Hz, 1H), 6.96-6.93 (m, 1H); 
13C NMR (acetone-d6): δ 157.9, 154.3, 138.8, 135.4, 134.9, 128.7, 127.8, 127.2, 125.0, 122.6, 
120.4, 119.4, 113.7, 109.5, 60.5; IR: 3361, 1691, 1322 cm-1; GC/MS m/z: 304 (M)+. 
 
6-[4-Methoxy-3-(trifluoromethyl)phenyl]-1-naphthol (18). The title compound was 
prepared by reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (100 mg, 0.34 
mmol, 1 equiv) with 4-methoxy-3-trifluoromethylphenylboronic acid (98 mg, 0.44 mmol, 1.3 
equiv) according to method A. The product was purified by column chromatography 
(hexane/ethyl acetate 8:2) to afford 34 mg (32%) of the analytically pure product as a brown 
solid. C18H13F3O2; MW 318; mp: 138-139°C; 1H NMR (acetone-d6): δ 9.04 (s, br, 1H), 8.33 
(d, J = ca. 8.8 Hz, 1H), 8.11 (d, J = ca. 2.0 Hz, 1H), 8.04 (dd, J = ca. 2.0 Hz, J = ca. 8.6 Hz, 
1H), 8.01 (d, J = ca. 2.3 Hz, 1H), 7.78 (dd, J = ca. 2.0 Hz, J = ca. 8.6 Hz, 1H), 7.47 (d, J = ca. 
8.4 Hz, 1H), 7.38 (d, J = ca. 8.4 Hz, 1H), 7.34 (m, 1H), 6.94 (dd, J = ca. 0.8 Hz, J = ca. 7.6 
RESULTS   
 - 77 - 
Hz, 1H), 4.01 (s, 3H); 13C NMR (acetone-d6): δ 158.0, 154.0, 137.7, 136.2, 134.0, 133.2, 
127.8, 126.3, 126.2, 125.8, 125.0, 124.4, 123.9, 123.8, 120.4, 114.1, 109.2, 56.7; IR: 3387, 
2981, 1419, 1214 cm-1, GC/MS m/z: 318 (M)+. 
  
6-[4-Hydroxy-3-(trifluoromethyl)phenyl]-1-naphthol (19). The title compound was 
prepared by reaction of 6-[4-methoxy-3-(trifluoromethyl)phenyl]-1-naphthol 18 (100 mg, 
0.15 mmol, 1 equiv) with pyridinium hydrochloride (15 mmol, 100 equiv) according to 
method E. The product was purified by column chromatography (hexane/ethyl acetate 7:3) to 
afford 40 mg (42%) of the analytically pure product as a brown solid. C17H11F3O2; MW 304; 
mp: 158-160°C; 1H NMR (acetone-d6): δ 8.28 (d, J = ca. 8.5 Hz, 1H), 8.04 (d, J = ca. 2.0 Hz, 
1H), 7.91 (d, J = ca. 2.0 Hz, 1H), 7.85 (dd, J = ca. 2.0 Hz, J = ca. 8.5 Hz, 1H), 7.71 (dd, J = 
ca. 2.0 Hz, J = ca. 8.5 Hz, 1H), 7.42 (d, J = ca. 8.5 Hz, 1H), 7.29 (m, 1H), 7.22-7.19 (m, 1H), 
6.89 (dd, J = ca. 0.9 Hz, J = ca. 7.3 Hz, 1H); 13C NMR (acetone-d6): δ 156.3, 154.1, 138.0, 
136.3, 133.0, 127.7, 125.5, 124.9, 124.4, 123.9, 120.2, 118.6, 109.1; IR: 3229, 3066, 2986, 
1619, 1263 cm-1; GC/MS m/z: 304 (M)+. 
 
6-(3-Chloro-4-hydroxyphenyl)-1-naphthol (20). The title compound was prepared by 
reaction of 5-hydroxy-2-naphthyl trifluoromethanesulfonate 1a (200 mg, 0.68 mmol, 1 equiv) 
and 3-chloro-4-hydroxyphenylboronic acid (153 mg, 0.89 mmol, 1.3 equiv) according to 
method B. The product was purified by column chromatography (hexane/ethyl acetate 7:3) to 
give 117 mg (64%) of the analytically pure compound as a beige solid. C16H11ClO2; MW 270; 
mp: 112-114°C; 1H NMR (acetone-d6): δ 9.10 (s, br, 2H), 8.31 (d, J = ca. 8.5 Hz, 1H), 8.07 
(d, J = ca. 2.0 Hz, 1H), 7.80 (d, J = ca. 2.0 Hz, 1H), 7.75 (dd, J = ca. 2.0 Hz, J = ca. 8.5 Hz, 
1H), 7.64 (dd, J = ca. 2.0 Hz, J = ca. 8.5 Hz, 1H), 7.47 (d, J = ca. 8.4 Hz, 1H), 7.36-7.32 (m, 
1H), 7.19 (d, J = ca. 8.4 Hz, 1H), 6.94 (dd, J = ca. 1.0 Hz, J = ca. 7.4 Hz, 1H); 13C NMR 
(acetone-d6): δ 154.0, 153.5, 137.9, 136.2, 134.5, 129.2, 127.7, 127.6, 125.4, 125.3, 124.4, 
123.8, 121.7, 120.2, 118.1, 109.0; IR: 3330, 1599, 1283, 1187 cm-1; GC/MS m/z: 270-272 
(M)+. 
 
2-Hydroxy-5-(5-methoxy-2-naphthyl)benzonitrile (21a). The title compound was prepared 
by reaction of 2-(5-methoxy-2-naphthyl)-5,5-dimethyl-1,3,2-dioxaborinane 9c (100 mg, 0.37 
mmol, 1.05 equiv) with 5-bromo-2-hydroxybenzonitrile (69 mg, 0.35 mmol, 1 equiv) 
according to method A. The product was purified by column chromatography (hexane/ethyl 
acetate 8:2) to afford 30 mg (29%) of 21a. C18H13NO2; MW 275; 1H NMR (CDCl3): δ 8.23 
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(d, J = ca. 2.1 Hz, 1H), 7.86 (d, J = ca. 2.1 Hz, 1H), 7.79 (d, J = ca. 1.9 Hz, 1H), 7.72 (d, J = 
ca. 1.9 Hz, 1H), 7.60-7.56 (m, 1H), 7.42-7.38 (m, 3H), 7.12-7.10 (m, 1H), 6.77 (d, J = ca. 8.7 
Hz, 1H), 3.96 (s, 3H); 13C NMR (CDCl3): δ 142.4, 142.3, 140.0, 138.3, 136.9, 131.9, 130.5, 
130.3, 129.9, 129.1, 125.5, 125.4, 122.0, 109.3, 109.2, 60.6. 
 
2-Hydroxy-5-(5-hydroxy-2-naphthyl)benzonitrile (21). The title compound was prepared 
by reaction of 2-hydroxy-5-(5-methoxy-2-naphthyl)benzonitrile 21a (20 mg, 0.06 mmol, 1 
equiv) with boron trifluoride dimethylsulfide complex (4.50 mmol, 75 equiv) according to 
method D. The product was purified by column chromatography (hexane/ethyl acetate 7:3) to 
give 15 mg (96%) of the analytically pure product as a beige solid. C17H11NO2; MW 261; mp: 
152-154°C; 1H NMR (acetone-d6): δ 9.67 (s, br, 1H), 9.07 (s, br, 1H), 8.33 (d, J = ca. 8.5 Hz, 
1H), 8.17 (d, J = ca. 2.4 Hz, 1H), 8.11-8.08 (m, 2H), 7.76 (dd, J = ca. 1.9 Hz, J = ca. 8.7 Hz, 
1H), 7.48 (d, J = ca. 8.5 Hz, 1H), 7.35 (m, 1H), 7.17 (d, J = ca. 8.5 Hz, 1H), 6.94 (dd, J = ca. 
0.9 Hz, J = ca. 7.4 Hz, 1H); 13C NMR (acetone-d6): δ 178.9, 157.9, 137.8, 137.2, 136.2, 
133.4, 127.8, 125.9, 125.7, 125.4, 124.4, 124.0, 120.3, 109.2, 99.4. 
 
Biological Assays 
[2,4,6,7-3H]-E2 and [2,4,6,7-3H]-E1 were bought from Perkin-Elmer, Boston. Quickszint 
Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. Cytosolic (17β-
HSD1) and microsomal (17β-HSD2) fractions were obtained from human and Callithrix 
jacchus placenta according to previously described procedures28, 64, 65, and from rat and mouse 
liver tissues66. Fresh tissue was homogenized and centrifuged. The pellet fraction contains the 
microsomal 17β-HSD2 and was used for the determination of E1-formation, while 17β-HSD1 
was obtained after precipitation with ammonium sulphate from the cytosolic fraction for use 
of testing of E2 formation. 
Human 17β-HSD4 and 17β-HSD5 were cloned into the modified pGEX-2T vector55. For the 
multidomain enzyme 17β-HSD4, only the steroid converting SDR-domain was subcloned55.  
 
Inhibition of 17β-HSD2/E1-formation 
Inhibitory activities were evaluated by a well established method with minor modifications.67-
69 Briefly, the enzyme preparation was incubated with NAD+ [1500 μM] in the presence of 
potential inhibitors at 37°C in a phosphate buffer (50 mM) supplemented with 20% of 
glycerol and EDTA 1 mM. Inhibitor stock solutions were prepared in DMSO. Final 
concentration of DMSO was adjusted to 1% in all samples. The enzymatic reaction was 
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started by addition of a mixture of unlabelled- and [2,4,6,7-3H]-E2 (final concentration: 500 
nM, 0.11 μCi). After 20 min at 37°C, the incubation was stopped with HgCl2 and the mixture 
was extracted with ether. After evaporation, the steroids were dissolved in acetonitrile. E1 and 
E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 rp 
chromatography column (Nucleodur C18 Gravity, 3 μm, Macherey-Nagel, Düren) connected 
to a HPLC-system (Agilent 1100 Series, Agilent Technologies, Waldbronn). Detection and 
quantification of the steroids were performed using a radioflow detector (Berthold 
Technologies, Bad Wildbad). The conversion rate was calculated according to following 
equation: ( )
( ) ( ) 1002%1%
1%% ×
+
=
EE
Econversion . Each value was calculated from at least three 
independent experiments. 
 
Inhibition of 17β-HSD1/E2-formation 
The 17β-HSD1 inhibition assay was performed similarly to the 17β-HSD2 procedure. The 
cytosolic fraction was incubated with NADH [500 μM], test compound and a mixture of 
unlabelled- and [2,4,6,7-3H]-E1 (final concentration: 500 nM, 0.15 μCi) for 10 min. Further 
treatment of the samples and HPLC separation was carried out as mentioned above. 
 
Inhibition of 17β-HSD4 
Inhibitory activity was assessed as originally described70, 71 with minor modifications55. 
Briefly, bacteria containing recombinant 17β-HSD4 were resuspended in PBS and enzymatic 
assay was performed at pH 7.7. The enzyme preparation was incubated with NAD+ [7.5 mM]. 
Inhibitor (dissolved in DMSO) was added in a final concentration of 1μM. Final 
concentration of DMSO was adjusted to 1% in all samples. The enzymatic reaction was 
started with the addition of [6,7-3H]-E2 at a concentration of 21 nM. The incubation at 37°C 
was stopped with 0.21 M ascorbic acid in methanol/acetic acid (99:1) after the time needed to 
convert approximately 30% of the substrate in a control assay without inhibitor. Steroids were 
extracted from the assay mixture by SPE using Strata C18-E columns (Phenomenex), eluted 
with methanol and separated by RP-HPLC (column Luna 5μm C18(2), 150 mm; 
Phenomenex) at a flow rate of 1 ml/min acetonitrile/water (43:57). Radioactivity was detected 
by scintillation counting after mixing with ReadyFlowIII (Beckman). Conversion was 
calculated from integration of substrate and product peaks. Assay was run in triplicate of three 
independent experiments. 
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Inhibition of 17β-HSD5 
The 17β-HSD5 inhibition assay was performed similarly to the 17β-HSD4 procedure. The 
recombinant enzyme was incubated with NADPH [6 mM], inhibitor [1 µM] and [1,2,6,7-3H]-
A-dione at a concentration of 21 nM. Further treatment of the samples and HPLC separation 
was carried out as mentioned above55. 
 
Inhibition of 17β-HSD2 in a cellular assay 
Cellular 17β-HSD2 activity is measured using the breast cancer cell-line MDA-MB-23157 
(17β-HSD1 activity negligible). [3H-E2] (200 nM) is taken as substrate, and is incubated with 
the inhibitor for 3,5h at 37°C. After ether extraction, substrate and product are separated by 
HPLC and detected with a radioflow detector. Potency is evaluated as percentage of inhibition 
(inhibitor concentration: 1μM) and as IC50 values. 
 
ER affinity28 
The binding affinity of selected compounds to the ERα and ERβ was determined according to 
Zimmermann et al.72 using recombinant human proteins. Briefly, 0.25 pM of ERα or ERβ, 
respectively, were incubated with [3H]-E2 (10 nM) and test compound for 1h at room 
temperature. The potential inhibitors were dissolved in DMSO (5% final concentration). 
Evaluation of non-specific-binding was performed with diethylstilbestrol (10 µM). After 
incubation, ligand-receptor complexes were selectively bound to hydroxyapatite (5 g/ 60 ml 
TE-buffer). The formed complex was separated, washed and resuspended in ethanol. For 
radiodetection, scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was added 
and the samples were measured in a liquid scintillation counter (Rack Beta Primo 1209, 
Wallac, Turku). From these results the percentage of [3H]-E2 displacement by the compounds 
was calculated. The plot of % displacement versus compound concentration resulted in 
sigmoidal binding curves. The compound concentration to displace 50% of the receptor bound 
[3H]-E2 were determined. Unlabelled E2 was used as a reference. For determination of the 
relative binding affinity (RBA) the ratio was calculated according to the following equation: 
[ ] ( )( ) 100
2%
50
50
×=
compoundIC
EICRBA 73. This results in an RBA value of 100% for E2. After the 
assay was established and validated a modification was made to increase throughput. 
Compounds were tested at concentrations of 1000 × IC50(E2) and 10000 × IC50(E2). Results 
were reported as RBA ranges. Compounds with less than 50% displacement of [3H]-E2 at a 
concentration of 10,000 × IC50 (E2) were classified as RBA <0.01%, compounds that displace 
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more than 50% at 10,000 × IC50 (E2) but less than 50% at 1000 × IC50(E2) were classified as 
0.01%<RBA<0.1%.  
 
LogP determination  
The LogP values were calculated from CambridgeSoft Chem & Bio Draw 11.0 using the 
ChemDrawPro 11.0 program. 
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Abstract 
 
E2 deficiency in elderly people has directly an effect on the skeleton and can lead to 
osteoporosis. As 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyses the 
conversion between active 17β-hydroxysteroid estradiol (E2) and testosterone (T) into their 
less active 17-ketosteroid and has been found in bones, 17β-HSD2 inhibitor may provide a 
new approach in the onset of osteoporosis. Bicyclic substituted hydroxyphenylmethanone 
derivatives were synthesised as steroidomimetics of the substrate E2 and were evaluated for 
their 17β-HSD2 inhibition and their selectivity toward 17β-HSD1, catalysing the reverse 
reaction the conversion of estrone (E1) into E2. Highly selective compounds (11, 12, 14, 21 
and 22) have been identified, the most promising one (12) showing an IC50 value in the low 
nanomolar range (101 nM) and a selectivity factor of 13 toward 17β-HSD1. These results 
make compound 12 an interesting candidate for further biological evaluation. 
 
Introduction 
 
Healthy bones are continuously regenerated by a mechanism of balance between osteoblasts 
(OBs) and osteoclasts (OCs), which are responsible for bone formation and bone resorption, 
respectively. The abnormal increase of the activity of OCs compared to the one of OBs in 
elderly people leads to osteoporosis [1]. Osteoporosis is a silent and systemic skeletal disease, 
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characterised by reduced bone mineral density and increased risk of fractures often at the hips, 
spine and wrist. Bone loss often takes place in post-menopausal women and elderly men, after 
the level of active sex steroids 17β-estradiol (hereafter “estradiol” or E2) or testosterone (T) 
(Chart 1) has dropped down. 
 
Chart 1: Interconversion of 17β-estradiol (E2) to estrone (E1) by 17β-HSD2 and 17β-HSD1 
and of testosterone (T) to androstenedione (A-dione) by 17β-HSD2 and 17β-HSD3. 
O
OH
OH
OH
O
O
OH
O
17β-HSD1, NADPH
17β-HSD2, NAD+
E1E2
17β-HSD2, NAD+
T A-dione
17β-HSD3, NADPH
 
 
Several drugs can be administered for the treatment of osteoporosis. Among the antiresorptive 
agents, the bisphosphonate alendronate [2] is the most potent one used, but reduces the risk of 
hip fractures only by 50% in post-menopausal women [2, 3] and elderly men [4]. Raloxifene 
[5], a selective estrogen receptor modulator (SERM) is also often used to treat osteoporosis, 
but leads to various adverse effects as increased risk of thromboembolism [6], hot flushes or 
leg cramps. Denosumab [7], an inhibitor of the receptor activator of nuclear factor κB ligand 
(RANKL) [8] inhibits the osteoclastogenesis (OC differentiation) by binding to RANKL. It 
has proven its efficacy [7, 9] in post-menopausal women and elderly men with high risk of 
fractures but is associated with high cholesterol levels, muscle pain and bladder infection. 
Among all current marketed osteoporosis drugs, none of them offers a complete cure, there is 
therefore a need to develop new drugs for this disease with higher efficiency. 
Estrogens [10] and androgens [10] play a key role in the development of the disease. It has 
been show that administration of E2 can help in the treatment of osteoporosis, but has adverse 
effects. Mechanism by which estrogens act on bones is not well understood yet, but one 
theory points out the importance of RANKL and osteoprotegerin (OPG) [11]. The production 
of OPG is stimulated by E2 in the OBs. Binding of OPG to RANKL inhibits the activation of 
the RANK receptor on osteoclasts, limiting the resorptive activity of OCs. OPG and RANKL 
knockout (KO) mice confirm the possible involvement of OPG and RANKL in bone 
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regulation, as OPG KO mice [12, 13] exhibit severe osteoporosis due to an increase of 
osteoclastogenesis, while RANKL KO mice [14] show serious osteopetrosis and a complete 
lack of OCs. A drug which could increase the concentration of estrogens in bones, would raise 
OPG levels, and thus might diminish bone resorption and should have favorable effects on 
osteoporosis. 
17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) is an enzyme converting the highly 
active E2 and T into their less active form, estrone (E1) and 4-androstene-3,17-dione (A-
dione), respectively, using NAD+ as cofactor. It is mainly localised in placenta, liver, small 
intestine and can be found in osteoblastic cells [15]. Inhibitors of 17β-HSD2 could therefore 
maintain a high level of E2 and T in bones, and protect them against bone loss. Considering 
that systemic and intracellular modulation of hormone concentrations has already been 
successfully applied for the treatment of breast and prostate cancer and begnign prostatic 
hyperplasia by inhibition of the steroidogenic enzymes aromatase [16-18], CYP17 [19-22] 
and 5α-reductase [23-25], respectively, or - as in case of 17β-HSD1 [26-34]- is considered 
beneficial for endometriosis therapy, inhibition of 17β-HSD2 could be a new approach for the 
treatment of osteoporosis. 
Few inhibitors of 17β-HSD2 have been identified until now [35-40]. Among them, the 
pyrrolidinone A [38] (Chart 2) is the most potent one described in the literature (IC50 = 
10nM). Efficacy of a derivative of A has been evaluated in vivo in an osteoporotic monkey 
model [41]. This study proved that inhibition of 17β-HSD2 recovers the balance between 
bone formation and bone resorption. A strong variability is observed, certainly due to non 
appropriate pharmacokinetic properties of this compound. New 17β-HSD2 inhibitors with 
good pharmacokinetic properties should be identified for further in vivo experiments. 
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Chart 2: Inhibitors of 17β-HSD2 
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In the frame of our 17β-HSD1 project, the hydroxyphenylketothiophene B (Chart 2) was 
identified [32] as moderate 17β-HSD2 inhibitor (IC50 = 382 nM). The scaffold of B can 
therefore be considered as an interesting starting point for development of a new class of 17β-
HSD2 inhibitors. Optimisation of HSD2 activity and gain in selectivity toward HSD1 might 
be obtained by 1) exchange of the thiophene ring by bioisosteres, 2) exchange of the methyl 
substituent on the A ring, and 3) introduction of substituents on the B moiety. Convenience of 
these compounds is the easy four steps synthesis and purification, contrary to the 
pyrrolidinone A, which requires a separation of stereoisomers. 
In this paper, we will report on the synthesis and the biological evaluation of a novel class of 
17β-HSD2 inhibitors, with a bicyclic substituted hydroxyphenylmethanone core structure. 
 
Results 
 
Chemistry 
 
The synthesis of compounds 1-24 was achieved in a four step procedure and is depicted in 
Scheme 1. First, the nucleophilic addition of Grignard reagent (phenylmagnesiumbromide 
derivatives) to the appropriate aromatic carbaldehyde (Method A) afforded the alcohol 
intermediates 1c, 2c, 9c-12c, 14c and 22c-24c. Then the OH-group was further oxidized into 
the corresponding ketone with 2-iodoxybenzoic acid (Method B). Subsequent Suzuki cross 
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couplings [42] with different substituted phenylboronic acids led to compounds 1a-24a 
(Method C or D). Ether cleavage [43] was performed using boron tribromide for compounds 
1, 2, 10, 11, 14-19 and 21, (method E), boron trifluoride dimethylsulfide complex for 
compounds 3, 5, 6, 13 and 23 (method F) or pyridinium hydrochloride for compounds 4, 7-9, 
12, 20, 22 and 24, (method G). 
 
Scheme 1: Synthesis of compounds 1-24a 
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R1
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R2R1
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R2R1
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O
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R4
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1c, 2c, 9c-12c, 14c, 22c-24c
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a b
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1b, 2b, 9b-12b, 14b, 22b-24b
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arom
1a-24a
c or d
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arom
1-24  
aReagents and conditions: a. anhydrous THF, 80°C, 3h, Method A; b. 2-iodoxybenzoic acid, 
anhydrous THF, 60°C, overnight, Method B; c. Na2CO3, Pd(PPh3)4, R-B(OH)2, DME/water 
(2:1), microwave irradiation (25 min, 150W, 150°C, 15 bar), for compounds 15a-17a, Method 
C; d. Cs2CO3, Pd(PPh3)4, R-B(OH)2, DME/water (2:1), 80°C, overnight, for compounds 1a-
14a, 18a-24a, Method D; e. BBr3, CH2Cl2, -78°C to rt, overnight, for compounds 1, 2, 10, 11, 
14-19 and 21, Method E; f. BF3SMe2, CH2Cl2, rt, overnight, for compounds 3, 5, 6, 13 and 
23, Method F; g. pyridinium hydrochloride, 180°C, 2h, for compounds 4, 7-9, 12, 20, 22 and 
24, Method G. 
 
Biological results 
 
Inhibition of human 17β-HSD2 and selectivity toward 17β-HSD1 and estrogen receptors 
(ERs) 
 
17β-HSD2 and 17β-HSD1 inhibitory activities of the synthesised compounds were evaluated. 
As 17β-HSD1 catalyses the reduction of E1 to E2, it should not be affected by 17β-HSD2 
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inhibitors. Moreover, inhibitors of 17β-HSD2 should have no affinity for the estrogen 
receptors (ER) α and β, as most E2 effects are ER mediated. 
Human placental enzymes were used for both assays and were obtained according to 
described methods [44-46]. Briefly, in the 17β-HSD2 assay, incubations were run with 
microsomal fractions, tritiated E2, cofactor and inhibitor. The separation of substrate and 
product was accomplished by HPLC. The 17β-HSD1 assay was performed similarly using 
tritiated E1 as substrate and the cytosolic fraction. The percent inhibition values of 
compounds 1-24 are shown in Table 1, and the IC50 values determined for selected 
compounds are reported in Table 2. Compounds showing less than 10% inhibition tested at a 
concentration of 1µM were considered to be inactive. The spiro-δ-lactone described by Poirier 
et al. [36] was taken as external reference (68% at 1µM in our test; 62-66% at 1µM in their 
test). 
In a previous work [32], focusing on the development of 17β-HSD1 inhibitors, compound B 
has been identified as an interesting scaffold for 17β-HSD2 inhibition with an IC50-value of 
382 nM. The goal of this study was to increase the 17β-HSD2 inhibitory activity and reverse 
selectivity in favour of HSD2. The thiophene ring of B was first exchanged by the bioisostere 
benzene with 1,3- and 1,4- substitution pattern to afford compounds 1 and 2, respectively. 1 
turned out to be a moderate 17β-HSD2 inhibitor (IC50 = 379 nM), while the 1,4- substituted 
compound 2 is a very active compound (IC50 = 132 nM). Compound 2 also shows a slight 
selectivity toward 17β-HSD1 (SF: 3). Thus, exchange of the thiophene ring by a 1,4-
substituted benzene reverses the selectivity of the starting compound B toward 17β-HSD2. 
These results encouraged us to extend this SAR study on bicyclic substituted 
hydroxyphenylmethanones by changing the methyl group on the A ring and by adding further 
substituents on the B ring (compounds 3-10) to improve their activity for 17β-HSD2.  
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Table 1: Inhibition of human 17β-HSD2 and 17β-HSD1 by compounds 1-24 
O
OHR1
R2
OH
O
F
F
OH
(het-)
arom
B, 1-8, 10-24
2
3
4
3 4
9
A
B A
B
 
Compd (Het-) arom R1 R2 
Position 
of the OH 
group 
Inhibition of 
17β-HSD2a 
[%] 
at 1 µM 
Inhibition of 
17β-HSD1b 
[%] 
at 1 µM 
Spiro-δ-
lactone - - - - 69 n.i. 
B 
S  
H 3-CH3 4 75 94 
1 
 
H 3-CH3 4 77 50 
2 
 
H 3-CH3 4 90 58 
3 H 3-F 4 68 26 
4 H 2-Cl 4 80 43 
5 H 3-Cl 4 92 66 
6 4-F 3-CH3 4 98 79 
7 4-F 3-Cl 4 100 95 
8 3-F 3-CH3 4 100 84 
9 - -  11 16 
10 
N
 
H 3-CH3 4 84 58 
11 
N  
H 3-CH3 4 73 24 
12 4-F 3-CH3 4 84 47 
13 4-F 3-Cl 4 87 50 
14 
N  
H 3-CH3 4 84 n.i. 
15 H H 2 n.i. n.i. 
16 H H 3 n.i. n.i. 
17 H H 4 16 n.i. 
18 H 2-CH3 4 18 n.i. 
19 H 2-F 4 56 64 
20 H 3-F 4 40 47 
21 H 3-Cl  4 55 n.i. 
22 4-F 3-CH3 4 62 n.i. 
23 4-CH3 3-CH3 4 28 n.i. 
24 3-F 3-CH3 4 57 n.i. 
a Human placental, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], NAD+ [1.5 mM], mean value of three 
determinations, relative standard deviation < 10%, b Human placental, cytosolic fraction, substrate [3H]-E1 + E1 
[500 nM], NADH [0.5 mM], mean value of three determinations, relative standard deviation < 10%, n.i.: no 
inhibition (inhibition < 10%). 
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Replacement of the electron donating methyl group (EDG) of 2 by an electron withdrawing 
group (EWG) like a fluoro (3) is not well tolerated by the enzyme, as compound 3 showed 
only 68% inhibition at 1µM. Exchange of the lipophilic methyl group (2) by a bioisosteric 
chlorine (5) led to a similar affinity to the enzyme and a similar selectivity factor toward 17β-
HSD1 (90% vs. 92% inhibition at 1µM, respectively). Advantageously compound 5 with a 
chlorine should be less susceptible to metabolic oxidation compared to the CH3 compound 2. 
Shifting the chlorine to the ortho position (4) led to a small loss in activity (80% and 92% 
17β-HSD2 inhibition at 1μM for 4: 2-Cl and 5: 3-Cl, respectively). As the exchange of the 
methyl group of 2 did not improve selectivity, additional substituents were added on the 
phenyl moiety B. Introduction of a fluorine (compounds 6-8) leads to highly active 17β-HSD2 
inhibitors (IC50 values between 24 and 34 nM), but only a small selectivity toward 17β-HSD1 
(SF between 2 and 9). Better selectivity is achieved in presence of the methyl group on the A 
ring (6, SF = 8) compared to the chlorinated analog 7 (SF = 2). Exchanging the m-OH group 
in the B ring by fluorine led to a completely inactive compound (11% inhibition at 1μM for 
9). New potent 17β-HSD2 inhibitors have been identified in the class of 1,4-disubstituted 
benzenes, but none of them is highly selective toward 17β-HSD1 (compounds 2-8).  
In a previous study [28], oxazole C and isoxazole D (Chart 2) were identified as inhibitors of 
17β-HSD2 (IC50 = 249 nM for C and 270 nM for D), indicating that polar moieties like O and 
N are well tolerated in the central core of this class of inhibitor. With the hypothesis that these 
two classes of compounds bind in the same area of HSD2 and trying to increase the selectivity 
of this new class of 17β-HSD2 inhibitors, a nitrogen was introduced in the 1,4-disubstituted 
central benzene ring leading to 2,5-pyridines 10 and 11 and 2,6-pyridine 14. These 
compounds turned out to be very active (84%, 73% and 84% 17β-HSD2 inhibition at 1µM for 
10, 11 and 14, respectively). In addition, the selectivity of 11 and 14 toward 17β-HSD1 was 
much increased compared to the 1,4- and 1,3-disubstituted benzenes (SF = 21 and 75 for 11 
and 14 respectively, to be compared with SF = 1 and 3 for 1 and 2, respectively). In the 2,5-
pyridine class, activity of 11 can be increased by addition of fluorine to the B phenyl moiety 
(compounds 12 and 13, IC50 = 101 nM and 153 nM respectively), but selectivity toward 17β-
HSD1 dropped down in case of compound 13. 
2,6-Substituted pyridine 14, the most selective compound of the pyridine class was further 
modified trying to increase its activity. Shifting the CH3-group from the meta- to the ortho-
position of the phenyl is detrimental for the activity (18% and 84% 17β-HSD2 inhibition at 
1µM for 18: 2-CH3 and 14: 3-CH3, respectively). Exchange of the methyl by an EWG like 
fluorine (19: 2-F and 20: 3-F) or chlorine (21: 3-Cl) led to a regain of activity (56%, 40% and 
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55% 17β-HSD2 inhibition at 1µM, respectively), but these compounds are not able to reach 
the activity of compound 14 (84% inhibition at 1μM). Furthermore, addition of an EWG 
(compounds 22 and 24) or an EDG (compound 23) group in the 3-hydroxyphenyl B moiety is 
detrimental for the activity, as the compounds show a weaker inhibition compared to the 
parent compound 14 (62%, 28% and 58% 17β-HSD2 inhibition at 1µM, respectively), 
independently of the position of the fluorine (62% and 57% 17β-HSD2 inhibition at 1 µM for 
22: 4-F and 24: 5-F, respectively).  
As none of the substituted 2,6-pyridines reached the activity of 14, the position of the OH 
group on the A ring has been studied in absence of the 3-methyl group to investigate whether 
the para-meta OH substitution pattern of 14 is the best one for a high 17β-HSD2 inhibitory 
activity. Compounds 15-17 as well as their analogues with methoxy groups (data not shown) 
turned out to be only weak HSD2 inhibitors. It can be concluded that the methyl group next to 
the OH in the A ring plays an important role for the inhibition of 17β-HSD2 and should not be 
omitted. 
 
Table 2: IC50 values, selectivity factor for selected compounds. 
Compd 
Cell-free assay 
17β-
HSD2 
IC50a 
[nM] 
17β-
HSD1 
IC50b 
[nM] 
Selectivity 
factorc 
B 382 8 0.02 
1 379 475 1 
2 133 413 3 
3 525 2429 5 
4 176 1764 11 
5 153 571 4 
6 34 289 9 
7 24 53 2 
8 31 159 5 
10 220 567 3 
11 260 5482 21 
12 101 1272 13 
13 153 1013 7 
14 263 19646 75 
21 752 60638 81 
22 757 22395 30 
a Human placental, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], cofactor NAD+ [1.5 mM], mean value 
of three determinations, relative standard deviation < 10%, b Human placental, cytosolic fraction, substrate [3H]-
E1 + E1 [500 nM], cofactor NADH [0.5 mM], mean value of three determinations, relative standard deviation < 
10%, c IC50 (17β-HSD1)/ IC50 (17β-HSD2). 
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Eleven compounds were identified as highly active 17β-HSD2 inhibitors with IC50-values 
below 300 nM, with three of them selective toward 17β-HSD1 (SF > 10). The most potent 
compounds have been evaluated for their binding affinities to the ER α and β, expressed as 
relative binding affinity (RBA). The RBA represents the ligand affinity to ER, relative to the 
one of E2, which is arbitrarily set up at 100%. The tested compounds showed very low 
affinities to both ER subtypes (< 0.1%). 
 
Discussion and conclusion 
 
In this study, starting from compound B [32] as moderate 17β-HSD2 inhibitor, we have 
developed a new class of active and selective 17β-HSD2 inhibitors. Exchange of the 
thiophene moiety of B by a six-membered ring (benzene or pyridine) with different 
substitution patterns inverses the selectivity of B in favour of 17β-HSD2 and leads to highly 
potent 17β-HSD2 inhibitors.  
The best inhibitory activity was obtained when the core structure is a 1,4-substituted benzene 
(compound 2). Changing the substitution pattern to 1,3-substituted benzene leads to a loss in 
activity, indicating that the linear geometry of the inhibitors suits better to the enzyme binding 
pocket. Furthermore, the compounds are believed to be steroidomimetics as the 1,4-
substituted benzene derivatives superimpose well with the substrate E2 (Fig. 1): because of 
the pseudosymmetry the inhibitors can overlay with E2 in two ways: either the carbonyl 
group of 2 mimicks the C17(OH) of E2 and the OH of the phenyl A ring the C3(OH) of the 
steroid (Fig. 1A) or vice versa (Fig. 1B). 
 
Figure 1: Superimposition of compound 2 (green) and E2 (blue); (A) carbonyl group of 2 
mimicks the C17(OH) of E2 and the OH of the phenyl A ring the C3(OH) of the steroid; (B) 
carbonyl group of 2 mimicks the C3(OH) of E2 and the OH of the phenyl A ring the C17(OH) 
of the steroid. 
A B  
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Introduction of a fluorine on the B ring in compounds bearing the 1,4- substitution pattern 
results in highly potent inhibitors (compounds 6-8, 12 and 13). This fluorine might interact 
with amino acids of the active site via H-bond interaction, which could stabilise the binding of 
the inhibitor. Interestingly, the position of the fluorine is not important for activity, as 
compounds 6 and 8 show similar HSD2 inhibition. As the 3D-structure of 17β-HSD2 is 
unknown, it is not possible to discuss the binding interactions of the compounds with the 
enzyme in more detail.  
Regarding the pyridine derivatives (compounds 10, 11 and 14), the introduction of a nitrogen 
in the phenyl ring decreases inhibitory activity. None of these compounds is as active as the 
corresponding 1,4-benzene derivative. With the aim to increase activity in the pyridine class, 
the best hydroxyphenyl substitution pattern was investigated in the class of the 2,6-pyridines 
(compounds 15-17) in absence of the methyl group. These compounds showed either very 
low activity (17) or were inactive (15 and 16). A similar compound to 15 with the OH group 
in ortho-position of the A ring was described by Oster et al. [32], with a 2,5-thiophene as 
central core. This compound is a highly potent 17β-HSD2 inhibitor (IC50 = 18 nM, SF = 5), 
while compound 15 is inactive. Comparison of these results indicates that the 2,5-thiophene 
and the 2,6-pyridine derivatives do not bind in the same way in the enzyme active site. 
Furthermore, the inactivity of 17 shows that the methyl group on the A ring plays a key role 
for the binding of the compound in the enzyme. The methyl group might be located in a small 
lipophilic pocket and might form Van der Waals interactions. In the 1,4-benzene class 
(compounds 2, 5, 6 and 7) and 2,5-pyridine class (compounds 12 and 13), the methyl could be 
replaced by a chlorine without loss of activity, confirming that the amino acids around this 
region of the enzyme should be lipophilic.  
Interestingly, the nitrogen of the pyridine seems to be responsible for the high selectivity 
observed toward 17β-HSD1. A similar effect of the nitrogen on selectivity was already 
identified in the frame of our 17β-HSD1 inhibitors development: polar atoms are not tolerated 
in the active site of 17β-HSD1[28] while they are advantageous in 17β-HSD2 (compounds C 
and D)[28, 47]. The position of the nitrogen on the central core also plays a key role for the 
selectivity. Compound 10, with the nitrogen next to the A ring is an unselective 17β-HSD2 
inhibitor, while compound 11 with the nitrogen next to the B ring is a highly selective 
inhibitor. 
In the optimisation process of the 2,5-pyridine class, activity of 11 can be increased by 
introduction of a fluorine into the B ring, thereby leading to the identification of the highly 
active and selective compound 12 as most promising 17β-HSD2 inhibitor in this study. This 
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compound as well as the most interesting molecules identified (2, 5, 6, 7, 8, 11 and 14) show a 
negligible affinity to both receptors ERα and β. 
In this paper, we described the synthesis and the biological evaluation of a new class of 17β-
HSD2 inhibitors, derived from substituted bicyclic hydroxyphenylmethanones. The influence 
of different six-membered rings as central core and different small substituents on the phenyl 
moieties A and B were investigated. Structural optimisation of the starting compound B led to 
new highly potent 17β-HSD2 inhibitors (compounds 6, 7, 8, 12 and 13) with inhibitory 
activities in the very low nanomolar range. Selectivity was achieved by introduction of a 
nitrogen in the central core, while activity was increased by addition of a fluorine in the B 
ring. Thereby, compound 12 was identified as the most promising derivative of this series 
with activity in the low nanomolar range, a striking selectivity toward 17β-HSD1 and no 
affinity on both ERs. This inhibitor seems to be the best candidate for being further evaluated 
for its pharmacokinetic profile and for its in vivo activity in a disease-oriented model to 
validate the concept of 17β-HSD2 inhibition. 
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Experimental section 
 
Chemical methods 
 
1H NMR and 13C NMR spectra were recorded on a Bruker DRX-500 instrument in CDCl3 or 
acetone-d6. Chemicals shifts are reported in δ values (ppm), the hydrogenated residues of 
deuterated solvent were used as internal standard (CDCl3: δ = 7.26 ppm in 1H NMR and δ = 
77 ppm in 13C NMR, acetone-d6: δ = 2.05 ppm in 1H NMR and δ = 30.8 ppm and 206.3 ppm 
in 13C NMR). Signals are described as s, br, d, t, dd, ddd, dt and m for singlet, broad, doublet, 
triplet, doublet of doublets, doublet of doublet of doublets, doubet of triplets and multiplet, 
respectively. All coupling constants (J) are given in Hertz.  
Tested compounds are ≥ 95 % chemical purity as measured by HPLC. The Surveyor®-LC-
system consisted of a pump, an autosampler, and a PDA detector. Mass spectrometry was 
performed on a TSQ® Quantum (ThermoFisher, Dreieich, Germany). The triple quadrupole 
mass spectrometer was equipped with an electrospray interface (ESI) and atmospheric 
pressure chemical ionisation (APCI), respectively. The system was operated by the standard 
software Xcalibur®. A RP C18 NUCLEODUR® 100-5 (3 mm) column (Macherey-Nagel 
GmbH, Dühren, Germany) was used as stationary phase. All solvents were HPLC grade. 
In a gradient run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) in 0.1 % 
trifluoroacetic acid in was increased from an initial concentration of 5 % at 0 min to 100 % at 
15 min and kept at 100 % for 5 min. The injection volume was 20 µL and flow rate was set to 
800 µL/min. MS analysis was carried out at a needle voltage of 3000 V and a capillary 
temperature of 350 °C. Mass spectra were acquired in positive mode and in negative mode 
when required from 100 to 1000 m/z and UV spectra were recorded at the wavelength of 254 
nm and in some cases at 360 nm. 
GC/MS spectra were measured on a GCD Series G1800A (Hewlett Packard) instrument with 
an Optima-5-MS (0.25 μM, 30 m) column (Macherey Nagel). 
All microwave irradiation experiments were carried out in a CEM-Discover microwave 
apparatus. 
Melting points were measured on a Stuart Scientific SMP3 apparatus. 
Flash chromatography was performed on silica gel 40 (35/40-63/70 μM) with hexane/ethyl 
acetate mixtures as eluents, and the reaction progress was determined by thin-layer 
chromatography analyses on Alugram SIL G/UV254 (Macherey-Nagel). Visualization was 
accomplished with UV light. Purification by preparative TLC was performed on 1 mm SIL G-
100 UV254 glass plates (Macherey-Nagel). Purification with preparative HPLC were carried 
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out on a Agilent 1200 series HPLC system from Agilent Technologies, using a RP C18 
Nucleodur 100-5 column (30∙100 m m/50 µm – from Macherey-Nagel GmbH) as stationary 
phase with acetonitrile/water or isopropanol/water as solvent in a gradient from 20:80 to 
100:0 in fourty minutes. 
Starting materials were used as obtained from Aldrich, Acros, Alfa Aeser and Combi-blocks 
without further purification. No attempts were made to optimise yields. 
 
General procedure for alcohol formation 
Method A. To a mixture of aldehyde (1 equiv) in dry THF was added the magnesiumbromide 
derivative (2.2 equiv) under nitrogen. The reaction mixture was heated to 80°C and stirred for 
3h at 80°C. The reaction mixture was cooled to room temperature, quenched with brine and 
the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried 
over sodium sulfate, filtered and concentrated to dryness. The product was purified by column 
chromatography. 
  
General procedure for oxidation of alcohol in ketone 
Method B. To a mixture of alcohol (1 equiv) in dry THF was added 2-iodoxybenzoic acid (2 
equiv). The reaction mixture was stirred at 60°C overnight, cooled to room temperature and 
quenched with Na2S2O3. The aqueous layer was extracted with ethyl acetate and the organic 
layer was washed with water, neutralised with 0.5N NaOH and dried over sodium sulfate, 
filtered and concentrated to dryness. The product was purified by column chromatography or 
by recrystallisation. 
 
General procedures for Suzuki coupling 
Method C. A mixture of arylbromide (1 equiv), boronic acid (1.2 equiv), sodium carbonate (2 
equiv), and tetrakis(triphenylphosphine) palladium (0.02 equiv) was suspended in a degazed 
DME/water (2:1) solution. The reaction mixture was exposed to microwave irradiation (25 
min, 150 W, 150°C, 15 bar). After reaching room temperature, water was added to quench the 
reaction and the aqueous layer was extracted with ethyl acetate. The combined organic layers 
were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The 
product was purified by column chromatography. 
 
Method D. A mixture of arylbromide (1 equiv), boronic acid (1.2 equiv), caesium carbonate 
(4 equiv), and tetrakis(triphenylphosphine) palladium (0.02 equiv) was suspended in a 
DME/water (2:1) solution and the mixture was degazed. The mixture was heated to 80°C and 
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stirred overnight at 80°C under nitrogen. The reaction mixture was cooled to room 
temperature, quenched by water and extracted with ethyl acetate. The organic layer was 
washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The 
product was purified by column chromatography or by recrystallisation. 
 
General procedures for ether cleavage 
Method E. To a solution of methoxy derivative (1 equiv) in dry dichloromethane cooled at -
78°C under nitrogen was slowly added boron tribromide (1M solution in dichloromethane, 5 
equiv per methoxy function). The reaction mixture was stirred at -78°C for 1h and then 
allowed to warm to room temperature overnight. The reaction was quenched by water and 
extracted with ethyl acetate. The combined organic layers were washed with brine and dried 
over sodium sulfate, filtered, evaporated to dryness under reduced pressure and purified by 
column chromatography. 
 
Method F. To a solution of methoxy derivative (1 equiv) in dry dichloromethane, 
borontrifluoride dimethylsulfide complex (35 equiv per methoxy function) was added 
dropwise at room temperature. The reaction mixture was stirred at room temperature 
overnight. Water was added to quench the reaction and the aqueous layer was extracted with 
ethyl acetate. The combined organic layers were washed with brine, dried over sodium 
sulfate, filtered, evaporated to dryness under reduced pressure and purified by column 
chromatography. 
 
Method G. To pyridinium hydrochloride (100 equiv) at 190°C was added the methoxy 
derivative (1 equiv). The reaction mixture was stirred for 2h, cooled to room temperature and 
then stirred with 1N HCl for 1h. The mixture was extracted in ethyl acetate. The combined 
organic layers were washed with water, dried over sodium sulfate, filtered, evaporated to 
dryness under reduced pressure and purified by column chromatography or by 
recrystallisation. 
 
Detailed synthesis procedure of the most active compounds 
 
(3-Bromophenyl)-(3-methoxyphenyl)-methanol (1c). The title compound was prepared by 
reaction of 3-bromophenyl carboxaldehyde (500 mg, 2.71 mmol, 1 equiv) with 3-
methoxyphenylmagnesiumbromide (1M in THF) (1.35 g, 5.95 mL, 5.95 mmol, 2.2 equiv) 
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according to method A. The product was used in the next step without further purification. 
C14H13BrO2; MW 293. 
 
(3-Bromophenyl)-(3-methoxyphenyl)-methanone (1b). The title compound was prepared 
by reaction of (3-bromophenyl)-(3-methoxyphenyl)-methanol 1c (460 mg, 1.57 mmol, 1 
equiv) with 2-iodoxybenzoic acid (885 mg, 3.14 mmol, 2 equiv) according to method B. The 
product was purified by column chromatography (hexane/ethyl acetate 9:1) to give 200 mg 
(44%) of the analytically pure compound as a yellow oil. C14H11BrO2; MW 291; 1H NMR 
(acetone-d6): δ 7.92-7.90 (m, 1H), 7.82 (ddd, J = 0.9 Hz, J = 1.9 Hz, J = 7.9 Hz, 1H), 7.76-
7.73 (m, 1H), 7.50 (t, J = 8.2 Hz, 1H), 7.48-7.44 (m, 1H), 7.34-7.30 (m, 2H), 7.23 (ddd, J = 
1.3 Hz, J = 2.5 Hz, J = 8.2 Hz, 1H), 3.86 (s, 3H); 13C NMR (acetone-d6): δ 195.8, 161.7, 
141.6, 140.1, 136.9, 134.0, 132.2, 131.4, 130.4, 124.1, 123.9, 120.6, 116.2, 56.8. 
 
(4´-Methoxy-3´-methylbiphenyl-3-yl)-(3-methoxyphenyl)-methanone (1a). The title 
compound was prepared by reaction of (3-bromophenyl)-(3-methoxyphenyl)-methanone 1b 
(200 mg, 0.69 mmol, 1 equiv) with 4-methoxy-3-methylphenylboronic acid (137 mg, 0.82 
mmol, 1.2 equiv) according to method D. The product was purified by column 
chromatography (hexane/ethyl acetate 95:5) to afford 200 mg (88%) of the analytically pure 
compound as a yellow oil. C22H20O3; MW 332; 1H NMR (acetone-d6): δ 8.00-7.98 (m, 1H), 
7.90-7.87 (m, 1H), 7.71-7.68 (m, 1H), 7.59 (t, J = 7.9 Hz, 1H), 7.52-7.45 (m, 3H), 7.38-7.35 
(m, 2H), 7.25-7.21 (m, 1H), 7.02 (d, J = 9.1 Hz, 1H), 3.87 (s, 6H), 2.25 (s, 3H); 13C NMR 
(acetone-d6): δ 196.3, 160.7, 158.8, 142.0, 140.0, 139.2, 134.8, 132.0, 131.2, 130.4, 130.0, 
129.7, 128.7, 128.4, 127.6, 126.4, 123.2, 119.3, 115.2, 111.4, 55.9, 55.8, 16.4. 
 
(4´-Hydroxy-3´-methylbiphenyl-3-yl)-(3-hydroxyphenyl)-methanone (1). The title 
compound was prepared by reaction of 4´-methoxy-3´-methylbiphenyl-3-yl)-(3-
methoxyphenyl)-methanone 1a (200 mg, 0.60 mmol, 1 equiv) with boron tribromide (6 mmol, 
10 equiv) according to method E. The product was purified by column chromatography 
(hexane/ethyl acetate 8:2) then by preparative TLC (hexane/ethyl acetate 7:3) to afford 44 mg 
(24%) of the analytically pure compound as a yellow oil. C20H16O3; MW 304; 1H NMR 
(acetone-d6): δ 8.72 (s, br, 1H), 8.38 (s, br, 1H), 7.97-7.95 (m, 1H), 7.86-7.83 (m, 1H), 7.67-
7.65 (m, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.46 (d, J = 2.2 Hz, 1H), 7.40-7.35 (m, 2H), 7.33-7.31 
(m, 1H), 7.30-7.28 (m, 1H), 7.14 (dd, J = 2.5 Hz, J = 7.9 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 
2.28 (s, 3H); 13C NMR (acetone-d6): δ 197.3, 159.1, 157.3, 143.0, 140.8, 140.1, 132.9, 131.8, 
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131.2, 131.1, 130.4, 129.3, 129.0, 127.1, 126.6, 122.9, 121.3, 117.9, 116.9, 17.1; IR: 3320, 
1641, 1581, 1476, 1358, 1220 cm-1; LC/MS m/z: 305 (M+H)+. 
 
(4-Bromophenyl)-(3-methoxyphenyl)-methanol (2c). The title compound was prepared by 
reaction of 4-bromophenyl carboxaldehyde (1 g, 5.41 mmol, 1 equiv) with 3-
methoxyphenylmagnesiumbromide (1M in THF) (2.70 g, 11.9 mmol, 11.9 mL, 2.2 equiv) 
according to method A. The product was purified by column chromatography (hexane/ethyl 
acetate 9:1) to afford 1.58 g (100%) of the analytically pure compound as a colorless oil. 
C14H13BrO2; MW 292; 1H NMR (acetone-d6): δ 7.50-7.47 (m, 2H), 7.41-7.38 (m, 2H), 7.23 (t, 
J = 7.9 Hz, 1H), 7.06-7.04 (m, 1H), 7.00-6.97 (m, 1H), 6.81 (ddd, J = 0.9 Hz, J = 2.5 Hz, J = 
8.2 Hz, 1H), 5.81 (d, J = 4.0 Hz, 1H), 5.01 (d, J = 4.0 Hz, 1H), 3.76 (s, 3H); 13C NMR 
(acetone-d6): δ 160.8, 147.5, 145.7, 132.0, 130.2, 129.4, 121.2, 119.6, 113.3, 113.1, 75.5, 
55.5. 
 
(4-Bromophenyl)-(3-methoxyphenyl)-methanone (2b). The title compound was prepared 
by reaction of (4-bromophenyl)-(3-methoxyphenyl)-methanol 2c (1.5 g, 5.12 mmol, 1 equiv) 
with 2-iodoxybenzoic acid (2.88 mg, 10.2 mmol, 2 equiv) according to method B. The 
product was purified by column chromatography (hexane/ethyl acetate 95:5) to afford 1.39 g 
(94%) of the analytically pure compound as a colorless oil. C14H11BrO2; MW 290; 1H NMR 
(acetone-d6): δ 7.73-7.70 (m, 4H), 7.46-7.42 (m, 1H), 7.32-7.29 (m, 2H), 7.21 (ddd, J = 0.9 
Hz, J = 2.5 Hz, J = 8.2 Hz, 1H), 3.85 (s, 3H); 13C NMR (acetone-d6): δ 195.3, 160.7, 139.5, 
137.5, 132.5, 130.4, 127.7, 123.1, 119.5, 115.2, 55.9; IR: 3003, 2834, 1651, 1575, 1234 cm-1. 
 
(4´-Methoxy-3´-methylbiphenyl-4-yl)-(3-methoxyphenyl)-methanone (2a). The title 
compound was prepared by reaction of (4-bromophenyl)-(3-methoxyphenyl)-methanone 2b 
(410 mg, 1.41 mmol, 1 equiv) with 4-methoxy-3-methylphenylboronic acid (281 mg, 1.69 
mmol, 1.2 equiv) according to method D. The product was used in the next step without 
further purification. C22H20O3; MW 332. 
 
(4´-Hydroxy-3´-methylbiphenyl-4-yl)-(3-hydroxyphenyl)-methanone (2). The title 
compound was prepared by reaction of (4´-methoxy-3´-methylbiphenyl-4-yl)-(3-
methoxyphenyl)-methanone 2a (460 mg, 1.38 mmol, 1 equiv) with boron tribromide (13.8 
mmol, 10 equiv) according to method E. The product was purified by column 
chromatography (hexane/ethyl acetate 8:2) then by preparative TLC (hexane/ethyl acetate 7:3 
+ 10 drops of HCOOH) to afford 120 mg (29%) of the analytically pure compound as an 
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orange solid. C20H16O3; MW 304; 1H NMR (acetone-d6): δ 8.68 (s, br, 1H), 8.46 (s, br, 1H), 
7.85-7.82 (m, 2H), 7.77-7.74 (m, 2H), 7.54 (d, J = 2.2 Hz, 1H), 7.44 (dd, J = 1.9 Hz, J = 7.9 
Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 7.29-7.24 (m, 2H), 7.13 (ddd, J = 0.9 Hz, J = 2.5 Hz, J = 8.2 
Hz, 1H), 6.96 (d, J = 8.2 Hz, 1H), 2.30 (s, 3H); 13C NMR (acetone-d6): δ 196.9, 159.3, 157.9, 
146.9, 141.3, 137.3, 132.7, 132.3, 131.5, 131.3, 127.8, 127.5, 126.8, 122.9, 121.2, 118.0, 
117.1, 17.3; IR: 3363, 1641, 1588, 1449 cm-1; LC/MS m/z: 305 (M+H)+. 
 
(3´-Fluoro-4´-methoxybiphenyl-4-yl)-(3-methoxyphenyl)-methanone (3a). The title 
compound was prepared by reaction of (4-bromophenyl)-(3-methoxyphenyl)-methanone 2b 
(200 mg, 0.69 mmol, 1 equiv) with 3-fluoro-4-methoxyphenylboronic acid (141 mg, 0.81 
mmol, 1.2 equiv) according to method D. The product was used in the next step without 
further purification. C21H17FO3; MW 336. 
 
(3´-Fluoro-4´-hydroxybiphenyl-4-yl)-(3-hydroxyphenyl)-methanone (3). The title 
compound was prepared by reaction of (3´-fluoro-4´-methoxy-biphenyl-4-yl)-(3-
methoxyphenyl)-methanone 3a (20 mg, 0.06 mmol, 1 equiv) with boron trifluoride 
dimethylsulfide complex (4.2 mmol, 70 equiv) according to method F. The product was 
purified by column chromatography (hexane/ethyl acetate 1:1). Yield: 8 mg (43%). 
C19H13FO3; MW 308; 1H NMR (acetone-d6): δ 8.88 (s, br, 1H), 8.68 (s, br, 1H), 7.87-7.80 (m, 
4H), 7.55 (dd, J = 2.3 Hz, J = 12.2 Hz, 1H), 7.47 (ddd, J = 0.9 Hz, J = 2.1 Hz, J = 8.4 Hz, 
1H), 7.39 (t, J = 7.8 Hz, 1H),  7.28-7.25 (m, 2H), 7.16-7.12 (m, 2H); 13C NMR (acetone-d6): δ 
195.9, 144.5, 140.1, 137.0, 131.3, 130.4, 127.0, 124.2, 121.9, 120.3, 116.9, 115.5, 115.4; IR: 
3333, 2981, 1637, 1305 cm-1; GC/MS m/z: 308 (M)+. 
 
(2´-Chloro-4´-methoxybiphenyl-4-yl)-(3-methoxyphenyl)-methanone (4a). The title 
compound was prepared by reaction of (4-bromophenyl)-(3-methoxyphenyl)-methanone 2b 
(262 mg, 0.90 mmol, 1 equiv) with 2-chloro-4-methoxyphenylboronic acid (201 mg, 1.08 
mmol, 1.2 equiv) according to the method D. The product was recrystallised in ethanol to 
afford 193 mg (61%) of the analytically pure compound as white crystals. C21H17ClO3; MW 
353; mp: 119-121°C; 1H NMR (CDCl3): δ 7.88-7.85 (m, 2H), 7.56-7.53 (m, 2H), 7.41-7.38 
(m, 3H), 7.29 (d, J = 8.5 Hz, 1H), 7.17-7.13 (m, 1H), 7.05 (d, J = 2.5 Hz, 1H), 6.91 (dd, J = 
2.8 Hz, J = 8.8 Hz, 1H), 3.89 (s, 3H), 3.86 (s, 3H); 13C NMR (CDCl3): δ 196.1, 159.8, 143.4, 
139.0, 136.3, 133.9, 131.9, 131.8, 129.9, 129.5, 129.2, 122.8, 118.8, 115.4, 114.3, 113.3, 55.6, 
55.5; IR: 2954, 1647, 1597, 1034 cm-1; GC/MS m/z: 352 (M)+. 
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(2´-Chloro-4´-hydroxybiphenyl-4-yl)-(3-hydroxyphenyl)-methanone (4). The title 
compound was prepared by reaction of (2´-chloro-4´-methoxybiphenyl-4-yl)-(3-
methoxyphenyl)-methanone 4a (100 mg, 0.28 mmol, 1 equiv) with pyridinium hydrochloride 
(28 mmol, 100 equiv) according to method G. The product was purified by recrystallisation in 
hexane to afford 67 mg (74%) of the analytically pure compound as a brown solid. 
C19H13ClO3; MW 325; mp: 212-214°C; 1H NMR (acetone-d6): δ 8.67 (s, br, 1H), 7.87-7.83 
(m, 2H), 7.61-7.58 (m, 2H), 7.42-7.37 (m, 1H), 7.33 (d, J = 8.2 Hz, 1H), 7.31-7.29 (m, 1H), 
7.27 (ddd, J = 0.9 Hz, J = 1.6 Hz, J = 7.6 Hz, 1H), 7.14 (ddd, J = 0.9 Hz, J = 2.5 Hz, J = 8.2 
Hz, 1H), 7.05 (d, J = 2.5 Hz, 1H), 6.95 (dd, J = 2.5 Hz, J = 8.5 Hz, 1H); 13C NMR (acetone-
d6): δ 159.0, 158.3, 144.3, 140.0, 137.3, 133.1, 131.5, 130.4, 122.0, 120.4, 117.6, 117.0, 
115.7; IR: 3292, 1645, 1589, 1451 cm-1; LC/MS m/z: 325 (M+H)+. 
 
(3´-Chloro-4´-hydroxybiphenyl-4-yl)-(3-methoxyphenyl)-methanone (5a). The title 
compound was prepared by reaction of (4-bromophenyl)-(3-methoxyphenyl)-methanone 2b 
(200 mg, 0.69 mmol, 1 equiv) with 3-chloro-4-hydroxyphenylboronic acid (143 mg, 0.83 
mmol, 1.2 equiv) according to method D. The product was purified by column 
chromatography (hexane/ethyl acetate 7:3) to afford 120 mg (51%) of the analytically pure 
compound. C20H15ClO3; MW 338; 1H NMR (acetone-d6): δ 9.03 (s, br, 1H), 7.86-7.83 (m, 
2H), 7.80-7.77 (m, 2H), 7.74 (d, J = 2.2 Hz, 1H), 7.57 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H), 7.47-
7.41 (m, 1H), 7.33-7.30 (m, 2H), 7.20 (ddd, J = 0.9 Hz, J = 2.7 Hz, J = 8.2 Hz, 1H), 7.14-7.11 
(m, 1H), 3.85 (s, 3H); 13C NMR (acetone-d6): δ 194.9, 159.8, 153.3, 143.4, 139.2, 136.0, 
132.4, 130.5, 130.0, 129.4, 128.5, 126.9, 126.8, 126.2, 122.1, 121.0, 118.2, 117.3, 114.3, 54.9. 
 
(3´-Chloro-4´-hydroxybiphenyl-4-yl)-(3-hydroxyphenyl)-methanone (5). The title 
compound was prepared by reaction of (3´-chloro-4´-hydroxybiphenyl-4-yl)-(3-
methoxyphenyl)-methanone 5a (60 mg, 0.18 mmol, 1 equiv) with boron trifluoride 
dimethylsulfide complex (6.2 mmol, 35 equiv) according to method F. The product was 
purified by column chromatography (hexane/ethyl acetate 1:1). Yield: 40 mg (69%). 
C19H13ClO3; MW 324; 1H NMR (acetone-d6): δ 9.00 (s, br, 1H), 8.67 (s, br, 1H), 7.84-7.81 
(m, 2H), 7.79-7.75 (m, 2H), 7.73 (d, J = 2.2 Hz, 1H), 7.56 (dd, J = 2.2 Hz, J = 8.4 Hz, 1H), 
7.35 (t, J = 7.9 Hz, 1H), 7.25-7.21 (m, 2H), 7.12 (d, J = 8.5 Hz, 1H), 7.09 (ddd, J = 1.1 Hz, J 
= 2.5 Hz, J = 8.2 Hz, 1H); 13C NMR (acetone-d6): δ 195.9, 158.3, 154.2, 144.2, 140.2, 137.1, 
133.3, 131.4, 130.4, 129.3, 127.7, 127.1, 121.9, 121.8, 120.3, 118.2, 117.0; GC/MS m/z: 324-
326 (M)+. 
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(4-Bromophenyl)-(4-fluoro-3-methoxyphenyl)-methanol (6c). To a solution of 5-bromo-2-
fluoroanisole (547 mg, 2.67 mmol, 1 equiv) in anhydrous THF was added granules of 
magnesium (68 mg, 2.80 mmol, 1.05 equiv) under nitrogen. The mixture was heated to 60°C 
for 2h. After cooling to room temperature, 4-bromobenzaldehyde (592 mg, 3.20 mmol, 1.2 
equiv) was added and the reaction mixture was stirred at 80°C overnight. The reaction was 
cooled to room temperature, quenched with brine and the aqueous layer was extracted with 
ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and 
concentrated to dryness under vacuum. The product was used in the next step without further 
purification. C14H12BrFO2; MW 311. 
 
(4-Bromophenyl)-(4-fluoro-3-methoxyphenyl)-methanone (6b). The title compound was 
prepared by reaction of (4-bromophenyl)-(4-fluoro-3-methoxyphenyl)-methanol 6c (468 mg, 
1.50 mmol, 1 equiv) with 2-iodoxybenzoic acid (3.00 mmol, 2 equiv) according to method B. 
The product was purified by column chromatography (hexane/ethyl acetate 7:3) to afford 280 
mg (60%) of the analytically pure compound. C14H10BrFO2; MW 309; 1H NMR (acetone-d6): 
δ 7.77-7.72 (m, 4H), 7.56 (dd, J = 1.9 Hz, J = 8.5 Hz, 1H), 7.39-7.36 (m, 1H), 7.33-7.28 (m, 
1H), 3.96 (s, 3H); 13C NMR (acetone-d6): δ 194.3, 137.5, 134.8, 132.5, 132.4, 127.6, 124.6, 
118.6, 117.8, 116.6, 116.5, 115.5, 56.7; GC/MS m/z: 308-310 (M)+. 
 
(4-Fluoro-3-methoxyphenyl)-(4´-methoxy-3´-methylbiphenyl-4-yl)-methanone (6a). The 
title compound was prepared by reaction of (4-bromophenyl)-(4-fluoro-3-methoxyphenyl)-
methanone 6b (142 mg, 0.46 mmol, 1 equiv) with 4-methoxy-3-methylphenylboronic acid (92 
mg, 0.55 mmol, 1.2 equiv) according to method D. The product was recrystallised in ethanol 
to afford 98 mg (61%) of the analytically pure compound as a white solid. C22H19FO3; MW 
350; mp: 145-146°C; 1H NMR (acetone-d6): δ 7.87-7.84 (m, 2H), 7.81-7.78 (m, 2H), 7.60-
7.56 (m, 3H), 7.40 (ddd, J = 1.9 Hz, J = 4.4 Hz, J = 8.2 Hz, 1H), 7.30 (dd, J = 8.2 Hz, J = 
11.0 Hz, 1H), 7.05 (d, J = 8.2 Hz, 1H), 3.97 (s, 3H), 3.90 (s, 3H), 2.27 (s, 3H); 13C NMR 
(acetone-d6): δ 194.7, 159.2, 148.8, 148.7, 145.7, 136.3, 138.6, 135.6, 132.3, 131.3, 130.1, 
127.7, 127.0, 126.6, 124.4, 124.3, 116.5, 115.5, 111.4, 56.7, 55.8, 16.4; IR: 2922, 1645, 1601, 
1027 cm-1; GC/MS m/z: 350 (M)+. 
 
(4-Fluoro-3-hydroxyphenyl)-(4´-hydroxy-3´-methylbiphenyl-4-yl)-methanone (6). The 
title compound was prepared by reaction of (4-fluoro-3-methoxyphenyl)-(4´-methoxy-3´-
methylbiphenyl-4-yl)-methanone 6a (98 mg, 0.30 mmol, 1 equiv) with pyridinium 
hydrochloride (30 mmol, 100 equiv) according to method G. The product was recrystallised in 
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hexane to afford 40 mg (41%) of the analytically pure compound as a green powder. 
C20H15FO3; MW 322; mp: 203-205°C; 1H NMR (acetone-d6): δ 9.04 (s, br, 1H), 8.47 (s, br, 
1H), 7.84-7.76 (m, 4H), 7.54 (d, J = 1.8 Hz, 1H),  7.48 (dd, J = 2.0 Hz, J = 8.6 Hz, 1H), 7.46 
(dd, J = 2.2 Hz, J = 8.2 Hz, 1H), 7.34-7.28 (m, 2H), 6.96 (d, J = 8.3 Hz, 1H), 2.29 (s, 3H); 13C 
NMR (acetone-d6): δ 194.7, 156.9, 156.0, 154.0, 145.9, 145.7, 136.2, 135.7, 131.7, 131.2, 
130.5, 126.8, 126.5, 125.9, 123.3, 123.2, 120.1, 116.8, 116.1, 16.3; IR: 3307, 1642, 1592, 
1429 cm-1; LC/MS m/z: 323 (M+H)+. 
 
(3´-Chloro-4´-hydroxybiphenyl-4-yl)-(4-fluoro-3-methoxyphenyl)-methanone (7a). The 
title compound was prepared by reaction of (4-bromophenyl)-(4-fluoro-3-methoxyphenyl)-
methanone 6b (127 mg, 0.41 mmol, 1 equiv) with 3-chloro-4-hydroxyphenylboronic acid (85 
mg, 0.49 mmol, 1.2 equiv) according to method D. The product was used in the next step 
without further purification. C20H14ClFO3; MW 357. 
 
(3´-Chloro-4´-hydroxybiphenyl-4-yl)-(4-fluoro-3-hydroxyphenyl)-methanone (7). The 
title compound was prepared by reaction of (3´-chloro-4´-hydroxybiphenyl-4-yl)-(4-fluoro-3-
methoxyphenyl)-methanone 7a (126 mg, 0.35 mmol, 1 equiv) with pyridinium hydrochloride 
(35 mmol, 100 equiv) according to method G. The product was purified by column 
chromatography (hexane/ethyl acetate 7:3) then by preparative HPLC (isopropanol/water) to 
afford 38 mg (32%) of the analytically pure compound as a yellow solid. C19H12ClFO3; MW 
343; 1H NMR (acetone-d6): δ 9.04 (s, br, 1H), 9.02 (s, br, 1H), 7.86-7.83 (m, 2H), 7.82-7.80 
(m, 2H), 7.76 (d, J = 2.2 Hz, 1H), 7.60 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H), 7.48 (dd, J = 1.9 Hz, 
J = 8.5 Hz, 1H), 7.34-7.31 (m, 1H), 7.31-7.26 (m, 1H), 7.16 (d, J = 8.5 Hz, 1H); 13C NMR 
(acetone-d6): δ 193.8, 153.3, 143.3, 136.1, 134.6, 132.4, 130.4, 128.4, 127.5, 126.2, 122.4, 
121.0, 119.2, 118.5, 118.4, 117.3, 117.0, 116.0, 115.8; IR: 3320, 1650, 1593, 1058 cm-1; 
LC/MS m/z: 344-346 (M+H)+. 
 
(4-Bromophenyl)-(3-fluoro-5-methoxyphenyl)-methanol (8c). To a solution of 3-bromo-5-
fluoroanisole (500 mg, 2.44 mmol, 1 equiv) in anhydrous THF was added granules of 
magnesium (64 mg, 2.56 mmol, 1.05 equiv) under nitrogen. The mixture was heated to 60°C 
for 2h. After reaching room temperature, 4-bromobenzaldehyde (542 mg, 2.93 mmol, 1.2 
equiv) was added and the reaction mixture was stirred at 80°C overnight. The reaction was 
cooled to room temperature, quenched with brine and the aqueous layer was extracted with 
ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and 
RESULTS   
 - 111 - 
concentrated to dryness under vacuum. The product was used in the next step without further 
purification. C14H12BrFO2; MW 311. 
 
(4-Bromophenyl)-(3-fluoro-5-methoxyphenyl)-methanone (8b). The title compound was 
prepared by reaction of (4-bromophenyl)-(3-fluoro-5-methoxyphenyl)-methanol 8c (306 mg, 
0.98 mmol, 1 equiv) with 2-iodoxybenzoic acid (553 mg, 1.96 mmol, 2 equiv) according to 
method B. The product was used in the next step without further purification. C14H10BrFO2; 
MW 309. 
 
(3-Fluoro-5-methoxyphenyl)-(4´-methoxy-3´-methylbiphenyl-4-yl)-methanone (8a). The 
title compound was prepared by reaction of (4-bromophenyl)-(3-fluoro-5-methoxyphenyl)-
methanone 8b (175 mg, 0.57 mmol, 1 equiv) with 4-methoxy-3-methylphenylboronic acid 
(113 mg, 0.68 mmol, 1.2 equiv) according to method D. The product was used in the next step 
without further purification. C22H19FO3; MW 350. 
 
(3-Fluoro-5-hydroxyphenyl)-(4´-hydroxy-3´-methylbiphenyl-4-yl)-methanone (8). The 
title compound was prepared by reaction of (3-fluoro-5-methoxyphenyl)-(4´-methoxy-3´-
methylbiphenyl-4-yl)-methanone 8a (100 mg, 0.29 mmol, 1 equiv) with pyridinium 
hydrochloride (29.0 mmol, 100 equiv) according to method G. The product was purified by 
preparative HPLC (gradient water/isopropanol) to afford 5 mg (5%) of the analytically pure 
compound. C20H15FO3; MW 322; 1H NMR (acetone-d6): δ 9.17 (s, br, 1H), 8.48 (s, br, 1H), 
7.87-7.84 (m, 2H), 7.80-7.77 (m, 2H), 7.56-7.54 (m, 1H), 7.45 (ddd, J = 0.6 Hz, J = 2.5 Hz, J 
= 8.2 Hz, 1H), 7.10-7.08 (m, 1H), 6.99 (ddd, J = 1.3 Hz, J = 2.5 Hz, J = 8.8 Hz, 1H), 6.96 (d, 
J = 8.5 Hz, 1H), 6.87 (dt, J = 2.2 Hz, J = 10.4 Hz, 1H), 2.29 (s, 3H); 13C NMR (acetone-d6): δ 
195.7, 160.9, 158.0, 147.3, 142.7, 142.6, 136.7, 132.6, 132.3, 131.5, 127.9, 127.5, 126.9, 
117.1, 114.6, 109.1, 108.2, 108.0, 17.3; LC/MS m/z: 323 (M+H)+. 
 
(4-Bromophenyl)-(3,4-difluorophenyl)-methanol (9c). To a solution of 1-bromo-3,4-
difluorobenzene (1.00 g, 0.59 mL, 5.18 mmol, 1 equiv) in anhydrous THF was added granules 
of magnesium (132 mg, 5.44 mmol, 1.05 equiv) under nitrogen. The mixture was heated to 
60°C for 2h. After cooling to room temperature, 4-bromobenzaldehyde (592 mg, 3.20 mmol, 
1.2 equiv) was added and the reaction mixture was stirred at 80°C overnight. The reaction 
was cooled to room temperature, quenched with brine and the aqueous layer was extracted 
with ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and 
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concentrated to dryness under vacuum. The product was used in the next step without further 
purification. C13H9BrF2O; MW 299. 
 
(4-Bromophenyl)-(3,4-difluorophenyl)-methanone (9b). The title compound was prepared 
by reaction of (4-bromophenyl)-(3,4-difluorophenyl)-methanol 9c (589 mg, 1.97 mmol, 1 
equiv) with 2-iodoxybenzoic acid (1.38  g, 4.93 mmol, 2.5 equiv) according to method B. The 
product was purified by recrystallisation in ethanol to afford 140 mg (24%) of the analytically 
pure compound as a white powder. C13H7BrF2O; MW 297; mp: 74-77°C; 1H NMR (acetone-
d6): δ 7.79-7.74 (m, 5H), 7.70-7.66 (m, 1H), 7.56-7.50 (m, 1H); 13C NMR (acetone-d6): δ 
193.3, 151.9, 151.8, 136.9, 135.5, 132.7, 132.4, 128.3, 128.2, 128.0, 119.8, 119.6, 118.6; IR: 
1650, 1604, 1280 cm-1; GC/MS m/z: 296-298 (M)+. 
 
(3,4-Difluorophenyl)-(4´-methoxy-3´-methylbiphenyl-4-yl)-methanone (9a). The title 
compound was prepared by reaction of (4-bromophenyl)-(3,4-difluorophenyl)-methanone 9b 
(168 mg, 0.52 mmol, 1 equiv) with 4-methoxy-3-methylphenylboronic acid (103 mg, 0.62 
mmol, 1.2 equiv) according to method D. The compound was recrystallised in ethanol to 
obtain 157 mg of the analytically pure product as a white powder. C21H16F2O2; MW 338; mp: 
123-125°C; 1H NMR (acetone-d6): δ 7.88-7.84 (m, 2H), 7.82-7.79 (m, 2H), 7.75 (ddd, J = 2.2 
Hz, J = 7.9 Hz, J = 11.0 Hz, 1H), 7.71-7.67 (m, 1H), 7.61-7.57 (m, 2H), 7.56-7.50 (m, 1H), 
7.06 (d, J = 8.2 Hz, 1H), 3.90 (s, 3H), 2.27 (s, 3H); 13C NMR (acetone-d6): δ 193.6, 159.3, 
146.1, 135.7, 131.4, 130.1, 128.1, 128.0, 127.8, 127.2, 126.7, 119.7, 119.5, 111.4, 55.9, 16.4; 
IR: 2930, 1645, 1596, 1141 cm-1; GC/MS m/z: 338 (M)+. 
 
(3,4-Difluorophenyl)-(4-hydroxy-3´-methylbiphenyl-4-yl)-methanone (9). The title 
compound was prepared by reaction of (3,4-difluorophenyl)-(4´-methoxy-3-methylbiphenyl-
4-yl)-methanone 9a (100 mg, 0.30 mmol, 1 equiv) with pyridinium hydrochloride (30 mmol, 
100 equiv) according to method G. The product was purified by recrystallisation in hexane to 
afford 35 mg (36%) of the analytically pure compound as a yellow solid. C20H14F2O2; MW 
324; mp: 174-176°C; 1H NMR (acetone-d6): δ 8.54 (s, br, 1H), 7.86-7.83 (m, 2H), 7.80-7.77 
(m, 2H), 7.77-7.74 (m, 1H), 7.71-7.67 (m, 1H), 7.56-7.50 (m, 2H), 7.45 (ddd, J = 0.6 Hz, J = 
2.5 Hz, J = 8.2 Hz, 1H), 6.96 (d, J = 8.2 Hz, 1H), 2.29 (s, 3H); 13C NMR (acetone-d6): δ 
193.7, 157.1, 152.7, 152.6, 151.8, 149.9, 146.4, 135.5, 131.4, 130.5, 127.0, 126.5, 119.7, 
119.5, 118.4, 118.3, 116.2, 16.3; IR: 3427, 1645, 1594, 1287 cm-1; GC/MS m/z: 324 (M)+. 
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(6-Bromopyridin-3-yl)-(3-methoxyphenyl)-methanol (10c). The title compound was 
prepared by reaction of 6-bromopyridin-3-yl carboxaldehyde (500 mg, 2.69 mmol, 1 equiv) 
with 3-methoxyphenylmagnesiumbromide (1M in THF) (1.35 g, 5.91 mmol, 2.2 equiv) 
according to method A. The product was purified by column chromatography (hexane/ethyl 
acetate 7:3) to afford 700 mg (89%) of the analytically pure compound as a colorless oil. 
C13H12BrNO2; MW 294; 1H NMR (acetone-d6): δ 8.45-8.43 (m, 1H), 7.71 (ddd, J = 0.6 Hz, J 
= 2.5 Hz, J = 8.2 Hz, 1H), 7.52 (d, J = 8.8 Hz, 1H), 7.25 (t, J = 8.2 Hz, 1H), 7.06-7.04 (m, 
1H), 7.00-6.97 (m, 1H), 6.82 (ddd, J = 0.9 Hz, J = 2.8 Hz, J = 8.2 Hz, 1H), 5.89 (d, J = 4.1 
Hz, 1H), 5.21 (d, J = 4.1 Hz, 1H), 3.77 (s, 3H); 13C NMR (acetone-d6): δ 161.8, 150.4, 147.6, 
142.4, 142.0, 139.0, 131.3, 129.5, 120.3, 114.6, 113.8, 74.3, 56.5. 
 
(6-Bromopyridin-3-yl)-(3-methoxyphenyl)-methanone (10b). The title compound was 
prepared by reaction of (6-bromopyridin-3-yl)-(3-methoxyphenyl)-methanol 10c (700 mg, 
2.38 mmol, 1 equiv) with 2-iodoxybenzoic acid (1.34 g, 4.76 mmol, 2 equiv) according to 
method B. The product was purified by column chromatography (hexane/ethyl acetate 9:1) to 
give 520 mg (75%) of the analytically pure compound as a colorless oil. C13H10BrNO2; MW 
292; 1H NMR (acetone-d6): δ 8.70 (d, J = 1.8 Hz, 1H), 8.07 (dd, J = 2.4 Hz, J = 8.2 Hz, 1H), 
7.80 (dd, J = 0.6 Hz, J = 8.2 Hz, 1H), 7.51-7.47 (m, 1H), 7.38-7.35 (m, 2H), 7.26 (ddd, J = 
0.9 Hz, J = 2.7 Hz, J = 8.2 Hz, 1H), 3.87 (s, 3H); 13C NMR (acetone-d6): δ 161.8, 152.9, 
147.2, 141.5, 139.8, 134.6, 131.6, 129.9, 124.2, 121.2, 116.0, 56.9. 
 
[6-(4-Methoxy-3-methylphenyl)-pyridin-3-yl]-(3-methoxyphenyl)-methanone (10a). The 
title compound was prepared by reaction of (6-bromopyridin-3-yl)-(3-methoxyphenyl)-
methanone 10b (520 mg, 1.80 mmol, 1 equiv) with 4-methoxy-3-methylphenylboronic acid 
(359 mg, 2.16 mmol, 1.2 equiv) according to method D. The product was purified by column 
chromatography (hexane/ethyl acetate 9:1) to afford 536 mg (89%) of the analytically pure 
compound as a yellow oil. C21H19NO3; MW 333; 1H NMR (acetone-d6): δ 8.74 (dd, J = 0.9 
Hz, J = 2.2 Hz, 1H), 7.91 (dd, J = 2.2 Hz, J = 8.2 Hz, 1H), 7.83-7.80 (m, 2H), 7.74 (dd, J = 
0.6 Hz, J = 8.5 Hz, 1H), 7.28-7.24 (m, 1H), 7.17-7.14 (m, 2H), 7.02 (ddd, J = 1.3 Hz, J = 2.5 
Hz, J = 8.5 Hz, 1H), 6.81 (d, J = 9.1 Hz, 1H), 3.68 (s, 3H), 3.66 (s, 3H), 2.05 (s, 3H); 13C 
NMR (acetone-d6): δ 195.5, 161.7, 161.5, 152.6, 140.6, 139.7, 131.9, 131.5, 131.3, 128.4, 
128.2, 124.0, 120.6, 120.3, 116.0, 112.0, 56.9, 56.8, 17.5. 
 
[6-(4-Hydroxy-3-methylphenyl)-pyridin-3-yl]-(3-hydroxyphenyl)-methanone (10). The 
title compound was prepared by reaction of [6-(4-methoxy-3-methylphenyl)-pyridin-3-yl]-(3-
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methoxyphenyl)-methanone 10a (466 mg, 1.40 mmol, 1 equiv) with boron tribromide (14.0 
mmol, 10 equiv) according to method E. The product was purified by column 
chromatography (hexane/ethyl acetate 8:2) to give 321 mg (75%) of the analytically pure 
compound as a yellow powder. C19H15NO3; MW 305; 1H NMR (acetone-d6): δ 8.94 (dd, J = 
0.6 Hz, J = 2.1 Hz, 1H), 8.73 (s, br, 2H), 8.14 (dd, J = 2.1 Hz, J = 8.2 Hz, 1H), 8.04 (dd, J = 
0.6 Hz, J = 2.1 Hz, 1H), 7.99 (dd, J = 0.6 Hz, J = 8.2 Hz, 1H), 7.94 (dd, J = 2.1 Hz, J = 8.5 
Hz, 1H), 7.44-7.39 (m, 1H), 7.32-7.29 (m, 2H), 7.17-7.14 (m, 1H), 6.97 (d, J = 8.2 Hz, 1H), 
2.30 (s, 3H); 13C NMR (acetone-d6): δ 194.7, 160.7, 158.4, 151.5, 139.7, 138.7, 131.4, 130.9, 
130.6, 130.4, 127.1, 125.6, 122.0, 120.7, 119.2, 116.9, 115.9, 16.3; IR: 3431, 1648, 1582, 
1473, 1268 cm-1; LC/MS m/z: 306 (M+H)+. 
 
(5-Bromopyridin-2-yl)-(3-methoxyphenyl)-methanol (11c). The title compound was 
prepared by reaction of 5-bromopyridin-2-yl carboxaldehyde (500 mg, 2.69 mmol, 1 equiv) 
with 3-methoxyphenylmagnesiumbromide (1M in THF) (1.35 g, 5.9 mL, 5.91 mmol, 2.2 
equiv) according to method A. The product was purified by column chromatography 
(hexane/ethyl acetate 8:2) to give 490 mg (62%) of the analytically pure compound as a red 
oil. C13H12BrNO2; MW 294; 1H NMR (acetone-d6): δ 8.57 (dd, J = 0.6 Hz, J = 2.5 Hz, 1H), 
7.94 (dd, J = 2.5 Hz, J = 8.5 Hz, 1H), 7.56-7.53 (m, 1H), 7.21 (t, J = 7.9 Hz, 1H), 7.07-7.05 
(m, 1H), 7.04-7.00 (m, 1H), 6.79 (ddd, J = 0.9 Hz, J = 2.5 Hz, J = 8.2 Hz, 1H), 5.80 (d, J = 
4.4 Hz, 1H), 5.25 (d, J = 4.4 Hz, 1H), 3.76 (s, 3H); 13C NMR (acetone-d6): δ 192.6, 164.4, 
161.6, 151.0, 147.2, 141.2, 131.0, 124.0, 120.6, 114.4, 114.0, 77.3, 56.4. 
 
(5-Bromopyridin-2-yl)-(3-methoxyphenyl)-methanone (11b). The title compound was 
prepared by reaction of (5-bromopyridin-2-yl)-(3-methoxyphenyl)-methanol 11c (490 mg, 
1.67 mmol, 1 equiv) with 2-iodoxybenzoic acid (940 mg, 3.33 mmol, 2 equiv) according to 
method B. The product was purified by column chromatography (hexane/ethyl acetate 9:1) to 
afford 365 mg (75%) of the analytically pure compound as a colorless oil. C13H10BrNO2; MW 
292; 1H NMR (acetone-d6): δ 8.80 (dd, J = 0.6 Hz, J = 2.2 Hz, 1H), 8.25 (dd, J = 2.2 Hz, J = 
8.2 Hz, 1H), 7.97 (dd, J = 0.6 Hz, J = 8.2 Hz, 1H), 7.65-7.61 (m, 2H), 7.45-7.41 (m, 1H), 7.21 
(ddd, J = 0.9 Hz, J = 2.5 Hz, J = 8.2 Hz, 1H), 3.86 (s, 3H); 13C NMR (acetone-d6): δ 193.7, 
161.3, 155.6, 151.3, 141.9, 139.3, 131.0, 127.7, 125.7, 125.3, 120.7, 117.3, 56.8. 
 
[5-(4-Methoxy-3-methylphenyl)-pyridin-2-yl]-(3-methoxyphenyl)-methanone (11a). The 
title compound was prepared by reaction of (5-bromopyridin-2-yl)-(3-methoxyphenyl)-
methanone 11b (365 mg, 1.25 mmol, 1 equiv) with 4-methoxy-3-methylphenylboronic acid 
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(249 mg, 1.50 mmol, 1.2 equiv) according to method D. The product was purified by column 
chromatography (hexane/ethyl acetate 9:1) to give 362 mg (87%) of the analytically pure 
compound as yellow solid. C21H19NO3; MW 333; 1H NMR (acetone-d6): δ 8.95 (dd, J = 0.6 
Hz, J = 2.2 Hz, 1H), 8.18 (dd, J = 2.5 Hz, J = 8.2 Hz, 1H), 8.06 (dd, J = 0.6 Hz, J = 8.2 Hz, 
1H), 7.75-7.71 (m, 2H), 7.62-7.59 (m, 2H), 7.45-7.41 (m, 1H), 7.20 (ddd, J = 0.9 Hz, J = 2.8 
Hz, J = 8.2 Hz, 1H), 7.06 (dd, J = 2.2 Hz, J = 7.3 Hz, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 2.27 (s, 
3H); 13C NMR (acetone-d6): δ 194.1, 161.3, 160.6, 154.9, 148.0, 140.3, 140.0, 136.1, 131.1, 
130.8, 130.3, 129.0, 127.9, 126.2, 125.4, 120.2, 117.6, 112.6, 56.8, 56.7, 17.4. 
 
[5-(4-Hydroxy-3-methylphenyl)-pyridin-2-yl]-(3-hydroxyphenyl)-methanone (11). The 
title compound was prepared by reaction of [5-(4-methoxy-3-methylphenyl)-pyridin-2-yl]-(3-
methoxyphenyl)-methanone 11a (362 mg, 1.09 mmol, 1 equiv) with boron tribromide (10.9 
mmol, 10 equiv) according to method E. The product was purified by column 
chromatography (hexane/ethyl acetate 8:3) then by preparative TLC (hexane/ethyl acetate 
7:3) to give 127 mg (45%) of the analytically pure compound as yellow powder. C19H15NO3; 
MW 305; mp: 178-180°C; 1H NMR (acetone-d6): δ 8.93 (d, J = 1.8 Hz, 1H), 8.62 (s, br, 1H), 
8.61 (s, br, 1H), 8.19 (dd, J = 2.1 Hz, J = 8.2 Hz, 1H), 8.04 (d, J = 8.2 Hz, 1H), 7.63-7.58 (m, 
3H), 7.50 (dd, J = 1.8 Hz, J = 8.2 Hz, 1H), 7.37-7.32 (m, 1H), 7.13-7.09 (m, 1H), 7.00 (d, J = 
8.2 Hz, 1H), 2.31 (s, 3H); 13C NMR (acetone-d6): δ 194.4, 158.9, 158.4, 154.9, 147.8, 140.6, 
140.1, 135.9, 131.6, 130.9, 129.7, 127.7, 127.3, 126.2, 124.3, 121.5, 119.2, 117.4, 17.3; IR: 
3350, 1644, 1580, 1514, 1240 cm-1; LC/MS m/z: 306 (M+H)+. 
 
(5-Bromopyridin-2-yl)-(4-fluoro-3-methoxyphenyl)-methanol (12c). To a solution of 5-
bromo-2-fluoroanisole (1.00 g, 4.88 mmol, 1 equiv) in anhydrous THF was added granules of 
magnesium (125 mg, 5.12 mmol, 1.05 equiv) under nitrogen. The mixture was heated to 60°C 
for 2h. After cooling to room temperature, 5-bromo-2-formylpyridine (1.09 g, 5.86 mmol, 1.2 
equiv) was added and the reaction mixture was stirred at 80°C overnight. The reaction was 
cooled to room temperature, quenched with brine and the aqueous layer was extracted with 
ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and 
concentrated to dryness under vacuum. The product was used in the next step without further 
purification. C13H11BrFNO2; MW 312. 
 
(5-Bromopyridin-2-yl)-(4-fluoro-3-methoxyphenyl)-methanone (12b). The title compound 
was prepared by reaction of (5-bromopyridin-2-yl)-(4-fluoro-3-methoxyphenyl)-methanol 12c 
(463 mg, 1.48 mmol, 1 equiv) with 2-iodoxybenzoic acid (2.96 mmol, 2 equiv) according to 
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method B. The product was purified by column chromatography (hexane) to afford 354 mg 
(77%) of the analytically pure compound as a yellow oil. C13H9BrFNO2; MW 310; 1H NMR 
(acetone-d6): δ 6.28 (dd, J = 2.2 Hz, J = 8.2 Hz, 1H), 8.06-8.03 (m, 2H), 7.99 (dd, J = 0.9 Hz, 
J = 8.5 Hz, 1H), 7.89 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H), 7.77 (ddd, J = 1.9 Hz, J = 4.4 Hz, J = 
8.5 Hz, 1H), 3.96 (s, 3H); 13C NMR (acetone-d6): δ 191.4, 167.6, 154.5, 150.3, 141.1, 133.8, 
130.4, 129.3, 126.8, 126.2, 116.6, 116.2, 56.7; IR: 2835, 1678, 1601, 1290 cm-1; LC/MS m/z: 
310-312 (M+H)+. 
 
(4-Fluoro-3-methoxyphenyl)-[5-(4-methoxy-3-methylphenyl)-pyridin-2-yl]-methanone 
(12a). The title compound was prepared by reaction of (5-bromopyridin-2-yl)-(4-fluoro-3-
methoxyphenyl)-methanone 12b (300 mg, 0.97 mmol, 1 equiv) with 4-methoxy-3-
methylphenylboronic acid (193 mg, 1.16 mmol, 1.2 equiv) according to method D. The 
product was recrystallised in acetonitrile to afford 279 mg (82%) of the analytically pure 
compound as a yellow powder. C21H18FNO3; MW 351; mp: 141-143°C; 1H NMR (CDCl3): δ 
8.89 (dd, J = 0.6 Hz, J = 2.2 Hz, 1H), 8.09 (dd, J = 0.6 Hz, J = 8.2 Hz, 1H), 8.02 (dd, J = 2.5 
Hz, J = 8.2 Hz, 1H), 7.82 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H), 7.77 (ddd, J = 2.2 Hz, J = 4.4 Hz, J 
= 8.5 Hz, 1H), 7.46 (dd, J = 2.5 Hz, J = 8.2 Hz, 1H), 7.44-7.42 (m, 1H), 7.15 (dd, J = 8.5 Hz, 
J = 10.7 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 3.95 (s, 3H), 3.88 (s, 3H), 2.30 (s, 3H); 13C NMR 
(CDCl3): δ 192.0, 158.9, 156.8, 153.0, 147.9, 147.8, 146.7, 139.2, 134.7, 133.3, 129.7, 128.8, 
126.1, 125.8, 125.2, 115.9, 115.8, 110.8, 56.6, 55.7, 16.6; GC/MS m/z: 351 (M)+. 
 
(4-Fluoro-3-hydroxyphenyl)-[5-(4-hydroxy-3-methylphenyl)-pyridin-2-yl]-methanone 
(12). The title compound was prepared by reaction of (4-fluoro-3-methoxyphenyl)-[5-(4-
methoxy-3-methylphenyl)-pyridin-2-yl]-methanone 12a (70 mg, 0.20 mmol, 1 equiv) with 
pyridinium hydrochloride (20.0 mmol, 100 equiv) according to method G. The product was 
purified by preparative HPLC (isopropanol/water) to give 21 mg (33%) of the analytically 
pure compound as a yellow powder. C19H14FNO3; MW 323; mp: 221-223°C; 1H NMR 
(acetone-d6): δ 8.94 (dd, J = 0.6 Hz, J = 2.2 Hz, 1H), 8.64 (s, br, 1H), 8.20 (dd, J = 2.2 Hz, J = 
8.2 Hz, 1H), 8.05 (dd, J = 0.9 Hz, J = 8.2 Hz, 1H), 7.87 (dd, J = 2.2 Hz, J = 8.8 Hz, 1H), 7.74 
(ddd, J = 2.2 Hz, J = 4.4 Hz, J = 8.5 Hz, 1H), 7.60 (dd, J = 0.6 Hz, J = 2.2 Hz, 1H), 7.50 (ddd, 
J = 0.6 Hz, J = 2.5 Hz, J = 8.2 Hz, 1H), 7.24 (dd, J = 8.5 Hz, J = 11.0 Hz, 1H), 7.00 (d, J = 
8.2 Hz, 1H), 2.30 (s, 3H); 13C NMR (acetone-d6): δ 192.7, 158.3, 157.2, 154.6, 147.6, 140.5, 
135.9, 131.5, 129.5, 127.5, 127.1, 126.1, 125.7, 125.6, 122.3, 117.3, 117.2, 117.1, 17.1; IR: 
3179, 2971, 1607, 1511, 1124 cm-1; LC/MS m/z: 324 (M+H)+. 
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(4-Fluoro-3-methoxyphenyl)-[5-(3-chloro-4-hydroxyphenyl)-pyridin-2-yl]-methanone 
(13a). The title compound was prepared by reaction of (5-bromopyridin-2-yl)-(4-fluoro-3-
methoxyphenyl)-methanone 12b (150 mg, 0.48 mmol, 1 equiv) with 3-chloro-4-
hydroxyphenylboronic acid (100 mg, 0.58 mmol, 1.2 equiv) according to method D. The 
product was recrystallised in ethyl acetate to afford 72 mg (42%) of the analytically pure 
product as a yellow solid. C19H13ClFNO3; MW 357; mp: 195-197°C; 1H NMR (acetone-d6): δ 
9.20 (s, br, 1H), 9.00 (dd, J = 0.6 Hz, J = 2.2 Hz, 1H), 8.28 (dd, J = 2.5 Hz, J = 8.2 Hz, 1H), 
8.11 (dd, J = 0.6 Hz, J = 8.2 Hz, 1H), 7.97 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H), 7.88-7.84 (m, 
2H), 7.67 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H), 7.28 (dd, J = 8.2 Hz, J = 11.4 Hz, 1H), 7.20 (d, J = 
8.5 Hz, 1H), 3.97 (s, 3H); 13C NMR (acetone-d6): δ 191.6, 154.8, 154.3, 147.0, 138.2, 135.5, 
130.2, 129.6, 128.0, 126.2, 126.1, 125.4, 122.2, 118.4, 116.8, 116.3, 116.1, 56.6; GC/MS m/z: 
356-358 (M)+. 
 
(4-Fluoro-3-hydroxyphenyl)-[5-(3-chloro-4-hydroxyphenyl)-pyridin-2-yl]-methanone 
(13). The title compound was prepared by reaction of (4-fluoro-3-methoxyphenyl)-[5-(3-
chloro-4-hydroxyphenyl)-pyridin-2-yl]-methanone 13a (59 mg, 0.17 mmol, 1 equiv) with 
boron trifluoride dimethylsulfide complex (5.95 mmol, 35 equiv) according to method F. The 
product was purified by column chromatography (hexane/ethyl acetate 6:4) then by 
preparative HPLC (isopropanol/water) to afford 10 mg (17%) of the analytically pure product. 
C18H11ClFNO3; MW 343; 1H NMR (acetone-d6): δ 9.10 (s, br, 2H), 8.98 (d, J = 2.2 Hz, 1H), 
8.27 (dd, J = 2.5 Hz, J = 7.9 Hz, 1H), 8.09-8.06 (m, 1H), 7.87 (dd, J = 2.2 Hz, J = 8.8 Hz, 
1H), 7.84 (d, J = 2.2 Hz, 1H), 7.73 (ddd, J = 1.9 Hz, J = 4.4 Hz, J = 8.5 Hz, 1H), 7.66 ( dd, J 
= 2.2 Hz, J = 8.5 Hz, 1H), 7.25 (dd, J = 8.5 Hz, J = 10.7 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H); 
13C NMR (acetone-d6): δ 191.8, 156.4, 154.8, 154.4, 147.0, 145.5, 145.4, 138.2, 135.5, 134.4, 
129.6, 128.0, 125.3, 122.2, 121.4, 119.4, 118.4, 116.5; IR: 3355, 1647, 1578, 1517, 1265 cm-
1; LC/MS m/z: 344-346 (M+H)+. 
 
(6-Bromopyridin-2-yl)-(3-methoxyphenyl)-methanol (14c). The title compound was 
prepared by reaction of 6-bromopyridin-2-yl carboxaldehyde (1 g, 5.41 mmol, 1 equiv) with 
3-methoxyphenylmagnesiumbromide (1M in THF) (2.70 g, 11.9 mL, 11.9 mmol, 2.2 equiv) 
according to method A. The product was purified by column chromatography (hexane/ethyl 
acetate 8:2) to afford 936 mg (59%) of the analytically pure product. C13H12BrNO2; MW 294; 
1H NMR (acetone-d6): δ 7.57 (t, J = 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 1H), 7.30 (d, J = 7.9 Hz, 
1H), 7.08 (t, J = 8.2 Hz, 1H), 6.93-6.90 (m, 1H), 6.87 (d, J = 7.6 Hz, 1H), 6.66 (dd, J = 2.4 
Hz, J = 8.2 Hz, 1H), 5.63 (d, J = 4.5 Hz, 1H), 5.05 (d, J = 4.5 Hz, 1H), 3.62 (s, 3H); 13C NMR 
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(acetone-d6): δ 165.5, 159.8, 145.1, 140.4, 139.7, 129.2, 126.4, 119.4, 118.8, 112.5, 75.5, 
54.5. 
 
(6-Bromopyridin-2-yl)-(3-methoxyphenyl)-methanone (14b). The title compound was 
prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxyphenyl)-methanol 14c (930 mg, 
3.19 mmol, 1 equiv) with 2-iodoxybenzoic acid (1.80 g, 6.39 mmol, 2 equiv) according to 
method B. The product was purified by column chromatography (hexane/ethyl acetate 9:1) to 
afford 727 mg (78%) of the analytically pure compound as a yellow solid. C13H10BrNO2; MW 
292; 1H NMR (acetone-d6): δ 8.02 (dd, J = 1.6 Hz, J = 7.6 Hz, 1H), 7.99 (t, J = 7.3 Hz, 1H), 
7.86 (dd, J = 1.6 Hz, J = 7.3 Hz, 1H), 7.65-7.61 (m, 2H), 7.47-7.43 (m, 1H), 7.23 (ddd, J = 
0.9 Hz, J = 2.5 Hz, J = 8.2 Hz, 1H), 3.87 (s, 3H); 13C NMR (acetone-d6): δ 193.5, 160.4, 
156.7, 141.2, 141.1, 138.0, 131.9, 124.4, 120.1, 119.2, 116.3, 115.2, 55.8; IR: 1667, 1425, 
1254, 1032 cm-1; LC/MS m/z: 292-294 (M+H)+. 
 
[6-(4-Methoxy-3-methylphenyl)-pyridin-2-yl]-(3-methoxyphenyl)-methanone (14a). The 
title compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxyphenyl)-
methanone 14b (410 mg, 1.40 mmol, 1 equiv) with 4-methoxy-3-methylphenylboronic acid 
(280 mg, 1.69 mmol, 1.2 equiv) according to method D. The product was purified by column 
chromatography (hexane/ethyl acetate 9:1) to give 432 mg (92%) of the analytically pure 
compound as a yellow powder. C21H19NO3; MW 333; 1H NMR (acetone-d6): δ 8.10 (dd, J = 
0.9 Hz, J = 7.9 Hz, 1H), 8.07-8.03 (m, 1H), 7.99-7.95 (m, 2H), 7.89 (dd, J = 0.9 Hz, J = 7.6 
Hz, 1H), 7.80-7.78 (m, 1H), 7.75 (dt, J = 0.9 Hz, J = 7.6 Hz, 1H), 7.48 (t, J = 7.9 Hz, 1H), 
7.24 (ddd, J = 0.9 Hz, J = 2.8 Hz, J = 8.2 Hz, 1H), 7.02 (d, J = 8.2 Hz, 1H), 3.89 (s, 3H), 3.88 
(s, 3H), 2.24 (s, 3H); 13C NMR (acetone-d6): δ 193.6, 160.4, 160.1, 156.5, 155.7, 139.0, 
138.9, 131.3, 129.9, 127.3, 126.7, 124.5, 122.6, 122.5, 119.8, 116.4, 111.1, 55.9, 55.8, 16.5. 
 
[6-(4-Hydroxy-3-methylphenyl)-pyridin-2-yl]-(3-hydroxyphenyl)-methanone (14). The 
title compound was prepared by reaction of [6-(4-methoxy-3-methylphenyl)-pyridin-2-yl]-(3-
methoxyphenyl)-methanone 14a (341 mg, 1.02 mmol, 1 equiv) with boron tribromide (10.2 
mmol, 10 equiv) according to method E. The product was purified by column 
chromatography (hexane/ethyl acetate 8:2) then by preparative TLC (hexane/ethyl acetate 
65:35) to afford 120 mg (38%) of the analytically pure compound as a yellow solid. 
C19H15NO3; MW 305; 1H NMR (acetone-d6): δ 8.64 (s, br, 1H), 8.54 (s, br, 1H), 8.06 (dd, J = 
1.3 Hz, J = 7.9 Hz, 1H), 8.04-8.00 (m, 1H), 7.93 (d, J = 2.2 Hz, 1H), 7.85-7.81 (m, 2H), 7.67-
7.63 (m, 2H), 7.41-7.37 (m, 1H), 7.14 (ddd, J = 0.9 Hz, J = 2.5 Hz, J = 7.9 Hz, 1H), 6.91 (d, J 
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= 8.2 Hz, 1H), 2.27 (s, 3H); 13C NMR (acetone-d6): δ 195.1, 157.0, 140.1, 140.0, 131.9, 
131.6, 131.2, 127.8, 126.6, 124.5, 123.4, 123.3, 121.9, 119.5, 117.0, 17.5; IR: 3372, 1642, 
1581, 1426 cm-1; LC/MS m/z: 306 (M+H)+. 
 
(3-Methoxyphenyl)-[6-(2-methoxyphenyl)-pyridin-2-yl]-methanone (15a). The title 
compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxyphenyl)-methanone 
14b (100 mg, 0.34 mmol, 1 equiv) with 2-methoxyphenylboronic acid (62 mg, 0.41 mmol, 
1.2 equiv) according to method C. The product was purified by column chromatography 
(hexane/ethyl acetate 8:2) to afford 53 mg (49%) of the analytically pure product as a light 
yellow oil. C20H17NO3; MW 319; 1H NMR (acetone-d6): δ 8.19 (dd, J = 0.9 Hz, J = 7.9 Hz, 
1H), 8.05 (t, J = 7.9 Hz, 1H), 7.94 (dd, J = 1.2 Hz, J = 7.7 Hz, 1H), 7.86 (dd, J = 1.8 Hz, J = 
7.7 Hz, 1H), 7.78-7.76 (m, 1H), 7.76-7.73 (m, 1H), 7.46-7.40 (m, 2H), 7.21 (ddd, J = 1.0 Hz, 
J = 2.6 Hz, J = 8.2 Hz, 1H), 7.17 (dd, J = 0.9 Hz, J = 8.5 Hz, 1H), 7.05 (dt, J = 1.2 Hz, J = 7.6 
Hz, 1H), 3.93 (s, 3H), 3.86 (s, 3H); 13C NMR (acetone-d6): δ 193.6, 160.4, 158.4, 155.8, 
155.6, 138.9, 137.9, 131.9, 131.3, 129.9, 128.9, 128.3, 124.5, 122.9, 121.6, 119.7, 116.4, 
112.7, 56.0, 55.8; LC/MS m/z : 320 (M+H)+. 
 
(3-Hydroxyphenyl)-[6-(2-hydroxyphenyl)-pyridin-2-yl]-methanone (15). The title 
compound was prepared by reaction of (3-methoxyphenyl)-[6-(2-methoxyphenyl)-pyridin-2-
yl]-methanone 15a (40 mg, 0.13 mmol, 1 equiv) with boron tribromide (1.3 mmol, 10 equiv) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 
1:1). Yield: 30 mg (79%). White oil. C18H13NO3; MW 291; 1H NMR (acetone-d6): δ 8.42 (d, J 
= 7.9 Hz, 1H), 8.28-8.24 (m, 1H), 8.06 (dd, J = 1.5 Hz, J = 8.1 Hz, 1H), 7.94 (dd, J = 0.7 Hz, 
J = 7.5 Hz, 1H), 7.43-7.41 (m, 3H), 7.35-7.30 (m, 1H), 7.19-7.16 (m, 1H), 6.97-6.93 (m, 1H), 
6.88 (dd, J = 1.2 Hz, J = 8.2 Hz, 1H); GC/MS m/z: 291 (M)+. 
 
(3-Methoxyphenyl)-[6-(3-methoxyphenyl)-pyridin-2-yl]-methanone (16a). The title 
compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxyphenyl)-methanone 
14b (150 mg, 0.51 mmol, 1 equiv) with 3-methoxyphenylboronic acid (94 mg, 0.62 mmol, 
1.2 equiv) according to method C. The product was purified by column chromatography 
(hexane/ethyl acetate 8:2). Yield: 70 mg (43%). C20H17NO3; MW 319; 1H NMR (acetone-d6): 
δ 8.19 (dd, J = 1.1 Hz, J = 7.9 Hz, 1H), 8.12 (t, J = 7.9 Hz, 1H), 7.99 (dd, J = 0.9 Hz, J = 7.6 
Hz, 1H), 7.79-7.74 (m, 3H), 7.70 (ddd, J = 0.9 Hz, J = 1.8 Hz, J = 7.9 Hz, 1H), 7.48 (t, J = 7.9 
Hz, 1H), 7.40 (t, J = 8.1 Hz, 1H), 7.24 (ddd, J = 0.9 Hz, J = 2.6 Hz, J = 8.2 Hz, 1H), 7.02 
(ddd, J = 0.7 Hz, J = 2.6 Hz, J = 8.7 Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H); 13C NMR (acetone-
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d6): δ 193.4, 161.3, 160.4, 156.2, 155.6, 140.7, 139.3, 138.8, 130.7, 130.0, 124.5, 123.6, 
119.9, 119.6, 116.6, 116.2, 113.0, 55.8, 55.6; IR: 2981, 1658, 1579, 1234 cm-1; GC/MS m/z: 
319 (M)+. 
 
(3-Hydroxyphenyl)-[6-(3-hydroxyphenyl)-pyridin-2-yl]-methanone (16). The title 
compound was prepared by reaction of (3-methoxyphenyl)-[6-(3-methoxyphenyl)-pyridin-2-
yl]-methanone 16a (50 mg, 0.16 mmol, 1 equiv) with boron tribromide (1.6 mmol, 10 equiv) 
according to method E. The product was purified by preparative TLC (hexane/ethyl acetate 
1:1) to afford 32 mg (69%) of the analytically pure product as a beige powder. C18H13NO3; 
MW 291; 1H NMR (acetone-d6): δ 8.68 (s, br, 1H), 8.50 (s, br, 1H), 8.13 (dd, J = 1.3 Hz, J = 
7.9 Hz, 1H), 8.11-8.07 (m, 1H), 7.90 (dd, J = 1.3 Hz, J = 7.3 Hz, 1H), 7.66-7.63 (m, 2H), 
7.63-7.62 (m, 1H), 7.61 (ddd, J = 0.9 Hz, J = 1.6 Hz, J = 7.6 Hz, 1H), 7.41-7.37 (m, 1H), 7.32 
(t, J = 8.2 Hz, 1H), 7.14 (ddd, J = 0.9 Hz, J = 2.5 Hz, J = 8.2 Hz, 1H), 6.93 (ddd, J = 0.9 Hz, J 
= 2.5 Hz, J = 8.2 Hz, 1H); 13C NMR (acetone-d6): δ 193.9, 158.8, 156.4, 156.1, 139.1, 138.7, 
130.7, 130.1, 123.4, 123.3, 120.9, 119.0, 118.2, 117.4, 114.6; IR: 3282, 1641, 1581, 1325, 
1213 cm-1; LC/MS m/z: 292 (M+H)+. 
 
[6-(4-Hydroxyphenyl)-pyridin-2-yl]-(3-methoxyphenyl)-methanone (17a). The title 
compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxyphenyl)-methanone 
14b (150 mg, 0.51 mmol, 1 equiv) with 4-hydroxyphenylboronic acid (84 mg, 0.61 mmol, 1.2 
equiv) according to method C. The product was purified by column chromatography 
(hexane/ethyl acetate 8:2). Yield: 45% (70 mg). C19H15NO3; MW 305; 1H NMR (acetone-d6): 
δ 8.73 (s, br, 1H), 8.09 (dd, J = 1.2 Hz, J = 8.0 Hz, 1H), 8.06 (d, J = 7.5 Hz, 1H), 8.04-8.01 
(m, 2H), 7.87 (dd, J = 1.5 Hz, J = 7.3 Hz, 1H), 7.76-7.72 (m, 2H), 7.47 (t, J = 7.8 Hz, 1H), 
7.23 (ddd, J = 1.0 Hz, J = 2.7 Hz, J = 8.3 Hz, 1H), 6.97-6.93 (m, 2H), 3.87 (s, 3H); 13C NMR 
(acetone-d6): δ 193.7, 160.4, 159.9, 156.5, 155.7, 139.0, 138.9, 130.7, 130.0, 129.2, 124.5, 
122.4, 122.3, 119.8, 116.5, 116.2, 55.8; GC/MS m/z: 305 (M)+. 
 
(3-Hydroxyphenyl)-[6-(4-hydroxyphenyl)-pyridin-2-yl]-methanone (17). The title 
compound was prepared by reaction of [6-(4-hydroxyphenyl)-pyridin-2-yl]-(3-
methoxyphenyl)-methanone 17a (30 mg, 0.10 mmol, 1 equiv) with boron tribromide (0.50  
mmol, 5 equiv) according to method E. The product was recrystallised in ethyl acetate to 
afford 15 mg (51%) of the analytically pure compound. C18H13NO3; MW 291; mp: 177-
179°C; 1H NMR (acetone-d6 + MeOH): δ 8.21-8.16 (m, 1H), 8.15-8.11 (m, 1H), 7.94 (d, J = 
8.9 Hz, 2H), 7.90 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.50-7.48 (m, 1H), 7.35 (t, J = 8.1 Hz, 
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1H), 7.11-7.08 (m, 1H), 6.91 (d, J = 8.5 Hz, 2H); IR: 3140, 1605, 1453, 1340, 1193 cm-1; 
LC/MS m/z: 292 (M+H)+. 
 
[6-(4-Methoxy-2-methylphenyl)-pyridin-2-yl]-(3-methoxyphenyl)-methanone (18a). The 
title compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxyphenyl)-
methanone 14b (200 mg, 0.68 mmol, 1 equiv) with 4-methoxy-2-methylphenylboronic acid 
(136 mg, 0.82 mmol, 1.2 equiv) according to method D. The product was purified by column 
chromatography (hexane/ethyl acetate 7:3) to afford 100 mg (44%) of the analytically pure 
compound. C21H19NO3; MW 333; 1H NMR (acetone-d6): δ 8.08 (t, J = 7.9 Hz, 1H), 7.94 (dd, 
J = 0.9 Hz, J = 7.6 Hz, 1H), 7.73 (dd, J = 0.9 Hz, J = 7.9 Hz, 1H), 7.70-7.66 (m, 2H), 7.46-
7.43 (m, 1H), 7.43-7.39 (m, 1H), 7.18 (ddd, J = 1.3 Hz, J = 2.5 Hz, J = 8.2 Hz, 1H), 6.87-6.84 
(m, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 2.39 (s, 3H); 13C NMR (acetone-d6): δ 160.4, 159.4, 155.7, 
139.0, 138.5, 138.4, 132.1, 129.8, 127.2, 124.3, 122.4, 119.5, 117.2, 117.1, 116.3, 112.2, 
112.1, 55.7, 55.5, 14.4; IR: 2959, 1661, 1579, 1450, 1237 cm-1; GC/MS m/z: 333 (M)+. 
 
[6-(4-Hydroxy-2-methylphenyl)-pyridin-2-yl]-(3-hydroxyphenyl)-methanone (18). The 
title compound was prepared by reaction of [6-(4-methoxy-2-methylphenyl)-pyridin-2-yl]-(3-
methoxyphenyl)-methanone 18a (90 mg, 0.27 mmol, 1 equiv) with boron tribromide (2.7 
mmol, 10 equiv) according to method E. The product was purified by column 
chromatography (hexane/ethyl acetate 7:3) to afford 45 mg (55%) of the analytically pure 
compound as a brown oil. C19H15NO3; MW 305; 1H NMR (acetone-d6): δ 8.60 (s, br, 1H), 
8.43 (s, br, 1H), 8.05-8.00 (m, 1H), 7.85 (dd, J = 1.1 Hz, J = 7.8 Hz, 1H), 7.69 (dd, J = 0.9 
Hz, J = 7.8 Hz, 1H), 7.55-7.50 (m, 2H), 7.35-7.28 (m, 2H), 7.07 (dd, J = 0.9 Hz, J = 8.1 Hz, 
1H), 6.76-6.69 (m, 2H), 2.32 (s, 3H); 13C NMR (acetone-d6): δ 158.6, 158.0, 138.3, 132.3, 
129.9, 127.0, 123.2, 122.1, 120.7, 118.4, 118.0, 113.8, 21.2; IR: 3255, 2924, 1689, 1583, 
1219 cm-1; LC/MS m/z: 306 (M+H)+. 
 
[6-(2-Fluoro-4-methoxyphenyl)-pyridin-2-yl]-(3-methoxyphenyl)-methanone (19a). The 
title compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxyphenyl)-
methanone 14b (170 mg, 0.58 mmol, 1 equiv) with 2-fluoro-4-methoxyphenylboronic acid 
(119 mg, 0.70 mmol, 1.2 equiv) according to method D. The product was used in the next step 
without further purification. C20H16FNO3; MW 337. 
 
[6-(2-Fluoro-4-hydroxyphenyl)-pyridin-2-yl]-(3-hydroxyphenyl)-methanone (19). The 
title compound was prepared by reaction of [6-(2-fluoro-4-methoxyphenyl)-pyridin-2-yl]-(3-
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methoxyphenyl)-methanone 19a (100 mg, 0.3 mmol, 1 equiv) with boron tribromide (3.0 
mmol, 10 equiv) according to method E. The product was recrystallised in ethyl acetate to 
afford 50 mg (54%) of the analytically pure product as a yellow powder. C18H12FNO3; MW 
309; mp: 246-248°C; 1H NMR (acetone-d6): δ 8.27-8.22 (m, 1H), 8.11-8.08 (m, 1H), 7.98-
7.95 (m, 1H), 7.84 (t, J = 8.2 Hz, 1H), 7.49 (dt, J = 1.1 Hz, J = 7.8 Hz, 1H), 7.47-7.45 (m, 
1H), 7.33 (t, J = 7.9 Hz, 1H), 7.11-7.07 (m, 1H), 6.77-6.73 (m, 1H), 6.69-6.64 (m, 1H); 13C 
NMR (acetone-d6): δ 158.7,  137.0, 133.3, 130.8, 129.7, 128.9, 125.9, 122.8, 122.3, 119.3, 
119.2, 118.4, 118.2, 117.5, 113.7, 108.2, 104.7; IR: 3251, 3027, 1608, 1468, 1235 cm-1; 
LC/MS m/z: 310 (M+H)+. 
 
[6-(3-Fluoro-4-methoxyphenyl)-pyridin-2-yl]-(3-methoxyphenyl)-methanone (20a). The 
title compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxyphenyl)-
methanone 14b (150 mg, 0.51 mmol, 1 equiv) with 3-fluoro-4-methoxyphenylboronic acid 
(104 mg, 0.61 mmol, 1.2 equiv) according to method D. The product was recrystallised in 
ethanol to afford 130 mg (76%) of the analytically pure compound as a white powder. 
C20H16FNO3; MW 337; mp: 100-102°C; 1H NMR (acetone-d6): δ 8.17 (dd, J = 1.3 Hz, J = 8.2 
Hz, 1H), 8.10 (t, J = 7.6 Hz, 1H), 7.97-7.94 (m, 2H), 7.92 (dd, J = 1.3 Hz, J = 5.7 Hz, 1H), 
7.74-7.70 (m, 2H), 7.50-7.46 (m, 1H), 7.28-7.23 (m, 2H), 3.95 (s, 3H), 3.88 (s, 3H); 13C NMR 
(acetone-d6): δ 193.5, 160.5, 155.7, 155.1, 152.4, 149.9, 139.3, 138.8, 132.4, 130.0, 124.4, 
123.9, 123.2, 122.8, 119.9, 116.2, 115.1, 114.9, 56.6, 55.8; IR: 2926, 1662, 1581, 1283 cm-1; 
GC/MS m/z: 337 (M)+. 
 
[6-(3-Fluoro-4-hydroxyphenyl)-pyridin-2-yl]-(3-hydroxyphenyl)-methanone (20). The 
title compound was prepared by reaction of [6-(3-fluoro-4-methoxyphenyl)-pyridin-2-yl]-(3-
methoxyphenyl)-methanone 20a (120 mg, 0.36 mmol, 1 equiv) with pyridinium 
hydrochloride (36 mmol, 100 equiv) according to method G. The analytically pure product 
was obtained after recrystallisation with hexane and ethyl acetate as a brown solid. Yield: 103 
mg (94%). C18H12FNO3; MW 309; mp: 224-226°C; 1H NMR (acetone-d6): δ 8.32 (d, J = 1.9 
Hz, 1H), 7.89-7.87 (m, 1H), 7.75-7.74 (m, 1H), 7.38 (dd, J = 2.2 Hz, J = 8.2 Hz, 1H), 7.21 (t, 
J = 1.6 Hz, 1H), 7.19 (dd, J = 0.6 Hz, J = 8.2 Hz, 1H), 7.15 (t, J = 1.6 Hz, 1H), 6.80 (dd, J = 
0.6 Hz, J = 1.6 Hz, 1H), 6.60 (dd, J = 0.9 Hz, J = 1.9 Hz, 1H), 5.35 (d, J = 8.2 Hz, 1H); 13C 
NMR (acetone-d6): δ 183.5, 164.7, 161.0, 160.4, 156.5, 149.4, 147.7, 143.6, 143.3, 139.0, 
132.2, 129.5, 120.9; IR: 3225, 3027, 1608, 1468, 1285 cm-1; LC/MS m/z: 310 (M+H)+. 
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[6-(3-Chloro-4-hydroxyphenyl)-pyridin-2-yl]-(3-methoxyphenyl)-methanone (21a). The 
title compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxyphenyl)-
methanone 14b (200 mg, 0.68 mmol, 1 equiv) with 3-chloro-4-hydroxyphenylboronic acid 
(141 mg, 0.82 mmol, 1.2 equiv) according to method D. The product was purified by column 
chromatography (hexane/ethyl acetate 7:3) to afford 120 mg (50%) of the analytically pure 
compound as white oil. C19H14ClNO3; MW 339; 1H NMR (acetone-d6): δ 9.13 (s, br, 1H), 
8.18 (d, J = 2.2 Hz, 1H), 8.15 (dd, J = 0.8 Hz, J = 8.0 Hz, 1H), 8.10 (t, J = 7.7 Hz, 1H), 7.97 
(dd, J = 2.1 Hz, J = 8.4 Hz, 1H), 7.93 (dd, J = 0.9 Hz, J = 7.5 Hz, 1H), 7.76-7.74 (m, 1H), 
7.73-7.70 (m, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.25 (ddd, J = 0.6 Hz, J = 2.8 Hz, J = 8.2 Hz, 1H), 
7.13 (d, J = 8.5 Hz, 1H), 3.88 (s, 3H); 13C NMR (acetone-d6): δ 193.5, 155.7, 155.2, 155.1, 
139.3, 132.1, 130.0, 129.3, 128.5, 127.5, 126.9, 124.4, 123.0, 122.7, 120.0, 118.0, 117.9, 
116.2, 55.8; GC/MS m/z: 339-341 (M)+. 
 
[6-(3-Chloro-4-hydroxyphenyl)-pyridin-2-yl]-(3-hydroxyphenyl)-methanone (21). The 
title compound was prepared by reaction of [6-(3-chloro-4-hydroxyphenyl)-pyridin-2-yl]-(3-
methoxyphenyl)-methanone 21a (200 mg, 0.59 mmol, 1 equiv) with pyridinium 
hydrochloride (59 mmol, 100 equiv) according to method G. The product was purified by 
recrystallisation in ethanol and ethyl acetate to give 82 mg (43%) of the analytically pure 
compound as a green powder. C18H12ClNO3; MW 325; mp: 206-208°C; 1H NMR (acetone-
d6): δ 9.10 (s, br, 1H), 8.76 (s, br, 1H), 8.17 (d, J = 2.2 Hz, 1H), 8.13 (dd, J = 0.9 Hz, J = 7.9 
Hz, 1H), 8.10-8.06 (m, 1H), 7.97 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H), 7.88 (dd, J = 0.9 Hz, J = 
7.6 Hz, 1H), 7.64-7.60 (m, 2H), 7.42-7.38 (m, 1H), 7.15 (ddd, J = 1.3 Hz, J = 2.2 Hz, J = 7.9 
Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H); 13C NMR (acetone-d6): δ 193.8, 158.1, 156.0, 155.2, 155.1, 
139.2, 132.2, 130.1, 129.4, 127.5, 123.3, 122.9, 122.5, 121.8, 120.9, 118.2, 117.8; IR: 3345, 
1639, 1580, 1324, 1290 cm-1; LC/MS m/z: 326 (M+H)+. 
 
(6-Bromopyridin-2-yl)-(4-fluoro-3-methoxyphenyl)-methanol (22c). To a solution of 5-
bromo-2-fluoroanisole (200 mg, 0.98 mmol, 1 equiv) in anhydrous THF was added granules 
of magnesium (24 mg, 0.98 mmol, 1 equiv) under nitrogen. The mixture was heated to 60°C 
for 2h. After reaching room temperature, 6-bromopyridin-2-yl carboxaldehyde (182 mg, 0.98 
mmol, 1 equiv) was added and the reaction mixture was heated to 80°C and stirred overnight 
at 80°C. The reaction was cooled to room temperature, quenched with brine and the aqueous 
layer was extracted with ethyl acetate. The combined organic layers were dried over sodium 
sulfate, filtered and concentrated to dryness under vacuum. The product was used in the next 
step without further purification. C13H11BrFNO2; MW 312. 
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(6-Bromopyridin-2-yl)-(4-fluoro-3-methoxyphenyl)-methanone (22b). The title compound 
was prepared by reaction of (6-bromopyridin-2-yl)-(4-fluoro-3-methoxyphenyl)-methanol 22c 
(150 mg, 0.48 mmol, 1 equiv) with 2-iodoxybenzoic acid (269 mg, 0.96 mmol, 2 equiv) 
according to method B. The product was purified by column chromatography (hexane/ethyl 
acetate 7:3) to afford 130 mg (87%) of the analytically pure compound as orange oil. 
C13H9BrFNO2; MW 310; 1H NMR (acetone-d6): δ 8.05 (dd, J = 1.3 Hz, J = 7.6 Hz, 1H), 8.02 
(t, J = 7.6 Hz, 1H), 7.94 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H), 7.89 (dd, J = 1.3 Hz, J = 7.6 Hz, 
1H), 7.74 (ddd, J = 2.2 Hz, J = 4.4 Hz, J = 8.5 Hz, 1H), 7.33-7.28 (m, 1H), 3.98 (s, 3H); 13C 
NMR (acetone-d6): δ 190.3, 157.4, 156.5, 148.5, 141.3, 141.0, 133.4, 132.0, 126.0, 124.5, 
116.7, 108.3, 56.6; IR: 3058, 1686, 1585, 1514, 1421, 1293 cm-1; LC/MS m/z: 310-312 
(M+H)+. 
 
(4-Fluoro-3-methoxyphenyl)-[6-(4-methoxy-3-methylphenyl)-pyridin-2-yl]-methanone 
(22a). The title compound was prepared by reaction of (6-bromopyridin-2-yl)-(4-fluoro-3-
methoxyphenyl)-methanone 22b (100 mg, 0.32 mmol, 1 equiv) with 4-methoxy-3-
methylphenylboronic acid (64 mg, 0.39 mmol, 1.2 equiv) according to method D. The product 
was purified by column chromatography (hexane/ethyl acetate 7:3) to give 70 mg (62%) of 
the analytically pure compound. C21H18FNO3; MW 351; 1H NMR (acetone-d6): δ 8.13 (dd, J 
= 1.1 Hz, J = 7.8 Hz, 1H), 8.09-8.04 (m, 2H), 7.99 (dd, J = 2.3 Hz, J = 8.6 Hz, 1H), 7.97 (d, J 
= 1.7 Hz, 1H), 7.91 (dd, J = 1.0 Hz, J = 7.6 Hz, 1H), 7.88-7.84 (m, 1H), 7.35-7.30 (m, 1H), 
7.05 (d, J = 8.6 Hz, 1H), 3.97 (s, 3H), 3.90 (s, 3H), 2.25 (s, 3H); 13C NMR (acetone-d6): δ 
190.1, 160.1, 156.5, 155.5, 139.1, 129.8, 127.4, 126.7, 126.1, 122.7, 122.6, 117.0, 116.4, 
116.2, 111.1, 56.6, 55.9, 16.5; LC/MS m/z: 352 (M+H)+. 
 
(4-Fluoro-3-hydroxyphenyl)-[6-(4-hydroxy-3-methylphenyl)-pyridin-2-yl]-methanone 
(22). The title compound was prepared by reaction of (4-fluoro-3-methoxyphenyl)-[6-(4-
methoxy-3-methylphenyl)-pyridin-2-yl]-methanone 22a (30 mg, 0.09 mmol, 1 equiv) with 
pyridinium hydrochloride (9 mmol, 100 equiv) according to method G. The analytically pure 
product was obtained after purification by column chromatography (hexane/ethyl acetate 7:3) 
and preparative HPLC using isopropanol/water as eluent in 66% yield (19 mg). C19H14FNO3; 
MW 323; 1H NMR (acetone-d6): δ 9.01 (s, br, 1H), 8.57 (s, br, 1H), 8.07 (dd, J = 1.3 Hz, J = 
8.2 Hz, 1H), 8.05-8.01 (m, 1H), 7.93 (dd, J = 0.6 Hz, J = 2.2 Hz, 1H), 7.90 (dd, J = 2.2 Hz, J 
= 8.8 Hz, 1H), 7.85-7.82 (m, 2H), 7.75 (ddd, J = 2.2 Hz, J = 4.7 Hz, J = 8.5 Hz, 1H), 7.32-
7.27 (m, 1H), 6.93 (d, J = 8.2 Hz, 1H), 2.27 (s, 3H); 13C NMR (acetone-d6): δ 193.2, 163.8, 
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158.0, 157.9, 156.8, 155.6, 139.0, 130.5, 126.6, 124.9, 122.4, 122.3, 122.2, 118.8, 116.6, 
116.5, 115.9, 16.4; IR: 3332, 1656, 1583, 1181 cm-1; LC/MS m/z: 324 (M+H)+. 
 
(6-Bromopyridin-2-yl)-(3-methoxy-4-methylphenyl)-methanol (23c). To a solution of 5-
bromo-2-methylanisole (200 mg, 0.99 mmol, 1 equiv) in anhydrous THF was added granules 
of magnesium (24 mg, 0.99 mmol, 1 equiv) under nitrogen. The mixture was heated to 60°C 
for 2h. After cooling down to room temperature, 6-bromopyridin-2-yl carboxaldehyde (182 
mg, 0.99 mmol, 1 equiv) was added and the reaction mixture was heated to 80°C and stirred 
overnight at 80°C. The reaction was cooled to room temperature, quenched with brine and the 
aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over 
sodium sulfate, filtered and concentrated to dryness under vacuum. The product was purified 
by column chromatography (hexane/ethyl acetate 8:2) to afford the analytically pure 
compound in 76% yield (232 mg) as a yellow oil. C14H14BrNO2; MW 308; 1H NMR (acetone-
d6): δ 7.71 (t, J = 7.8 Hz, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.44 (d, J = 7.9 Hz, 1H), 7.07-7.04 
(m, 2H), 6.89 (dd, J = 1.3 Hz, J = 7.5 Hz, 1H), 5.75 (d, J = 4.5 Hz, 1H), 5.11 (d, J = 4.5 Hz, 
1H), 3.80 (s, 3H), 2.12 (s, 3H); 13C NMR (acetone-d6): δ 166.6, 158.6, 143.4, 141.3, 140.6, 
131.0, 127.2, 126.0, 120.3, 119.2, 109.3, 76.5, 55.6, 16.0; IR: 3396, 2923, 1581, 1555, 1252 
cm-1; GC/MS m/z: 307-309 (M)+. 
 
(6-Bromopyridin-2-yl)-(3-methoxy-4-methylphenyl)-methanone (23b). The title 
compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxy-4-methylphenyl)-
methanol 23c (60 mg, 0.19 mmol, 1 equiv) with 2-iodoxybenzoic acid (106 mg, 0.38 mmol, 2 
equiv) according to method B. The product was purified by column chromatography 
(hexane/ethyl acetate 8:2) to afford the analytically pure compound in 98% yield (57 mg) as a 
yellow powder. C14H12BrNO2; MW 306; 1H NMR (acetone-d6): δ 8.03-8.01 (m, 1H), 8.00 (d, 
J = 1.4 Hz, 1H), 7.89-7.85 (m, 1H), 7.69 (d, J = 1.4 Hz, 1H), 7.58 (dd, J = 1.5 Hz, J = 7.7 Hz, 
1H), 7.30 (dd, J = 0.9 Hz, J = 7.7 Hz, 1H), 3.92 (s, 3H), 2.28 (s, 3H); 13C NMR (acetone-d6): 
δ 191.5, 158.5, 157.1, 141.2, 141.1, 135.7, 133.6, 131.6, 131.0, 124.8, 124.3, 112.4, 55.8, 
16.6; IR: 2929, 1651, 1553, 1302, 1247 cm-1; LC/MS m/z: 306-308 (M+H)+. 
 
(3-Methoxy-4-methylphenyl)-[6-(4-methoxy-3-methylphenyl)-pyridin-2-yl]-methanone 
(23a). The title compound was prepared by reaction of (6-bromopyridin-2-yl)-(3-methoxy-4-
methylphenyl)-methanone 23b (50 mg, 0.16 mmol, 1 equiv) with 4-methoxy-3-
methylphenylboronic acid (31 mg, 0.19 mmol, 1.2 equiv) according to method D. The product 
was purified by column chromatography (hexane/ethyl acetate 7:3) to afford the analytically 
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pure compound in 68% yield (38 mg) as an orange powder. C22H21NO3; MW 347; 1H NMR 
(acetone-d6): δ 8.11 (dd, J = 0.9 Hz, J = 8.1 Hz, 1H), 8.05 (t, J = 7.5 Hz, 1H), 8.01-7.97 (m, 
2H), 7.86 (dd, J = 0.9 Hz, J = 7.5 Hz, 1H), 7.82 (d, J = 1.6 Hz, 1H), 7.71 (dd, J = 1.4 Hz, J = 
7.7 Hz, 1H), 7.32 (dd, J = 0.6 Hz, J = 7.7 Hz, 1H), 7.04 (d, J = 8.5 Hz, 1H), 3.91 (s, 3H), 3.90 
(s, 3H), 2.29 (s, 3H), 2.24 (s, 3H); 13C NMR (acetone-d6): δ 193.2, 160.1, 158.4, 156.4, 156.1, 
139.0, 133.0, 131.4, 130.8, 129.8, 127.3, 125.0, 122.5, 122.4, 113.3, 112.6, 112.1, 111.1, 55.9, 
55.8, 16.6, 16.5; IR: 2916, 1651, 1566, 1233 cm-1; LC/MS m/z: 348 (M+H)+. 
 
(3-Hydroxy-4-methylphenyl)-[6-(4-hydroxy-3-methylphenyl)-pyridin-2-yl]-methanone 
(23). The title compound was prepared by reaction of (3-methoxy-4-methylphenyl)-[6-(4-
methoxy-3-methylphenyl)-pyridin-2-yl]-methanone 23a (30 mg, 0.09 mmol, 1 equiv) with 
borontrifluoride dimethylsulfide complex (6.3 mmol, 70 equiv) according to method F. The 
product was purified by column chromatography (hexane/ethyl acetate 7:3) then by 
preparative HPLC with isopropanol/water as eluent to afford 10 mg (35%) of the analytically 
pure compound as a white powder. C20H17NO3; MW 319; 1H NMR (acetone-d6): δ 8.60 (s, br, 
2H), 8.05 (dd, J = 1.4 Hz, J = 8.0 Hz, 1H), 8.01 (t, J = 8.3 Hz, 1H), 7.94-7.92 (m, 1H), 7.84 
(dd, J = 2.1 Hz, J = 8.4 Hz, 1H), 7.77 (dd, J = 1.3 Hz, J = 7.3 Hz, 1H), 7.66 (d, J = 1.6 Hz, 
1H), 7.61 (dd, J = 1.8 Hz, J = 7.8 Hz, 1H), 7.27 (d, J = 7.8 Hz, 1H), 6.93 (d, J = 8.3 Hz, 1H), 
2.31 (s, 3H), 2.26 (s, 3H); 13C NMR (acetone-d6): δ 190.9, 174.6, 161.0, 138.8, 131.2, 130.4, 
126.6, 123.7, 122.0, 121.9, 118.8, 16.5, 16.4; IR: 3340, 1671, 1585 cm-1; LC/MS m/z: 320 
(M+H)+. 
 
(6-Bromopyridin-2-yl)-(5-fluoro-3-methoxyphenyl)-methanol (24c). To a solution of 3-
bromo-5-fluoroanisole (250 mg, 1.22 mmol, 1 equiv) in anhydrous THF was added granules 
of magnesium (32 mg, 1.28 mmol, 1.05 equiv) under nitrogen. The mixture was heated to 
60°C for 2h. After cooling down to room temperature, 6-bromopyridin-2-yl carboxaldehyde 
(271 mg, 1.47 mmol, 1.2 equiv) was added and the reaction mixture was stirred at 80°C 
overnight. The reaction was cooled to room temperature, quenched with brine and the 
aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over 
sodium sulfate, filtered and concentrated to dryness under vacuum. The product was purified 
by column chromatography (hexane/ethyl acetate 8:2) to afford the analytically pure 
compound in 21% yield (80 mg). C13H11BrFNO2; MW 312; 1H NMR (acetone-d6): δ 7.74 (t, J 
= 7.6 Hz, 1H), 7.64-7.61 (m, 1H), 7.47 (dd, J = 0.9 Hz, J = 7.2 Hz, 1H), 6.92-6.90 (m, 1H), 
6.81 (ddd, J = 0.6 Hz, J = 1.3 Hz, J = 9.1 Hz, 1H), 6.59 (dt, J = 2.5 Hz, J = 10.7 Hz, 1H), 5.77 
(d, J = 4.7 Hz, 1H), 5.35 (d, J = 4.7 Hz, 1H), 3.79 (s, 3H); 13C NMR (acetone-d6): δ 165.8, 
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165.3, 140.8, 127.5, 120.3, 109.4, 106.1, 105.9, 101.0, 100.8, 75.8, 56.0; LC/MS m/z: 312-314 
(M+H)+. 
 
(6-Bromopyridin-2-yl)-(5-fluoro-3-methoxyphenyl)-methanone (24b). The title compound 
was prepared by reaction of (6-bromopyridin-2-yl)-(5-fluoro-3-methoxyphenyl)-methanol 24c 
(190 mg, 0.61 mmol, 1 equiv) with 2-iodoxybenzoic acid (342 mg, 1.22 mmol, 2 equiv) 
according to method B. The product was purified by column chromatography (hexane/ethyl 
acetate 17:3) to afford 150 mg (79%) of the analytically pure compound as a brown solid. 
C13H9BrFNO2; MW 310; 1H NMR (acetone-d6): δ 8.08 (dd, J = 0.9 Hz, J = 7.6 Hz, 1H), 8.03 
(t, J = 7.6 Hz, 1H), 7.91 (dd, J = 0.9 Hz, J = 7.6 Hz, 1H), 7.53-7.51 (m, 1H), 7.41 (ddd, J = 
1.3 Hz, J = 2.5 Hz, J = 9.1 Hz, 1H), 7.05 (dt, J = 2.2 Hz, J = 10.4 Hz, 1H), 3.91 (s, 3H); 13C 
NMR (acetone-d6): δ 190.6, 164.9, 161.9, 161.8, 141.4, 132.2, 124.6, 110.2, 107.0, 56.4; IR: 
3080, 2980, 1668, 1555, 1152 cm-1; LC/MS m/z: 310-312 (M+H)+. 
 
(5-Fluoro-3-methoxyphenyl)-[6-(4-methoxy-3-methylphenyl)-pyridin-2-yl]-methanone 
(24a). The title compound was prepared by reaction of (6-bromopyridin-2-yl)-(5-fluoro-3-
methoxyphenyl)-methanone 24b (80 mg, 0.26 mmol, 1 equiv) with 4-methoxy-3-
methylphenylboronic acid (52 mg, 0.31 mmol, 1.2 equiv) according to method D. The 
analytically pure product was obtained after purification by column chromatography (gradient 
hexane/ethyl acetate 1:0 to 8:2) in 81% yield (74 mg). C21H18FNO3; MW 351; 1H NMR 
(acetone-d6): δ 8.13 (dd, J = 1.3 Hz, J = 8.2 Hz, 1H), 8.07 (t, J = 7.9 Hz, 1H), 7.99-7.96 (m, 
2H), 7.93 (dd, J = 0.9 Hz, J = 7.6 Hz, 1H), 7.66-7.64 (m, 1H), 7.54 (ddd, J = 1.3 Hz, J = 2.5 
Hz, J = 9.5 Hz, 1H), 7.06-7.05 (m, 1H), 7.04-7.02 (m, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 2.25 (s, 
3H); 13C NMR (acetone-d6): δ 192.1, 161.8, 161.7, 160.2, 154.9, 139.2, 131.2, 129.9, 127.4, 
126.7, 123.0, 122.7, 113.5, 111.1, 110.7, 110.5, 106.7, 106.5, 56.4, 55.9, 16.5; LC/MS m/z: 
352 (M+H)+. 
 
(5-Fluoro-3-hydroxyphenyl)-[6-(4-hydroxy-3-methylphenyl)-pyridin-2-yl]-methanone 
(24). The title compound was prepared by reaction of (5-fluoro-3-methoxyphenyl)-[6-(4-
methoxy-3-methylphenyl)-pyridin-2-yl]-methanone 24a (39 mg, 0.11 mmol, 1 equiv) with 
pyridinium hydrochloride (11 mmol, 100 equiv) according to method G. The product was 
purified by column chromatography (hexane/ethyl acetate 6:4) to give 10 mg (28%) of the 
analytically pure compound as a yellow solid. C19H14FNO3; MW 323; 1H NMR (acetone-d6): 
δ 9.14 (s, br, 1H), 8.58 (s, br, 1H), 7.86 (dd, J = 1.3 Hz, J = 8.2 Hz, 1H), 7.84-7.80 (m, 1H), 
7.72-7.70 (m, 1H), 7.65 (dd, J = 0.9 Hz, J = 7.3 Hz, 1H), 7.63-7.59 (m, 1H), 7.32-7.30 (m, 
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1H), 7.22 (ddd, J = 1.3 Hz, J = 2.2 Hz, J = 9.5 Hz, 1H), 6.71 (d, J = 8.5 Hz, 1H), 6.68 (dt, J = 
2.2 Hz, J = 10.4 Hz, 1H), 2.27 (s, 3H); 13C NMR (acetone-d6): δ 192.4, 164.9, 159.6, 159.5, 
155.1, 140.1, 140.0, 139.0, 130.6, 130.5, 126.6, 122.7, 122.3, 115.9, 115.1, 109.6, 109.4, 
107.8, 16.4; IR: 3399, 2921, 1613, 1584, 1146 cm-1; LC/MS m/z: 324 (M+H)+. 
 
Biological Assays 
 
[2,4,6,7-3H]-E2 and [2,4,6,7-3H]-E1 were bought from Perkin-Elmer, Boston. Quickszint 
Flow 302 scintillator fluid was bought from Zinsser Analytic, Frankfurt. 17β-HSD2 and 17β-
HSD1 were obtained from human placenta according to previously described procedures [46, 
48, 49]. Fresh human placenta was homogenised and centrifuged. The pellet fraction contains 
the microsomal 17β-HSD2, while 17β-HSD1 was obtained after precipitation with 
ammonium sulfate from the cytosolic fraction. 
 
1. Inhibition of 17β-HSD2 
 
Inhibitory activities were evaluated by a well established method with minor modifications 
[44, 46, 48, 50]. Briefly, the microsomal enzyme was incubated with NAD+ [1500 μM] in the 
presence of potential inhibitors at 37°C in a phosphate buffer (50 mM) supplemented with 
20% of glycerol and EDTA 1 mM. Inhibitor stock solutions were prepared in DMSO. Final 
concentration of DMSO was adjusted to 1% in all samples. The enzymatic reaction was 
started by addition of a mixture of unlabelled- and [2,4,6,7-3H]-E2 (final concentration: 500 
nM, 0.11 μCi). After 20 min at 37°C, the incubation was stopped with HgCl2 and the mixture 
was extracted with ether. After evaporation, the steroids were dissolved in acetonitrile/water 
(45:55). E1 and E2 were separated using acetonitrile/water (45:55) as mobile phase in a C18 
rp chromatography column (Nucleodur C18 Gravity, 3 μm, Macherey-Nagel, Düren) 
connected to a HPLC-system (Agilent 1100 Series, Agilent Technologies, Waldbronn). 
Detection and quantification of the steroids were performed using a radioflow detector 
(Berthold Technologies, Bad Wildbad). The conversion rate was calculated according to 
following equation: ( )( ) ( ) 1002%1%
1%% ×
+
=
EE
Econversion . Each value was calculated from at 
least three independent experiments. 
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2. Inhibition of 17β-HSD1 
 
The 17β-HSD1 inhibition assay was performed similarly to the 17β-HSD2 procedure. The 
cytosolic fraction was incubated with NADH [500 μM], test compound and a mixture of 
unlabelled- and [2,4,6,7-3H]-E1 (final concentration: 500 nM, 0.15 μCi) for 10 min. Further 
treatment of the samples and HPLC separation was carried out as mentioned above. 
 
3. ER affinity 
 
The binding affinity of selected compounds to the ERα and ERβ was determined according to 
Zimmermann et al. [51] using recombinant human proteins. Briefly, 0.25 pmoles of ERα or 
ERβ, respectively, were incubated with [3H]-E2 (10 nM) and test compound for 1h at room 
temperature. The potential inhibitors were dissolved in DMSO (5% final concentration). 
Evaluation of non-specific-binding was performed with diethylstilbestrol (10 µM). After 
incubation, ligand-receptor complexes were selectively bound to hydroxyapatite (5 g/ 60 mL 
TE-buffer). The formed complex was separated, washed and resuspended in ethanol. For 
radiodetection, scintillator cocktail (Quickszint 212, Zinsser Analytic, Frankfurt) was added 
and samples were measured in a liquid scintillation counter (Rack Beta Primo 1209, Wallac, 
Turku). From these results the percentage of [3H]-E2 displacement by the compounds was 
calculated. The plot of % displacement versus compound concentration resulted in sigmoidal 
binding curves. The compound concentration to displace 50% of the receptor bound [3H]-E2 
were determined. Unlabelled E2 was used as a reference. For determination of the relative 
binding affinity the ratio was calculated according to the following equation: 
[ ] ( )( ) 100
2%
50
50
×=
compoundIC
EICRBA
 
[52]. This results in an RBA value of 100% for E2. After 
the assay was established and validated a modification was made to increase throughput. 
Compounds were tested at concentrations of 1000 × IC50(E2). Compounds with less than 50% 
displacement of [3H]-E2 at a concentration of 1000 × IC50(E2) were classified as RBA <0.1%. 
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4. SUMMARY AND CONCLUSION 
 
 
 
 
The aim of the present work was to develop novel highly potent and selective 17β-HSD2 
inhibitors for the treatment of osteoporosis. Ligand based design has been used to find new 
molecules with high 17β-HSD2 inhibitory activity and selectivity towards 17β-HSD1, 
catalysing the reverse reaction. Compounds should also be active in an animal model to 
evaluate their ability to inhibit osteoclastogenesis and to induce bone formation, and therefore 
to prove our concept that inhibition of 17β-HSD2 could be a promising approach to treat 
osteoporosis. So the most interesting compounds have to be investigated for their in vitro 
activity on different species enzymes. 
 
In Chapter 3.I, the synthesis and the biological evaluation of fourty four compounds 
derived from hydroxynaphthyl, 4-hydroxymethylphenyl and 4-hydroxyphenyl have been 
described in order to find an interesting scaffold for the development of new 17β-HSD2 
inhibitors. The distance and the substitution pattern between both hydroxy groups of the 
naphthalene derivatives have been studied and seemed to be very important. Thus compound 
I.B§
 
, bearing OH groups in position 2 on the naphthalene core and in 3´ on the phenyl moiety 
is a highly active 17β-HSD1 inhibitor, while when the OH groups are switched to position 1 
on the naphthalene and 4´on the phenyl (I-8) the activity is reversed in favour of 17β-HSD2 
(Table 5). Thus, either 17β-HSD1 or 17β-HSD2 inhibitors can be obtained by shifting the 
position of the hydroxy groups, in spite of the fact that the active sites of 17β-HSD1 and 17β-
HSD2 are considered to be very similar (the substrate of one enzyme is the product of the 
catalytic reaction of the other enzyme and vice versa).  
 
 
 
 
 
                                                 
§ For a sake of clarity, all compounds that are referred to in chapter 4 are characterised by a roman numeral I-III 
to identify the paper in which they are published, and an Arabic numeral or a letter which is identical to the one 
of the publication (e.g. I.B is compound B from Paper I) 
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Table 5: Inhibition of human 17β-HSD2 and 17β-HSD1 by naphthalene derivatives 
R
R
I.B, I.7, I.8, I.9, I.11
4´
3´
2
1
1
2
 
Compd R1 R2 
Inhibition of 
17β-HSD2a [%] 
at 1μM 
Inhibition of 
17β-HSD1b [%] 
at 1μM 
I.B 2-OH 3´-OH 20 100 
I.7 1-OH 4´-OCH3 20 28 
I.8 1-OH 4´-OH 74 20 
I.11 1-OH 4´-NO2 13 15 
a Human placenta, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], NAD+ [1.5 mM], mean value of 3 
determinations, relative standard deviation < 10%, b Human placenta, cytosolic fraction, substrate [3H]-E1 + E1 
[500 nM], NADPH [0.5 mM], mean value of 3 determinations, relative standard deviation < 10%. 
 
A good superimposition of these two molecules (I.B and I.8) using their hydroxy groups 
is obtained when the OH phenyl group of I.B overlaps the OH group of the naphthalene of 
I.8. As it has been postulated by Frotscher et al.67 that the OH of the phenyl moiety of 
compound I.B replaces the steroidal OH group of the A-ring, it is expected that the OH-
phenyl of I.8 mimicks the D ring of the steroid (Figure 13).  
 
Figure 13: Structure of E2  
OH
OH
E2
A B
C D
 
 
Furthermore, as the only difference between I.B (17β-HSD1 inhibitor) and I.8 (17β-
HSD2 inhibitor) are the BB and 8B rings, a hindrance can be expected between the BB ring 
and at least one amino acid of the active site of 17β-HSD2 (Figure 14). This amino acid 
should be therefore responsible for the selectivity observed for I.8 in favour of 17β-HSD2 
(IC50 = 302 nM, selectivity factor (SF) = 8). It is difficult to discuss more precisely the 
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interactions achieved by the compounds with the enzyme, because the 3D-structure of 17β-
HSD2 has not been elucidated until now.  
 
Figure 14: Superimposition of compounds I.B and I.8 
 
 Compound I.8 is an interesting scaffold for further development of 17β-HSD2 inhibitors. 
The hydroxy group which is linked to the phenyl was exchanged by some substituents to 
decrease the numbers of hydroxy groups of I.8, highly susceptible for phase II metabolism69
 
. 
But neither electron withdrawing groups like nitro (I.11) nor electron donating group like 
OCH3 (I.7) can improve activity of compound I.8. A series of sulfonamides and amides were 
also introduced (I.19-I.25) on the phenyl ring. Sulfonamide I.20 and amide I.24 show similar 
activity as I.8 (75 % and 64 % inhibition, respectively to be compared to compound I.8 with 
74 % 17β-HSD2 inhibition at 1 μM). There is evidence that a H-bond donor group directly 
bound to the phenyl core is highly necessary for high 17β-HSD2 inhibition. Thus, the NH-
groups of the sulfonamide I.20 and the amide I.24 are able to replace the OH group of I.8 
(Table 6) and to make similar interactions with amino acid residues in the active site. 
Table 6: Influence of hydroxyphenyl and hydroxymethylphenyl moieties on human 17β-
HSD2 and 17β-HSD1 inhibitory activities 
Compd Structure 
Inhibition of 
17β-HSD2a [%] 
at 1μM 
Inhibition of 
17β-HSD1b [%] 
at 1μM 
I.20 
OH
N
H
S
O O
 
75 52 
I.33 
OH
N
H
S
O O
 
n.i. n.i. 
I.43 
OH
N
H
S
O O
 
n.i. n.i. 
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Table 6 continued 
Compd Structure 
Inhibition of 
17β-HSD2a [%] 
at 1μM 
Inhibition of 
17β-HSD1b [%] 
at 1μM 
I.24 NH
OH
O
 
64 12 
I.26 
OH
NH
O
 
n.i. n.i. 
I.35 
OH
NH
O  
n.i. n.i. 
a Human placenta, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], NAD+ [1.5 mM], mean value of 3 
determinations, relative standard deviation < 10%, b Human placenta, cytosolic fraction, substrate [3H]-E1 + E1 
[500 nM], NADPH [0.5 mM], mean value of 3 determinations, relative standard deviation < 10%; n.i.: no 
inhibition. 
  
To simplify the lipophilic scaffold, the naphthalene moiety was replaced either by 4-
hydroxymethylphenyl or by 4-hydroxyphenyl moieties. Unfortunately, exchange of the 
naphthalene core was detrimental for the activity. No inhibition was observed for the 
sulfonamides I.33 and I.43 substituted with 4-hydroxymethylphenyl and 4-hydroxyphenyl 
core, respectively, while the naphthalene derivative I.20 shows 74 % 17β-HSD2 inhibition at 
1 μM (Table 6). The same observation is made with the amides I.26 and I.35, which are 
devoid of activity, whereas their naphthalene analogue I.24 exhibited 64 % inhibition. It is 
therefore postulated that ring 8A of the naphthalene derivatives I.20 and I.24 is very 
important for the 17β-HSD2 activity, and should stabilise the molecule in the active site by π-
π or Van der Waals interactions. 
 In addition, the biological results obtained for the methylsulfonamide I.20 and the 
acetamide I.24, showing no loss of activity compared to compound I.8 confirm the hypothesis 
postulated above regarding the position of compound I.8 in the active site: the OH-phenyl of 
I.8 would mimic the steroidal D-ring, close to the catalytic triad where space is available for 
large substituents. This hypothesis is further investigated in the following chapter by 
introduction of substituents on the phenyl moiety next to the hydroxy group of I.8 (Chapter 
3.II). 
 In summary, it has been shown in this study that shifting the position of the hydroxy 
groups from 2 to 1 on the naphthalene and from 3´ to 4´ on the phenyl delivers either selective 
17β-HSD1 or 17β-HSD2 inhibitors. The positive result of exchanging the hydroxy on the 
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phenyl moiety by H-bond donator groups points out the implication of this substituent in 
interactions with amino acid residues of the enzyme. In addition, the A ring of the 
naphthalene seems also be implicated in interactions with amino acids of the protein, 
stabilising the molecule in the active site. 
 
Novel highly potent and selective 17β-HSD2 inhibitors derived from the naphthalene 
scaffold have been identified in chapter 3.II. Most of the hydroxylated derivatives reported in 
chapter 3.II turned out to be as active as the unsubstituted parent compound I.8 (= II.A) or 
even more active with IC50 values in the low nanomolar range (19 nM - 307 nM). The 
hypothesis previously reported about the binding mode of the naphthalene compounds is 
verified here thanks to compound II.9, substituted with a phenyl ring in 3´-position of the 4-
hydroxyphenyl moiety. There is space available around the phenyl ring but the additional 
phenyl is not able to make specific interactions with amino acid residues of the enzyme 
(similar activity for scaffold II.A and compound II.9, Table 7).  
 
Table 7: Inhibition of human 17β-HSD2 and 17β-HSD1 by selected naphthalene derivatives 
OH
OH
R2´
3´
5´
 
Compd R 
Cell free assay 
ERα 
RBAd 
(%) 
ERβ 
RBAd 
(%) 
LogP 
17β-
HSD2 
IC50a 
[nM] 
17β-
HSD1 
IC50b 
[nM] 
Selectivity 
factorc 
II.A=I.8 H 302 2425 8 5 5 3.93 
II.3 3´-CH3 275 1748 6 < 0.1 0.1-1.0 4.41 
II.9 3´-Ph 261 919 4 < 0.1 < 0.1 5.60 
II.11 2´-F 132 2245 17 < 0.1 < 0.1 4.09 
II.15 2´,5´-diF 238 309 1 0.1-1.0 0.1-1.0 4.24 
II.17 2´-CF3 156 926 6 1.0-10 1.0-10 4.85 
II.19 3´-CF3 19 611 32 < 0.1 0.1-1.0 4.85 
II.20 3´-Cl 307 1130 4 0.1-1.0 0.1-1.0 4.49 
II.21 3´-CN 45%e n.i. n.d. n.d. n.d. 3.95 
a Human placenta, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], cofactor NAD+ [1500 μM], mean 
value of three determinations, relative standard deviation < 10%, b Human placenta, cytosolic fraction, substrate 
[3H]-E1 + E1 [500 nM], cofactor NADH [500 μM], mean value of three determinations, relative standard 
deviation < 20%, c IC50 (17β-HSD1)/ IC50 (17β-HSD2), d RBA: Relative Binding Affinity, E2: 100%, e % 
inhibition at 1μM, n.i.: no inhibition, n.d.: not determined. 
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 In order to elucidate the role of the substituents for the 17β-HSD2 inhibitory activity, 
groups with different properties (electronic, lipophilic) have been introduced on the phenyl 
moiety. Thus, electron donating groups (EDG) and hydrophilic groups are certainly not able 
to make specific interactions, as no real increase in activity is observed for these compounds 
compared to the scaffold II.A. On the other hand most of the compounds bearing electron 
withdrawing groups (EWG) displayed higher potency than the parent compound II.A. 
Especially, the fluorine seems to be responsible for the high activity as shown by compounds 
II.11, II.17 and II.19 (IC50 = 132 nM, 156 nM and 19 nM, respectively). The CF3 substituent 
of the most active and selective compound (II.19) was exchanged by bioisosteric Cl (II.20) or 
CN group (II.21) in the 3´-position, in order to modify properties hoping for example to 
increase selectivity and solubility. Unfortunately, none of the compounds II.20 and II.21 
displayed better activity than the CF3 compound II.19 (logP = 4.85). The high hydrophilic 
properties of the nitrile group can explain the moderate activity observed by compound II.21 
(45% 17β-HSD2 inhibition at 1 μM, logP = 3.95), but also its linear conformation, which 
probably does not permit the molecule to establish interactions with amino acid residues of 
the active site. 
 Selectivity toward 17β-HSD1 and the ERs demonstrated by the compounds of this study 
is an important aspect. Indeed, 17β-HSD1 catalysing the reverse reaction should not be 
affected by 17β-HSD2 inhibitors. Furthermore, to avoid activation of the ERs or systemic 
effects as observed by the use of the SERMs, compounds should have no or very little 
affinities to the ERs. Thus, the most active and selective compounds II.11 and II.19 with 
relative binding affinities (RBA) of less than 1.0% show very weak affinities to the ERs, 
whereas the reference compound II.A with a RBA value of 5% is considered as a weak ligand 
of the ERs. Due to these results, compounds II.11 and II.19 are not expected to have ER-
mediated effects under in vivo conditions. 
 The most potent and selective compounds of this series, compounds II.11 and II.19 were 
further tested for their cellular activity in MDA-MB-231 cells, expressing naturally 17β-
HSD2. Compounds II.11 and II.19 showed very similar activity in MDA-MB-231 cells as in 
the cell-free assay (IC50 = 171 nM for II.11 and 31 nM for II.19 in cellular assay vs. 156 nM 
and 19 nM, respectively in cell-free assay). Consequently, these compounds seem to be 
appropriate to permeate the cell membrane. 
 Further in vitro assays have been performed with compound II.19 (IC50 = 19 nM, SF = 
32) in order to get insight in its biological profile (selectivity towards others 17β-HSDs) and 
to find a suitable species for validation of our therapeutical approach. Thus, compound II.19 
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is highly selective towards 17β-HSD4 (catalysing the same reaction as 17β-HSD2) and 17β-
HSD5 (catalysing the conversion of A-dione into T). II.19 displayed also high inhibition E1-
formation in mouse and rat enzymes (72 % and 77 % inhibition at 1 μM, respectively) to very 
high inhibition in monkey enzyme (99 % inhibition at 1 μM) (Figure 15). Selectivity in 
monkey enzyme toward E2-formation seems to be similar than the one observed in human 
enzyme and makes Callithrix Jacchus an appropriate species for validation of our concept. 
 
Figure 15: Inhibition of E1- and E2-formation by compound II.19 in different species at 1μM 
 
 
Results found for E1-formation in the different species are justified by the identity and 
homology sequences obtained by alignment (Figure 16) of the amino acids of these species: 
human (Homo sapiens, P37059), monkey (Callithrix Jacchus, Q9GME5), mouse (Mus 
musculus, P51658) and rat (Rattus norvegicus, Q62730). Thereby, 62% identity is observed 
between rat and human protein, while only 60% identity between mouse and human. 
Concerning the Callithrix Jacchus enzyme, just a fragment of the 17β-HSD2 sequence has 
been resolved until now (from AA86 to AA228, corresponding to the Rossmann fold 
domain). This fragment represents 92% identity to the human one. High sequence identity 
between the whole sequence of Callithrix Jacchus and human enzymes is expected, as 93% 
identity and 98% homology is observed between Cynomolgus monkey (Q4JK76) and human 
proteins.  
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Figure 16: Alignment of human, monkey, mouse and rat 17β-HSD2 sequence 
 
Human  MSTFFSDTAWICLAVPTVLCGTVFCKYKKSSGQLWSWMVCLAGLCA-VCLLILSPFWGLI 59 
CalJac ------------------------------------------------------------ 
Mouse  MSPFASESAWLCLAAAAVLGGTLLCGCR-SGRQLRSQAVCLAGLWGGACLLSLSLLCTLF 59 
Rat    MNPFSSESAWLCLTATAVLGGMLLCKAW-SSGQLRSQVVCLAGLWGGACLLSLSLLCSLF 59 
 
Human  LFSVSCF-LMYTYLSGQELLPVDQKAVLVTGGDCGLGHALCKYLDELGFTVFAGVLNENG 118 
CalJac ---------------------------LVTGGDCGLGHALCKYLDELGFTVFAGVLNENG 33 
Mouse  LLSVACFLLLYMSSSDQDLLPVDQKAVLVTGADSGFGHGLAKHLDKLGFTVFAGVLDKEG 119 
Rat    LLSVSCFFLLYVSSSDQDLLPVDQKAVLVTGADSGFGHALAKHLDKLGFTVFAGVLDKEG 119 
 
Human  PGAEELRRTCSPRLSVLQMDITKPVQIKDAYSKVAAMLQDRGLWAVINNAGVLGFPTDGE 178 
CalJac PGAAELRRSCSPRLSVLQMDVTNPVQIKDAYSKVVATLQDRGLWAVINNAGVLGFPCDGE 93 
Mouse  PGAEELRKHCSERLSVLQMDVTKPEQIKDAHSKVTEKIQDKGLWAVVNNAGVFHLPIDGE 179 
Rat    PGAEELRKNCSERLSVLQMDVTKPEQIKDVHSEVAEKIQDKGLWAVVNNAGVLHFPIDGE 179 
 
Human  LLLMTDYKQCMAVNFFGTVEVTKTFLPLLRKSKGRLVNVSSMGGGAPMERLASYGSSKAA 238 
CalJac LIPMTDYKQCMAVNFFGTVEVTKTFLPLLRKSKGRLVNVSSMGGGAPMAK---------- 143 
Mouse  LIPMSIYRKCMAVNFFGTVEVTKAFLPLLRKSKGRLVNVSSMGGTVPLQMTSAYAATKAA 239 
Rat    LIPMTVYRKCMAVNFFGAVEVTKVFLPLLRKSKGRLVNVSSMGAMIPFQMVAAYASTKAA 239 
 
Human  VTMFSSVMRLELSKWGIKVASIQPGGFLTNIAGTSDKWEKLEKDILDHLPAEVQEDYGQD 298 
CalJac ------------------------------------------------------------ 
Mouse  LTMFSTIIRQELDKWGVKVVTIKPGGFKTNITGSQDIWDKMEKEILDHFSKDIQENYGQD 299 
Rat    ISMFSAVIRQELAKWGVKVVTIHPGGFQTNIVGSQDSWDKMEKEILDHFSKEIQENYGQE 299 
 
Human  YILAQRNFLLLINSLASKDFSPVLRDIQHAILAKSPFAYYTPGKGAYLWICLAHYLPIGI 358 
CalJac ------------------------------------------------------------ 
Mouse  YVHTQKLIIPTLKERSNPDITPVLRDIQHAISARNPSSFYYPGRMAYLWVCLAAYCPTSL 359 
Rat    YVHTQKLALPVMREMSNPDITPVLRDIQHAICAKNPSSFYCSGRMTYLWICFAAYSPISL 359 
 
Human  YDYFAKRHFGQDKPMPRALRMPNYKKKAT 387 
CalJac ----------------------------- 
Mouse  LDYVIKKGFYP-QPTPRALRTVH------ 381 
Rat    LDYILKNYFTP-KLMPRALRTAS------ 381 
 
In conclusion, in this second study additional highly potent and selective 17β-HSD2 
inhibitors with enhanced biological properties compared to the compounds of chapter 3.I have 
been identified. The binding mode of the naphthalene derivatives has been verified by 
introduction of substituents on the phenyl moiety. Results obtained for compound II.19 are of 
significant relevance for future in vivo studies in monkey, due to its high inhibition of the E1-
formation in Callithrix Jacchus enzyme.  
 
To have a large structural diversity of potential drugs, another compound class was 
investigated. In the frame of our 17β-HSD1 project, compound III.B was found as a highly 
potent 17β-HSD1 inhibitor, but also a moderate 17β-HSD2 inhibitor (IC50 = 382 nM). The 
goal of the subsequent study was to reverse the selectivity of III.B in favour of 17β-HSD2, 
and increase its 17β-HSD2 inhibitory activity (Chapter 3.III). 
Thus, exchange of the thiophene ring by a bioisosteric 1,4-phenyl moiety led to a highly 
potent 17β-HSD2 inhibitor (III.2) with a reversed selectivity in favour of HSD2 (Table 8). 
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The linear geometry of the 1,4-phenyl class seems to be responsible for the high activity, as 
compound III.1 with a 1,3-substituted benzene is only a moderate inhibitor. The central ring 
of this class of compounds is therefore of a high importance for the development of either 
17β-HSD1 or 17β-HSD2 inhibitors. 
Regarding the 1,4-substitution pattern, the methyl group can be replaced by a chlorine 
without loss of activity (III.2, III.6 and III.11 to be compared to III.5, III.7 and III.12, 
respectively), pointing out the presence of lipophilic amino acids in this region of the enzyme. 
Furthermore, introduction of a fluorine on the phenyl moiety B led to highly potent inhibitors 
(III.6-III.8, III.11 and III.12). The position of this fluorine might not be important for 
activity, as compounds III.6 (4-F) and III.8 (3-F) displayed similar HSD2 inhibitory potency. 
To sum up, the 1,4-substitution pattern seems crucial for activity and these derivatives are 
considered to be steroidomimetics, as they are able to superimpose well with the substrate E2 
with their polar moieties (Figure 17). 
 
Figure 17: Superimposition of compound III.2 (green) and E2 (blue); (A) carbonyl group of 
III.2 mimicks the C17(OH) of E2 and the OH of the phenyl A ring the C3(OH) of the steroid; 
(B) carbonyl group of III.2 mimicks the C3(OH) of E2 and the OH of the phenyl A ring the 
C17(OH) of the steroid. 
A B  
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Table 8: Inhibition of 17β-HSD2 and 17β-HSD1 by selected hydroxyphenylmethanone 
derivatives 
OH
O
OH
R1
R2
(het-)
arom 2
3
34
BA
 
Compd (Het-) arom R1 R2 
Cell-free assay 
17β-
HSD2 
IC50a 
[nM] 
17β-
HSD1 
IC50b 
[nM] 
Selectivity 
factorc 
III.B 
S  
H 3-CH3 382 8 0.02 
III.2 
 
H 3-CH3 133 413 3 
III.4 H 2-Cl 176 1764 11 
III.6 4-F 3-CH3 34 289 9 
III.7 4-F 3-Cl 24 53 2 
III.8 3-F 3-CH3 31 159 5 
III.10 N
 
H 3-CH3 220 567 3 
III.11 
N  
H 3-CH3 260 5482 21 
III.12 4-F 3-CH3 101 1272 13 
III.14 
N  
H 3-CH3 263 19646 75 
a Human placenta, microsomal fraction, substrate [3H]-E2 + E2 [500 nM], cofactor NAD+ [1.5 mM], mean value 
of three determinations, relative standard deviation < 10%, b Human placenta, cytosolic fraction, substrate [3H]-
E1 + E1 [500 nM], cofactor NADH [0.5 mM], mean value of three determinations, relative standard deviation < 
10%, c IC50 (17β-HSD1)/ IC50 (17β-HSD2). 
 
While the 1,4-substitution pattern and the fluorine on the A ring are important for 
activity, the nitrogen of the central ring and its position seem to be responsible for selectivity 
toward 17β-HSD1 in case of the pyridine class. Indeed, compound III.10 is an unselective 
17β-HSD2 inhibitor, whereas compound III.11 with the nitrogen close to the A ring is a 
highly selective inhibitor. Additionally, the 1,3-disubstituted pyridine derivatives show higher 
selectivity compared to the 1,4-disubstituted pyridines (SF = 75 (III.14) for the 2,6-pyridine 
class to be compared with SF = 3 (III.10) and 21 (III.11) for the 2,5-pyridines). However, 
none of the compound synthesised in the 2,6-pyridine class (exchange of the methyl group on 
the B ring or introduction of further substituent on the A ring) reach a better activity as the 
parent compound III.14. Nevertheless, highly potent 17β-HSD2 inhibitors have been 
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identified in this new class of compounds (III.2, III.5-III.8, III.11 and III.12), which showed 
slight or moderate selectivity toward 17β-HSD1. These compounds displayed negligible 
affinities to the ERs. 
To summarise, a new class of 17β-HSD2 inhibitors, derived from substituted bicyclic 
hydroxyphenylmethanones has been identified. Selectivity was achieved by introduction of a 
nitrogen on the central six-membered ring, whereas activity was enhanced by addition of a 
fluorine on the A ring of the 1,4-disubstituted derivatives. Combination of both modifications 
does not lead to highly active and selective compounds. Either activity or selectivity is 
increased, depending on the substitution pattern and on the central moiety. Thereby, a 
compromise should be found in order to have potent and relatively selective 17β-HSD2 
inhibitors. Compounds III.6 and III.12 were therefore identified as the most promising 
derivatives of this series with activity in the low nanomolar range (IC50 = 34 nM and 101 nM, 
respectively) and selectivity factors of 9 and 13, respectively toward 17β-HSD1. 
 
Werth et al. studied the mechanism of potent compounds of both classes (II.19, III.5 and 
III.14, PhD thesis of Ruth Werth). Full competitive and mixed partial type inhibition pattern 
were identified. In fact, a full competitive inhibitor directly competes with the binding of 
substrate, whereas a partial mixed inhibitor may bind both free enzyme and enzyme-substrate 
complex. Thus, compounds II.19 and III.14 display a partial mixed inhibition and bind 
preferentially to the free enzyme, while III.5 is a full competitive inhibitor. It is striking that 
compound II.19 does not act as competitive inhibitor contrary to the design idea of a 
steroidomimetic.  
To better understand the mechanism of action of inhibitors, two homology models have 
been generated. The models differ principally from their hydrophobic loop in front of the 
catalytic Tyr232 (AA167 to AA175), which plays an essential role either for competitive or 
partial mixed inhibitors. More precisely, in the first case, Leu171 is turned up leading to a 
competitive binding mode for the inhibitors, no space is available below NAD+, while in the 
second case Leu171 is flat leading to a partial mixed binding mode for the inhibitors and there 
is space below NAD+. Therefore, both homology models are in accordance with results of the 
kinectic studies. 
For instance, the most potent compound II.19, being a partial mixed inhibitor binds below 
NAD+ in the second model, where Leu171 has to flip down (Figure 18). According to the 
model, the molecule is stabilised in the active site by Van der Waals interactions with Lys275, 
Leu171, Leu279, Gly264, π-π interactions with the cofactor and H-bond interactions with 
Ser219 and NAD+. 
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Figure 18: (A) Schematic representation and (B) homology model of compound II.19 (partial 
mixed inhibitor) in the active site of 17β-HSD2  
 
 
Despite the fact that both classes consist of a hydrophobic core and two polar moieties at a 
distance of circa 11Å, they do not bind in the same area of the active site and they can not be 
superimposed. Therefore, the SAR of one class cannot be used for the second class and it is 
not possible to compare the classes. SAR studies of both classes are interesting tools to further 
improve homology models, as the sequence identity between templates and 17β-HSD2 is only 
43%. 
 
To conclude, the present work describes two novel classes of non-steroidal 17β-HSD2 
inhibitors. Besides a strong 17β-HSD2 inhibition with IC50 values in the low nanomolar range 
and an outstanding selectivity toward 17β-HSD1 (up to 30), the most promising compound of 
this thesis shows little affinity to the ERs, high selectivity towards other 17β-HSDs enzymes, 
namely 17β-HSD4 and 17β-HSD5 and a good cell permeability. Furthermore, it shows very 
high inhibition of the E1-formation in monkey (Callithrix Jacchus) enzyme and makes this 
species appropriate to prove that inhibition of 17β-HSD2 is able to induce bone formation and 
inhibit osteoclastogenesis. Furthermore, with the help of the SAR of both classes of 
compounds, two homology models have been generated in accordance with the results of 
kinetic studies. These models are of particular interest to design novel classes of 17β-HSD2 
inhibitors like azafluorenones as shown in Figure 19. 
Figure 19: azafluorenone class 
N
O
R1
R2
 
A B 
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